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ABSTRACT
The marked increase in life expectancy for individuals with human
immunodeficiency virus type 1 (HIV-1), following the great success of combination
antiretroviral therapy (cART), necessitates an investigation of the progression of HIV-1
associated neurocognitive disorders (HAND), and associated neural mechanisms, across
the functional lifespan. Furthermore, given the persistence of HAND in the post-cART era,
there remains a critical need to develop adjunctive therapeutics targeting the neural
mechanisms underlying HAND. Thus, the guiding hypothesis for the present study was
threefold. First, that there will be a differential progression of NCI in HIV-1 Tg and control
animals. Second, that synaptodendritic dysfunction will mechanistically underlie NCI and
progress throughout the early lifespan. Third, that the altered developmental trajectory of
NCI, as a function of the HIV-1 transgene, will be restored with SE, targeting
synaptodendritic dysfunction. Neurocognitive and neuroanatomical assessments were
utilized to critically test these hypotheses.
The HIV-1 transgenic (Tg) rat, resembling HIV-1 seropositive individuals on
lifelong cART, exhibits age-related progressive neurocognitive impairments in the absence
of sensory or motor system deficits and comorbidities. Independent of biological sex, the
HIV-1 Tg rat exhibits a differential progression of long-term episodic memory, temporal
processing, stimulus-reinforcement learning, sustained attention, and flexibility and
inhibition. Synaptic dysfunction in pyramidal neurons from layers II-III of the medial
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prefrontal cortex (mPFC) were characterized by alterations in dendritic branching
complexity, synaptic connectivity and dendritic spine morphology.
Critically testing the therapeutic efficacy of SE in the HIV-1 Tg rat revealed an
innovative therapeutic approach for the prevention of NCI in HAND; a therapeutic that, at
least partially, restores the developmental trajectory of neurocognitive function.
Mechanistically, SE remodels neuronal circuitry at the synaptic level, evidenced by
profound long-term modifications in neuronal morphology and dendritic spines in
pyramidal neurons from layers II-III of the mPFC.
A longitudinal experimental design was subsequently utilized to assess the
progression of synaptic function from postnatal day (PD) 30 to PD 180. Prominent
developmental alterations in regressive (i.e., pruning) processes, as well as synaptic
function, were observed, independent of biological sex, in pyramidal neurons from layers
II-III of the mPFC in the HIV-1 Tg rat, supporting a key neural mechanism underlying
HAND. Taken together, the present studies have defined HAND as a neurodegenerative
disease characterized by age-related, progressive neurocognitive impairments and synaptic
dysfunction; a disease which can be modified by therapeutics (i.e., SE) that mechanistically
target synaptic dysfunction.
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CHAPTER 1
INTRODUCTION

1

HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1)
HIV-1 remains a human health pandemic, afflicting approximately 37.9 million
individuals worldwide (UNAIDS, 2019). The great success of combination antiretroviral
therapy (cART) has dramatically increased the life expectancy for HIV-1 seropositive
individuals, leading to an increased prevalence (i.e., 30-50%) of older individuals (> 50
years of age) living with HIV-1 (UNAIDS, 2013); a prevalence that is expected to reach
approximately 73% by 2030 (Smit et al., 2015). In the post-cART era, milder forms of
neurocognitive impairments (NCI) have become a hallmark of the disease, afflicting
between 40-70% of HIV-1 seropositive individuals (Letendre et al., 2010; McArthur et al.,
2010; Heaton et al., 2011). Cross-sectional studies have provided a wealth of knowledge
on HIV-1 associated neurocognitive disorders (HAND), characterized by deficits in
higher-order cognitive processes (e.g., attention, working memory, executive function:
Cysique et al., 2004; Heaton et al., 2011). However, extrapolating cross-sectional findings
to age-related disease progression is inferentially fraught (Kraemer, 2000), heralding an
examination of the progression of HAND using a longitudinal experimental design. To
date, however, there has been no extant in vivo biological system available to provide a
truly longitudinal study of HAND.
BIOLOGICAL SYSTEMS TO MODEL NCI IN HIV-1
In a seminal paper, Reid et al. (2001) reported the development of the HIV-1
transgenic (Tg) rat, which contains a gag-pol-deleted HIV-1 provirus regulated by the viral
promotor. The highest levels of transgene (located on chromosome 2 and 9) expression
were observed in the lymph nodes, spleen, kidney, and thymus (Reid et al., 2001). Clinical
manifestations, including neurological abnormalities (i.e., circling behavior, hind-limb
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paralysis), skin lesions, cataract formation, and relatively early wasting (i.e, between 5 to
9 months of age) were also observed in the original derivation of the HIV-1 Tg rat (Reid
et al., 2001).
The contemporary HIV-1 Tg phenotype, however, is a healthier derivation than
those originally described. Similar growth rates (Peng et al., 2010; Moran et al., 2012;
Moran et al., 2013a; Roscoe et al., 2014) and a longer lifespan (i.e., 50% of HIV-1 Tg rats
survive through 21 months of age; Peng et al., 2010) have been reported in the current
derivation of the HIV-1 Tg rat. Viral proteins are expressed in the non-infectious HIV-1
Tg rat constitutively throughout development (Peng et al., 2010; Abbondanzo & Chang,
2014), resembling HIV-1 seropositive individuals on cART. Cross-sectional studies have
promoted the HIV-1 Tg rat as an advantageous model for NCI, reporting alterations in
temporal processing (e.g., Moran et al., 2013a; McLaurin et al., 2017a; McLaurin et al.,
2017b), sustained attention (e.g., Moran et al., 2014a), learning (Moran et al., 2014a;
Vigorito et al., 2007), and memory (Repunte-Canonigo et al., 2014). The neural
mechanisms underlying NCI in the HIV-1 Tg rat also support its utility as an advantageous
model in the post-cART era, with reports of neurotransmitter alterations (e.g., Sinharay et
al., 2017; Javadi-Paydar et al., 2017), synaptic dysfunction (e.g., Roscoe et al., 2014;
McLaurin et al., 2018a) and neuroinflammation (e.g., Royal et al., 2012).
A longitudinal assessment of NCIs for the progression of HAND, and associated
neural mechanisms, in the HIV-1 Tg rat, however, remains a critical knowledge gap.
Understanding the progression of neurocognitive impairment, and the effect of biological
sex in this progression, heralds an opportunity for the development of an advantageous
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model of progressive NCI in HIV-1 and establishes fundamental groundwork for the
development of neurorestorative treatments.
SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS (SERBAs)
Estrogen receptors (ER), which belong to the nuclear receptor family of
transcription factors, are classified into two primary subtypes, including ERα (Jensen,
1962), and ERβ (Kuiper et al., 1996). Although both ERα and ERβ bind to 17β-estradiol
with high affinity (Kuiper et al., 1996) and share structural characteristics (e.g., nearidentical DNA-binding domain (96%), Kuiper et al., 1996), significant differences in tissue
distribution and biological effects have been observed (e.g., Kuiper et al., 1997).
Specifically, ERα is predominant in reproductive organs (e.g., uterus, mammary glands),
skeletal muscle and bone, playing a critical role in maintaining female reproductive
functions (for review, Paterni et al., 2014). ERβ, however, is involved in mediating
estradiol signaling in the immune and central nervous systems (for review, Paterni et al.,
2014). Within the central nervous system, cells containing ERβ mRNA or immunoactivity
are widely dispersed (e.g., Li et al., 1997; Shughrue et al., 1997; Zhang et al., 2002;
Gonzalez et al., 2007), and observed in brain regions (e.g., prefrontal cortex, ventral
tegmental area, hippocampus) commonly associated with HAND (e.g., Maki et al., 2009;
Israel et al., 2019).
Phytoestrogens, which exhibit a higher affinity for ERβ than ERα (e.g., Kuiper et
al., 1998; Mueller et al., 2004), are plant-derived compounds that are structurally similar
to 17β-estradiol (Glazier & Bowman, 2001). Isoflavones, including genistein, daidzein
(DAI), and glycitein, are one class of phytoestrogens commonly found in soy products
(Murphy, 1982; Setchell, 1998). Equol is an active metabolite produced by gut microbiota
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following the ingestion of the soy derived phytoestrogen DAI (Setchell et al., 1984). SEquol (SE), the only enantiomer produced by humans (Setchell et al., 2005), exhibits
neuroprotective effects via its selective affinity for ERβ (Setchell et al., 2005; Bertrand et
al., 2015). Furthermore, when SE crosses the blood-brain-barrier it distributes most
significantly to the prefrontal cortex (Lund et al., 2001); a brain region associated with
higher-order cognitive functioning. Most critically, however, the translational relevance of
SE is evidenced by its progression into clinical trials for Alzheimer’s disease (AD; Ausio
Pharmaceuticls; NCT03101085), another progressive, neurodegenerative disorder.
SE has been implicated as a potential adjunctive therapeutic for HAND in both in
vitro (Bertrand et al., 2015) and in vivo (Moran et al., 2019; McLaurin et al., 2019a) studies.
In primary neuronal cell cultures, pretreatment with SE prevented synapse loss induced by
the HIV-1 viral protein, Tat (Bertrand et al., 2015). Precursors to SE, including daidzein
(DAI) and liquiritigenin (LQ), which also selectively target ERβ (DAI: Casanova et al.,
1999 ; LQ: Mersereau et al., 2008), similarly prevented Tat induced neuronal apoptosis
(Adams et al., 2012) and restored synaptodendritic injury (Bertrand et al., 2014). Crosssectional in vivo studies have further supported the utility of SE as a neuroprotective and/or
neurorestorative therapeutic for HAND in ovariectomized HIV-1 Tg animals (Moran et al.,
2019; McLaurin et al., 2019a). There remains, however, a critical need to utilize a
longitudinal experimental design to assess whether SE is able to alter the trajectory of NCI
and its mechanism of action.
EXPERIMENTAL QUESTIONS
The overarching aims of the present study are threefold. First, to establish the
progression of NCI, and associated neural mechanisms, across the functional lifespan

5

(Chapters 2-4). Second, to assess the utility of SE as a therapeutic strategy to alter the
trajectory of NCI in the post-cART era (Chapters 5-6). Third, to examine the progression
of synaptic dysfunction using a longitudinal experimental design (Chapter 7).
The guiding hypothesis for the present study was threefold. First, that there will be
a differential progression of NCI in HIV-1 Tg vs. control animals. Second,
synaptodendritic dysfunction will mechanistically underlie NCI. Third, that the altered
developmental trajectory of NCI, as a function of the HIV-1 transgene, will be restored
with SE, targeting synaptodendritic dysfunction.
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CHAPTER 2
PROGRESSION OF TEMPORAL PROCESSING DEFICITS IN THE HIV-1
TRANSGENIC RAT1

1

KA McLaurin, RM Booze, CF Mactutus. 2016. Scientific Reports. 6: 32831.
Reprinted here with permission of publisher.
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INTRODUCTION
Despite the success of cART in diminishing the prevalence of progressive HIV-1
encephalopathy (PHE), high rates of chronic neurological impairment are still being
reported in HIV-1 seropositive children (Franklin et al., 2005; Paramesparan, 2010; Smith
& Wilkins, 2015; Crowell et al., 2014). Approximately 3.2 million children (≤15 years of
age; Centers for Disease Control and Prevention, 2013) are currently living with HIV-1,
however, neurocognitive deficits in HIV-1 seropositive children, including disease
progression, are poorly understood (Crowell, 2014). The HIV-1 Tg rat may be used to
model the effects of long-term HIV-1 viral exposure on the development and progression
of chronic neurological deficits observed in children perinatally infected with HIV-1
(Vigorito et al., 2015). The HIV-1 Tg rat, originally developed by Reid et al., (2001), is
non-infectious, expresses 7 of the 9 HIV-1 genes, and exhibits many clinical phenotypes
(i.e. cataracts, low body weight) seen in HIV-1 seropositive individuals on cART (Peng et
al., 2010). Therefore, a longitudinal analysis of temporal processing deficits, a potential
underlying dimension of neurocognitive impairment in HIV-1, may provide insight into
the effect of long-term HIV-1 viral protein exposure on the development of chronic
neurologic impairment in HIV-1 seropositive children.
Deficits in temporal processing, caused by HIV-1, may manifest prior to early
symptoms of impairment in higher level cognitive processes (Castello et al., 1998; Fitting
et al., 2008a; Minassian et al., 2013; Moran et al., 2013a). Temporal processing deficits are
commonly assessed using translational experimental paradigms, including prepulse
inhibition (PPI) of the auditory startle response (ASR; Hoffman & Searle, 1965; Ison &
Hammond, 1971). PPI involves two stimuli: a punctate prestimulus or prepulse (i.e. a light
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or a tone) and a startle stimulus (Hoffman & Ison, 1980). Presentation of a prepulse 30500 msec prior to the startle stimulus, causes dramatic reductions in the ASR (Hoffman &
Ison, 1980; Fitch et al., 2008). Specifically, the degree to which the ASR is inhibited by
the prepulse is dependent upon the interstimulus interval (ISI), the time interval between
the prepulse and the startle stimulus. Use of PPI of the ASR, a behavioral approach, may
elucidate the underlying mechanisms of more complex neurological processes (Hoffman
& Ison, 1980).
Alterations in temporal processing observed in the HIV-1 Tg rat have been
observed in multiple preclinical models of HIV-1, as well as HIV-1 seropositive humans.
Specifically, deficits in temporal processing have been observed in Sprague-Dawley rats
stereotaxically injected with the HIV-1 viral proteins Tat and gp120. Neonatal (postnatal
day (PD) 1) intrahippocampal Tat injections flattened the ISI function in auditory PPI,
causing a shift in maximum peak inhibition (Fitting et al., 2006a; Fitting et al., 2008a). A
shift in the maximal peak inhibition for auditory PPI was also reported in 9-month old male
and female Sprague-Dawley rats neonatally (PD 1) injected with gp120 (Fitting et al.,
2006b). Temporal processing deficits have also been observed in SIV and FIV positive
animals (Huitron-Resendiz et al., 2004; Phipps et al., 2000; Prospero-Garcia, 1999;
Raymond et al., 1998), as well as HIV-1 seropositive individuals meeting criteria for
HAND (Minassian et al., 2013).
Analyses in the HIV-1 Tg rat have provided additional evidence that temporal
processing deficits may be a potential underlying dimension of neurocognitive impairment
in HIV-1. Cross-modal PPI was conducted in HIV-1 Tg and control rats between two and
six months (Moran et al., 2013a). HIV-1 Tg animals, in comparison to control animals,
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exhibited significant alterations in the development of temporal processing, evidenced by
a relative insensitivity to the manipulation of ISI on both visual and auditory prepulse trials
and a lack of perceptual sharpening with age (Moran et al., 2013a). The generalizability of
temporal processing deficits in the HIV-1 Tg rat, assessed using cross-modal PPI, were
extended to animals at a more advanced age (i.e., 9-10 months of age; McLaurin et al.,
2016a). HIV-1 Tg animals exhibited a relative insensitivity to the manipulation of ISI in
both auditory and visual PPI (McLaurin et al., 2016a). Consistent observations of temporal
processing deficits regardless of the agent (i.e., single proteins, HIV, SIV, FIV, and the
HIV-1 Tg rat) used to study neurocognitive deficits provide ample evidence for the critical
importance of understanding the progression of these deficits using a longitudinal
experimental design, as in the present study.
Lesioning (i.e., Leitner & Cohen, 1985) and electrical stimulation studies (i.e., Li
et al., 1998; Li & Yeomans, 2000) suggest that PPI of the ASR is mediated through a welldefined serial circuit. Excitatory input from the auditory pathway relays information the
inferior colliculus (IC), while input from the visual or tactile pathway relays information
to the superior colliculus (SC). From the SC, sensory input subsequently activates the
pedunculopontine tegmental nucleus (PPTg), triggering a cholinergic projection to the
caudal pontine reticular nucleus (PnC) mediating PPI of the ASR (Fendt et al., 1994; Fendt
et al., 2001; Koch et al., 1993; Koch & Schnitzler, 1997). Activation of the PnC is relayed
to motor neurons causing a startle response. Additionally, previous studies have established
the hierarchical regulation of PPI, commonly abbreviated as the “CSPP circuitry,” which
is comprised of both sequential and parallel neural connections (Koch et al., 1993; Koch
& Schnitzler, 1997).

10

Gap prepulse inhibition (gap-PPI) is another translational experimental paradigm
for sensorimotor ‘gating’ that may be used to study temporal processing deficits (Leitner
et al., 1993). Specifically, in gap-PPI the absence of a background stimulus (relative to the
presentation of an added stimulus) serves as the punctate prestimulus. Significant
reductions in startle amplitude have been observed when a gap in background noise occurs
between 30 and 200 msec prior to the startling stimulus (Ison et al., 1998). Analyses of
gap-PPI in HIV-1 Tg rat at an advanced age (i.e. 9-10 months of age) revealed a differential
sensitivity to the manipulation of ISI. Specifically, control animals exhibited maximal
inhibition at the 50 msec ISI, while HIV-1 Tg animals displayed a rightward shift, to
maximal inhibition at the 100 msec ISI (McLaurin et al., 2016a). Additionally, gap-PPI has
been used as an innovative paradigm for studies of tinnitus in animals, including guinea
pigs (Dehmel et al., 2012), mice (Ison et al., 1998) and rats (Turner et al., 2006; Turner &
Parrish, 2008; Sun et al., 2014), providing proof-of concept for the utility of gap-PPI as a
translational diagnostic tool for tinnitus in humans. Subsequently, the gap startle paradigm
was employed in adults with tinnitus offering new insight into the underlying neural
mechanisms involved in tinnitus (Fournier & Hebert, 2013). Use of the gap-PPI
experimental paradigms in HIV-1 seropositive children, therefore, may not only serve as a
screening tool for chronic neurological impairment in pediatric HIV-1, but may also offer
insight into the underlying neural mechanisms implicated in HIV-1.
Modeling the progression of neurocognitive deficits in the HIV-1 Tg rat is
fundamental to the advancement of our knowledge of pediatric HIV-1 as well as to the
long-term viral protein exposure present in successful cART-treated individuals with
HAND. Thus, the aims of the present study were threefold. First, using a longitudinal
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experimental design, establish the progression of temporal processing deficits using the
gap-PPI experimental paradigm in the HIV-1 Tg rat. All animals were tested at 30 day
intervals beginning at PD 30. Second, to investigate the role of sex in the progression of
temporal processing deficits in HIV-1; both male and female animals were integral to the
experimental design. Thirdly, to assess the ability of gap-PPI to correctly classify animals
in regard to their genotype based on measures of prepulse inhibition and temporal
sensitivity. Progression of temporal processing deficits in the HIV-1 Tg rat affords a
relatively untapped opportunity to increase our mechanistic understanding of the role of
long-term exposure to HIV-1 viral proteins, such as seen in pediatric HIV-1 (PHIV), in the
development of chronic neurological impairment, as well as suggest an innovative clinical
diagnostic screening tool.
METHODS
Progression of temporal processing deficits in the HIV-1 Tg rat was assessed using
a longitudinal analysis of gap-PPI. Alterations in the development of temporal processing
were explored using a 2(genotype) x 2(sex) x 6(age) x 6(ISI) mixed factor design. A
discriminant function analysis was conducted to determine the diagnostic accuracy, and
potential translational relevance, of gap-PPI.
Animals
A longitudinal analysis of gap-PPI was conducted using intact Fischer (F344/N;
Harlan Laboratories Inc., Indianapolis, IN) rats (Male HIV-1 Tg, n=26; Female HIV-1 Tg,
n=22; Male Control, n=20; Female Control, n=19). Animals were tested for gap-PPI
beginning at PD 30 and retested every thirty days at PD 60, PD 90, PD 120, PD 150, and
PD 180. Animals were delivered to the facility between PD 7 and PD 9 over the course of

12

four months. All animals were housed with their biological dam until PD 21 when animals
were weaned and separated by sex. Subsequently animals were pair- or group-housed with
animals of the same sex throughout experimentation. Rodent food (Pro-Lab Rat, Mouse,
Hamster Chow #3000) and water were provided ad libitum through 60 days of age.
Subsequently, all animals were under food restriction (85% body weight) due to their
participation in a subsequently conducted signal detection task.
Animals were maintained according to the National Institutes of Health (NIH)
guidelines in AAALAC-accredited facilities. The targeted environmental conditions for
the animal facility were 21° ± 2° C, 50% ± 10% relative humidity and a 12-h light:12-h
dark cycle with lights on at 0700 h (EST). The Institutional Animal Care and Use
Committee (IACUC) of the University of South Carolina approved the project protocol as
consistent with federal assurance (# A3049-01).
Apparatus
The startle platform (SR-Lab Startle Reflex System, San Diego Instruments, Inc.,
San Diego, CA) was enclosed in a 10 cm-thick double-walled, 81×81×116-cm isolation
cabinet (external dimensions) (Industrial Acoustic Company, INC., Bronx, NY), instead of
the 1.9 cm thick ABS plastic or laminate cabinets offered with this system. Sound
attenuation of 30dB (A) was provided in the isolation chamber relative to the external
environment. An ambient sound level of 22dB (A) was presented in the chamber without
any stimuli presented. The high-frequency loudspeaker of the SR-Lab system (Radio Shack
model#40-1278B), mounted inside the chamber 30 cm above the Plexiglas animal test
cylinder, delivered all auditory stimuli (frequency range of 5k-16k Hz). The animal’s
response to the auditory stimulus produced deflection of the test cylinder, which was
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converted into analog signals by a piezoelectric accelerometer integral to the bottom of the
cylinder. The response signals were digitized (12 bit A to D) and saved to a hard disk.
Response sensitivities were calibrated using a SR-LAB Startle Calibration System. Sound
levels were measured and calibrated with a sound level meter (Kjaer Bruel 2203) with the
microphone placed inside the Plexiglas cylinder.
Behavioral Assessments
Gap-Prepulse Inhibition Test
Intact Fischer rats (Male HIV-1 Tg, n=26; Female HIV-1 Tg, n=22; Male Control,
n=20; Female Control, n=19) were tested for gap-PPI of the ASR beginning at PD 30. A
20-min test session began with a 5-min acclimation period in the dark with 70 dB(A)
background white noise, followed by six pulse-only ASR trials, used for habituation, with
a 10s intertrial interval (ITI). Thirty-six trials were presented using 6-trial blocks
interdigitated using a Latin Square experimental design. Animals were tested with a 20msec gap in white noise preceding a startle stimulus presented at ISIs of 30, 50,100, and
200 msec. Two control trials, the 0 and 4000 msec ISI trials, were included to provide a
reference ASR within gap-PPI. The startle stimulus intensity was 100 dB (A) (20 msec
duration) measured inside the test cylinder. Mean peak ASR amplitude values were
collected for analysis. All test sessions were conducted in the dark. Because it is well
known that many stimulus parameters may influence the dependent measure of startle
response amplitude, e.g., duration, intensity, frequency, etc., we choose (and held constant)
stimulus parameters for robust prepulse inhibition, but that also would permit detection of
increases or decreases in responding. We manipulated the fundamental factor that
operationally defines prepulse inhibition, the ISI.
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Statistical Analyses
Data were analyzed using analysis of variance (ANOVA) techniques (SPSS
Statistics 20, IBM Corp., Somers, NY). Planned orthogonal contrasts The GreenhouseGeisser df correction factor (Greenhouse & Geisser, 1959) and were used for potential
violations of sphericity of within-subjects variables (Winer, 1971). Regression analyses
and graphs were completed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla,
CA). An alpha level of p≤0.05 was considered significant for all statistical tests.
The area of inflection of the ASR amplitude response curve, illustrated in Figure
2.1 (i.e., shaded gray area), was calculated for each animal at every testing session as a
measure of prepulse inhibition. A three-way mixed factor ANOVA was performed on the
mean area of peak inflection where genotype (HIV-1 Tg vs. control) and sex (male vs.
female) served as the between-subjects factor. Age served as the within-subjects factor.
The ISI indexing the point of peak inflection for prepulse inhibition, as illustrated
in Figure 2.1, was also determined for each animal at every testing session. Specifically, a
five-way mixed-factor ANOVA was performed on mean peak ASR amplitude for the 04000 msec ISIs as a measure of temporal sensitivity. Genotype (HIV-1 Tg vs. control) and
sex (male vs. female) served as the between-subjects factor, while age, ISI, and trial served
as the within-subjects factors.
The diagnostic accuracy of gap-PPI, i.e., the ability of the observed measures in
gap-PPI correctly identified animals in regard to their genotype (HIV-1 Tg vs. Control)
was determined with a discriminant function analysis (DFA). Prepulse inhibition
measurements (i.e., slope for the area of peak inflection, area of peak inflection at each test
session) and temporal sensitivity (i.e., age at which a shift in maximum inhibition was
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observed) were included in the analysis. Slope for the area of peak inflection was calculated
for each animal using the best-fit polynominal function.
RESULTS
HIV-1 Tg rats exhibited a profound alteration in the progression of temporal processing
assessed using prepulse inhibition.
The progression of PPI, assessed using mean area of the amplitude inflection, was
altered in HIV-1 Tg animals in comparison to control animals (Figure 2.2). PPI for control
animals was best fit using a first-order polynomial (R2: 0.99). In contrast, the best fit for
HIV-1 Tg animals was a one-phase association (R2: 0.96). Control animals exhibited a
significant development of temporal processing across age, while HIV-1 Tg animals failed
to exhibit any significant progression of temporal processing after PD 90. The overall
ANOVA on mean area of the amplitude inflection confirmed these observations, as
revealed by a significant age x genotype interaction [F(5,415)=6.3, pGG ≤0.001, ηp2=0.07]
with a prominent linear component [F(1,83)=19.0, p≤0.001, ηp2=0.19] as well as an age x
sex interaction [F(5,415) =2.6, pGG ≤0.034, ηp2=0.03], also with a prominent linear
component [F(1,83)=9.0, p≤0.001, ηp2=0.10]. Significant main effects of age [F(5,415)
=21.0, pGG≤0.001, ηp2=0.20] and sex [F(1, 83) =19.4, p≤0.001, ηp2=0.19] were also present.
Complementary results were obtained by conducting separate analyses of each
genotype, illustrated in Figure 2.2. A first-order polynomial was the best fit for both male
and female control animals (Male R2: 0.99; Female R2: 0.95), indicating an increase in PPI
across age. However, there was a significant difference in the rate of increase in PPI
[F(1,230)=4.3, pGG≤0.04]. The rate of temporal processing development was significantly
greater in male control animals (β1: 2820) in comparison to female control animals (β1:
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1824). The overall ANOVA for control animals confirmed these observations, as revealed
by significant main effects of age [F(5,185)=20.8, pGG≤0.001, ηp2=0.36] and sex
[F(1,37)=10.6, p≤0.001, ηp2=0.22]. In contrast, a one-phase association appeared to be the
best fit function for both male and female HIV-1 Tg animals (Male R2: 0.92; Female R2:
0.82). No significant differences in PPI were observed on PD 30. However, at PD 60 and
all subsequent test dates, male HIV-1 Tg animals exhibited significantly greater PPI in
comparison to female HIV-1 Tg animals. The overall ANOVA for HIV-1 Tg animals
confirmed these observations, as revealed by significant main effects of age [F(5,230)=5.8,
pGG≤0.001, ηp2=0.11] and sex [F(1,46)=11.4, p≤0.002, ηp2=0.20]. Female HIV-1 Tg
animals, therefore, may be more susceptible to the consequences of long-term HIV-1 viral
protein exposure in comparison to male HIV-1 Tg animals. However, regardless of sex,
PPI provided little, if any, compelling evidence for normal development of temporal
processing in the HIV-1 Tg rat.
HIV-1 Tg animals displayed a differential sensitivity to the manipulation of ISI.
HIV-1 Tg animals displayed a differential sensitivity to the manipulation of ISI, as
illustrated in Figure 2.3. A shift in maximal inhibition (from 30 msec to 50 msec) occurred
in both the HIV-1 Tg and control animals; however, the shift occurred significantly earlier
in the HIV-1 Tg animals. In the control group, a first-order polynomial (R2: 0.97) suggested
peak inhibition was observed at the 30 msec ISI during the first three test periods (PD 30,
PD 60 and PD 90), but that rightward shift to the 50 msec ISI occurred during the latter
three test periods (PD 120, PD 150 and PD 180). In contrast, the HIV-1 Tg group, well
described with a one-phase association (R2: 0.99), displayed peak inhibition at 30 msec
during the first testing period (PD 30), but displayed a rightward shift during all later testing
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periods. The overall ANOVA revealed significant three ways interactions: genotype x age
x ISI interaction [F(25,2050)=11.1, pGG≤0.001, ηp2=0.12] and genotype x age x sex
interaction [F(5,410)=4.5, pGG≤0.001, ηp2=0.05], and an age x ISI x sex interaction
[F(25,2050)=4.4, pGG≤0.001, ηp2=0.05]. Second order interactions were also confirmed
including: a genotype x age interaction [F(5,410)=54.4, pGG≤0.001, ηp2=0.40], an age x ISI
interaction [F(25,2050)=26.3, pGG≤0.01, ηp2=0.24], an age x sex interaction
[F(5,410)=10.2, pGG ≤0.001, ηp2=0.11], an ISI x genotype interaction [F(5,410)=7.1,
pGG≤0.001, ηp2=0.08] and an ISI x sex interaction [F(5,410)=23.3, pGG≤0.001, ηp2=0.22].
Significant main effects of age [F(5,410)=68.3,

pGG≤0.001, ηp2=0.45], ISI

[F(5,410)=164.9, pGG≤0.001, ηp2=0.67], genotype [F(1,82)=100.7, p≤0.001, ηp2=0.55],
and sex [F(1,82)=40.6, p≤0.001, ηp2=0.33] were also noted. Clearly, there was a
significantly greater effect of age on the variation of response amplitude by ISI for HIV-1
Tg animals in comparison to control animals.
Analyses of each genotype were conducted to further examine differences in the
progression of temporal processing (Figure 2.3). A first-order polynomial was a welldescribed fit for male control animals (R2: 0.98), while a one-phase association provided a
well-described fit for female control animals (R2: 0.99). Specifically, female control
animals exhibited a shift in maximal inhibition from 30 msec to 50 msec significantly
earlier than male control animals. The overall ANOVA for control animals revealed an age
x ISI x sex interaction [F(25,900)=2.9, pGG≤0.001, ηp2=0.08], an age x ISI interaction
[F(25,900) =23.3, pGG≤0.001, ηp2=.39], an age x sex interaction [F(5,180)=7.2, pGG≤0.001,
ηp2=0.17], and an ISI x sex interaction [F(5,180)=12.6, pGG≤0.001,

ηp2=0.26]. A

significant main effect of age [F(5,180) =62.8, pGG≤0.001, ηp2=0.64], ISI [F(5,180) =111.4,
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pGG≤0.001, ηp2=0.76], and sex [F(1,36)=16.0, p≤0.001, ηp2=0.31] were also revealed. In
contrast, a one-phase association provided a well-described fit for both female and male
HIV-1 Tg animals (R2: 0.99) suggesting that the shift in maximal inhibition from 30 msec
to 50 msec was not dependent upon sex in the presence of the HIV-1 transgene. The overall
ANOVA for the HIV-1 Tg group did not reveal a significant age x sex interaction
[F(5,230)=1.7, pGG≤0.146, ηp2=0.04], nor a main effect of age [F(5,230) =1.4, pGG≤0.246,
ηp2=0.03], confirming these observations. Most notably, therefore, regardless of sex, HIV1 Tg animals exhibited a significantly earlier shift in maximal inhibition, indicating a
differential sensitivity to the manipulation of ISI.
Longitudinal gap-PPI can accurately diagnose the presence of the HIV-1 Transgene.
Progression of temporal processing, assessed using gap-PPI, was further analyzed
using a DFA to determine the potential utility of gap-PPI as a diagnostic screening tool for
chronic neurological impairment associated with the HIV-1 transgene. Transgene presence
was best predicted using measures of PPI (i.e., mean area of the peak inflection) and
measures of temporal sensitivity (i.e., cumulative frequency), as illustrated in Figure 2.4.
The stepwise DFA selected four variables (slope of area of the peak inflection, area of the
peak inflection at PD 180 and cumulative frequency at PD 60 and PD 180) that maximally
separated the HIV-1 Tg and control animals (canonical correlation of 0.80). Animals were
correctly diagnosed for the presence of the HIV-1 transgene with 90.8% accuracy (F
approximation of Wilks’ λ of 0.368, F(4, 82) =35.2, p≤0.001).
DISCUSSION
Prominent temporal processing deficits in the HIV-1 Tg rat were detected using the
gap-PPI experimental paradigm. The developmental trajectory of PPI, assessed using the
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gap-PPI experimental paradigm, was altered in the HIV-1 Tg rat relative to control animals,
regardless of sex, from 30 to 180 days of age. Additionally, female HIV-1 Tg animals
exhibited significantly less PPI in comparison to male HIV-1 Tg animals. A differential
sensitivity to the manipulation of ISI was also observed in the HIV-1 Tg rat, regardless of
sex. Animals were correctly classified (90.8%) for the presence of the genotype (HIV-1 Tg
or control) using measures of PPI and temporal sensitivity. Temporal processing deficits
observed in the HIV-1 Tg rat resemble those reported in HIV-1 seropositive individuals,
providing insight into the effect of long-term exposure to HIV-1 viral proteins and the
potential for development of a diagnostic screening tool for chronic neurological
impairment.
HIV-1 Tg rats displayed a differential development of PPI, assessed using the gapPPI experimental paradigm, in a longitudinal experimental design. A one-phase association
was the best fit for HIV-1 Tg animals, while a first-order polynomial was the best fit for
control animals. No statistical differences in temporal processing between the HIV-1 Tg
and control groups were observed at PD 30. However, significant differences in the
progression of temporal processing, assessed using PPI, were exhibited at subsequent
testing sessions. Specifically, control animals displayed a linear increase in PPI from PD
30 to PD 180. In contrast, HIV-1 Tg animals only exhibited a significant increase in PPI
from PD 30 to PD 90, after which point a plateau in temporal processing was observed. To
our knowledge, the present study is the first to investigate the progression of temporal
processing deficits using gap-PPI in the HIV-1 Tg rat, which is vital for the development
of an extant model for HIV-1.
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Sex differences in the progression of temporal processing deficits, assessed using
PPI, provide fundamental information for our understanding of the long-term effect of
HIV-1 viral protein exposure in PHIV. Both female HIV-1 Tg and control animals
displayed significantly less PPI, in comparison to male HIV-1 Tg and control animals,
consistent with previous observations in healthy individuals (Abel et al., 1998; Ornitz et
al., 1991; Kumari et al., 2004). Regardless of sex, however, HIV-1 Tg animals exhibited
significant alterations in temporal processing, assessed using PPI; alterations which were
more profound in female HIV-1 Tg animals in comparison to male HIV-1 Tg animals. Sex
differences in the HIV-1 Tg rat expand on differences observed in HIV-1 seropositive
individuals. Recent studies have reported significantly greater neurological impairment in
HIV-1 seropositive women, in comparison to HIV-1 seropositive women (Royal et al.,
2016; Hestad et al., 2012). The effect of sex on the progression of neurocognitive
impairments in HIV-1 seropositive individuals has been relatively understudied; the need
for longitudinal study is critical (Maki et al., 2015).
A differential sensitivity to the manipulation of ISI was evidenced by a shift in the
point of maximal inhibition. Both HIV-1 Tg and control animals displayed maximal
inhibition at the 30 msec ISI on PD 30. However, HIV-1 Tg animals display a rightward
shift in peak inhibition, from 30 msec to 50 msec, at PD 60. Notably, no sex differences
were observed in the HIV-1 Tg animals. The point of maximal peak inhibition in control
animals shifts from 30 msec to 50 msec at PD 120. Female control animals exhibited a
significantly earlier shift in maximal inhibition in comparison to male control animals.
Results of differential sensitivity to the manipulation of ISI in the present study extend
those previously reported in the HIV-1 Tg rat (Moran et al., 2013a; McLaurin et al., 2016a)
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and Sprague-Dawley rats stereotaxically injected with the HIV-1 viral proteins (Fitting et
al., 2006a; Fitting et al., 2006b; Fitting et al., 2008a).
Temporal processing deficits observed using gap-PPI in the HIV-1 Tg rat may
provide a novel screening tool for the diagnosis of chronic neurological impairment in
PHIV. A DFA, used to evaluate the potential utility of gap-PPI, correctly identified animals
in regards to their genotype (HIV-1 Tg vs. control) with 90.8% accuracy. The presence of
the HIV-1 transgene was best predicted using four variables as assessments of PPI (i.e.,
slope of area of the peak inflection, area of the peak inflection at PD 180) and temporal
sensitivity (i.e., cumulative frequency at PD 60 and PD 180). Gap-PPI was previously
implicated as a novel screening tool for the diagnosis of tinnitus. Specifically, rats with
noise over-expression induced tinnitus (Dehmel et al., 2012) or salicylate-induced tinnitus
(Sun et al., 2014) exhibited little to no inhibition in gap-PPI studies. The gap-PPI
experimental paradigm was subsequently employed in adults with tinnitus offering new
insight into the neural mechanisms of tinnitus (Fournier & Hebert, 2013). Use of the gapPPI experimental paradigms in HIV-1 seropositive humans, therefore, may not only serve
as a screening tool for chronic neurological impairment in PHIV, but may also offer insight
into the underlying neural mechanisms implicated in HAND.
Clinical and preclinical studies have implicated disruptions in the development of
the dopamine (DA) system as an underlying factor in neurocognitive impairments observed
in pediatric HIV-1 (Webb et al., 2010; Moran et al., 2013b; Lee et al., 2014; Moran et al.,
2014a; Fitting et al., 2015). A case study of five HIV-1 seropositive children observed
improved motor function and activity with administration of levodopa (L-DOPA), a DA
agonist (Mintz, 1996). In addition, pharmacological assessments have previously been
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used to examine alterations in the midbrain DAergic system in the HIV-1 Tg rat (Webb et
al., 2010; Moran et al., 2013b). DAergic system dysfunction, assessed using Western
blotting, was evidenced by alterations in phosphorylated tyrosine hydroxylase (pTH),
dopamine transporter (DAT) mRNA, and/or monoamine oxidase A (MAO-A; Webb et al.,
2010; Moran et al., 2013b). In addition, young HIV-1 Tg rats exhibit deficits in D2/3
receptors in the dorsal striatum, assessed using [18F]fallypride positron emission
tomography (PET; Lee et al., 2014).
DA system dysfunction may underlie temporal processing deficits observed in the
HIV-1 Tg rat, as evidenced by previous behavioral and pharmacological studies (Geyer et
al., 2001; Moran et al., 2009; Zhang et al., 2000). Administration of direct (i.e.,
apomorphine) and indirect DA agonists (i.e., amphetamine) have been used to manipulate
DA, subsequently disrupting PPI (Geyer et al., 2001). We have previously observed an
insensitivity to the manipulation of ISI, assessed using crossmodal PPI, in rats administered
apomorphine; results that are comparable to those observed in the HIV-1 Tg rat (Moran et
al., 2009) and schizophrenic patients (Adler et al., 1982; Braff et al., 1978). Although
temporal processing deficits observed in the HIV-1 Tg rat may be mediated by multiple
neural systems, HIV-1 infection often affects DA system function and is associated with
subsequent cognitive deficits (Di Rocco et al., 2000; Wang et al., 2004).
The potential role of oxidative stress and neuroinflammation as well as
synaptodendritic injury are other potential mechanisms contributing to neurocognitive
impairment in the HIV-1 Tg rat. Prior research has reported evidence of chronic immune
activation in the brains of the HIV-1 Tg rat (Rao et al., 2011; Royal et al., 2012). Thus, in
the absence of viral replication, a chronic, mild, neuroinflammatory microenvironment
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exists in the HIV-1 Tg animals. Interestingly, the DAergic system appears to be particularly
sensitive to neuroinflammatory degenerative processes (Tansey et al., 2010; Gao et al.,
2008). Decifits in synaptic proteins as well as decreases in dendritic branching complexity
and shifts in dendritic spine parameters have also been established (Rao et al., 2011;
Roscoe et al., 2014). HAND is thought to be the result of dendritic injury (e.g., Ellis et al.,
2007) and synaptic dysfunction (Gelman & Nguyen, 2010).
The interpretation of the results presented herein and the longitudinal experimental
design employed deserves further consideration. Prior longitudinal assessments of
temporal processing provide evidence for experienced-based improvements (Dean et al.,
1990; Threlkeld et al., 2009; Friedman et al., 2004), a potential caveat for interpretation of
the present study. However, assessments of gap-PPI in the present study began at PD 30,
after the ontogeny of gap-PPI attains mature level (PD 28; Dean et al., 1990; Kellog et al.,
1983). Although the response amplitude per se may decrease as a function of experience
(Dean et al., 1990; Threlkeld et al., 2009; Friedman et al., 2004), there were no significant
shifts in the ISI for peak inhibition in the amplitude response curve, which are observed in
the present study as a function of age (i.e., Figure 3.3). Critically, all animals in the present
study were subjected to the same experiences during early development and immediately
prior to experimentation; a level of control not present in studies with humans. As
previously observed (Moran et al., 2013a), the protracted development of perceptual
sharpening across repeated testing, as indexed by the relative insensitivity to ISI, may
reflect, in part, impaired central nervous system (CNS) plasticity in the HIV-1 Tg rat.
The use of the classical ISI approach in the gap-PPI experimental paradigm also
merits further discussion. The classic approach, popularized by Ison and Hammond (1971),
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relies on the manipulation of the ISI as the fundamental operationally defined factor for
PPI to assess sensorimotor 'gating', i.e., a measure of temporal processing. The present
study employs a constant gap duration (i.e., 20 msec) and a range of ISI values to accurately
assess the response amplitude curves for gap-PPI. Temporal acuity per se, as may be
assessed via manipulation of the stimulus parameter of gap duration (Dean et al., 1990;
Threlkeld et al., 2009; Friedman et al., 2004), was not measured in the present study. Braff
et al. (1978) assessed the effect of re-test on the startle reflex employing the classical ISI
approach. Startle response is a relatively stable phenomenon when the classical ISI
approach is employed (Braff et al., 1978), providing additional evidence that the present
results are not an effect of experience. Thus, the use of a longitudinal experimental design
and manipulation of ISI in gap-PPI affords an undeniable opportunity to assess the effect
of age on the development of perceptual sharpening, of temporal sensitivity, which may be
a critical underlying dimension for the cognitive impairments observed in HAND.
The study of early neurological deficits is vital for the development of an extant
model for the progression of neurocognitive deficits in HIV-1, as well as the development
of an effective treatment for PHIV. The HIV-1 Tg rat, which resembles HIV-1 seropositive
individuals on cART, provides a vehicle for understanding the progression of neurological
impairment using a longitudinal experimental design. HIV-1 Tg rats used in the present
study displayed no significant health disparities in comparison to F344 controls (i.e. similar
growth rates), consistent with our previous studies (Moran et al., 2012; Moran et al., 2013a;
Roscoe et al., 2014). HIV-1 Tg animals used in the current study are a healthier derivation
of those originally described (Reid et al., 2001), which displayed severe phenotypical
alterations, and wasting at a relatively young age (5-9 months). In contrast, no general
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wasting or pathological phenotypes were observed in the HIV-1 Tg animals used in the
current study. Both HIV-1 Tg and control animals displayed similar inhibition in visual
PPI suggesting that, despite the presence of cataracts in the HIV-1 Tg group, animals were
able to detect the 20 msec visual stimulus presented (Moran et al., 2013a). Thus, the current
HIV-1 Tg rat displays a moderate phenotype closely resembling HIV-1 seropositive
children on cART, making it useful for longitudinal studies of HAND progression.
Temporal processing deficits observed in the HIV-1 Tg rat, assessed using gapPPI, resemble temporal processing deficits commonly exhibited in HIV-1 seropositive
individuals. Understanding the altered progression of temporal processing and differential
sensitivity to the manipulation of ISI fills previous gaps in our knowledge about the effect
of long-term exposure to HIV-1 viral proteins on neurocognitive impairment evident in
PHIV and may reveal information regarding the underlying neural circuitry. Temporal
processing measures suggest a diagnostic screening tool for chronic neurological
impairment, as well as a venue for the development of novel therapeutics.
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Figure 2.1 Derivation of Prepulse Inhibition. Diagram of the
methodology used to derive prepulse inhibition and cumulative
frequencies. PPI was derived using area of the peak inflection,
which is shaded in gray. The double arrow indicates the potential
shift in maximal inhibition, which occurred as a function of age.
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Figure 2.2 Progression of Temporal Processing: Gap-PPI. (A) PPI, assessed
using mean area of the peak inflection, is illustrated as a function of genotype (HIV1 Tg or Control) and age (± 95% CI). As age increases, control animals exhibit an
linear increase in PPI. PPI for HIV-1 Tg animals, however, was best fit using a onephase association. Although control animals develop increased PPI across age, HIV1 Tg animals failed to exhibit an increase in PPI after PD 90. Linear regression fit
(R2): HIV-1 Tg, 0.96; Control, 0.99. (B) PPI for control animals is illustrated as a
function of sex (Male or Female) and age (±95% CI). A first-order polynomial was
fit to both male and female control animals. Although a linear increase PPI was
exhibited by both male and female control animals, there was a significant difference
between groups in the rate at which PPI increases [F (1,230) =4.3, p≤0.04]. Linear
regression fit (R2): Male, 0.99; Female, 0.95. (C) PPI for HIV-1 Tg animals is
illustrated as a function of sex (Male or Female) and age (±95% CI). PPI for both
male and female HIV-1 Tg animals was best fit using a one-phase association.
Female HIV-1 Tg animals displayed significantly less PPI than male HIV-1 Tg
animals. Linear regression fit (R2): Male, 0.92; Female, 0.82.
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Figure 2.3 Progression of Temporal Processing: Shift in Maximal Inhibition. (A) The
cumulative frequency for the shift in maximal inhibition from 30 msec to 50 msec is
illustrated as a function of genotype (HIV-1 Tg or Control) and age (± 95% CI). A shift in
temporal processing occurred in both the HIV-1 Tg and control animals, however, the shift
occurred significantly earlier in the HIV-1 Tg animals. A one-phase association was the
best fit for HIV-1 Tg animals, while a first-order polynomial was the best fit for control
animals. Linear regression fit (R2): HIV-1 Tg, 0.99; Control, 0.97. (B) The cumulative
frequencies for the shift in maximal inhibition from 30 msec to 50 msec for control animals
are illustrated as a function of sex (Male or Female) and age (± 95% CI). Female control
animals, which were fit using a one-phase association, exhibited a significantly earlier shift
in maximal inhibition in comparison to control animals, which were best fit using a firstorder polynomial. Linear regression fit (R2): Male, 0.98; Female, 0.99. (C) The cumulative
frequencies for the shift in maximal inhibition from 30 msec to 50 msec for HIV-1 Tg
animals are illustrated as a function of sex (Male or Female) and age (± 95% CI). A onephase association global fit was the best fit for both male and female HIV-1 Tg animals.
Sex, therefore, did not have a significant effect on sensitivity to the manipulation of ISI in
HIV-1 Tg animals. Linear regression fit (R2): 0.99.
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Figure 2.4 Animal Classification. Animal classification is illustrated
as a function of the canonical variable representing the simplest linear
function that best separated the HIV-1 Tg and control groups
(canonical correlation 0.80) and correctly identified (jackknife
classification) group membership with 90.8% accuracy (79.5% of
controls, and 100% of HIV-1 Tg animals).
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THE PROGRESSION OF HIV-1 ASSOCIATED NEUROCOGNITIVE
DISORDERS2

2 KA McLaurin, RM

Booze, CF Mactutus. 2018. Journal of Neurovirology. 24(2):229-245.
Reprinted here with permission of publisher.
31

INTRODUCTION
Approximately 73% of individuals with HIV-1 will be 50 years or older by 2030
(Smit et al., 2015) due to the marked increase in life expectancy following the great success
of cART. The prevalence of the most severe forms of neurocognitive impairment,
including HIV-1 associated dementia, dramatically decreased following the advent of
cART. However, milder forms of neurocognitive impairments, including HAND, continue
to afflict between 40-70% of HIV-1 seropositive individuals (Letendre et al., 2010;
McArthur et al., 2010; Heaton et al., 2011). Cross-sectional studies have demonstrated that
older HIV-1 seropositive individuals are at an elevated risk for developing neurological
impairments compared to older HIV-1 seronegative individuals (Sheppard et al., 2015) and
younger HIV-1 seropositive individuals (Valcour et al., 2004; Fazeli et al., 2014).
Extrapolating findings from cross-sectional studies to age-related disease progression,
however, is inferentially fraught (Kraemer et al., 2000; Coleman, 2004). Longitudinal
experimental designs, in sharp contrast, provide an opportunity to understand age-related
disease progression using repeated measures across the lifespan (Kraemer et al., 2000;
West et al., 2004).
In a seminal paper, Reid et al. (2001) reported the development of the HIV-1 Tg
rat, which contains a gag-pol-deleted HIV-1 provirus regulated by the viral promotor. The
highest levels of transgene (located on chromosome 2 and 9) expression were observed in
the lymph nodes, spleen, kidney, and thymus (Reid et al., 2001). Clinical manifestations,
including neurological abnormalities (i.e., circling behavior, hind-limb paralysis), skin
lesions, cataract formation, and relatively early wasting (i.e, between 5 to 9 months of age)
were also observed in the original derivation of the HIV-1 Tg rat (Reid et al., 2001).
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The current derivation of the HIV-1 Tg rat, used in the present studies, is a healthier
derivation than those originally described, with the transgene now limited to chromosome
9, and in the F344/N, rather than Sprague Dawley, background strain. Similar growth rates
(Peng et al., 2010; Moran et al., 2012; Moran et al., 2013b; Roscoe et al., 2014) and a
longer lifespan (i.e., 50% of HIV-1 Tg rats survive through 21 months of age; Peng et al.,
2010) have been reported in the contemporary HIV-1 Tg phenotype. Viral proteins are
expressed in the non-infectious HIV-1 Tg rat constitutively throughout development (Peng
et al., 2010; Abbondanzo & Chang, 2014), resembling HIV-1 seropositive individuals on
cART. There is growing acceptance and confidence that the HIV-1 Tg rat is a valuable tool
to model the neurocognitive deficits observed in HAND (e.g., Vigorito et al., 2007;
Lashomb et al., 2009; Moran et al., 2013a; Moran et al., 2014a; Repunte-Canonigo et al.,
2014) and may provide an opportunity to assess the effect of long-term HIV-1 viral protein
exposure (Vigorito et al., 2015). However, there is a critical need to determine the integrity
of sensory and motor system function, which will help establish the utility of the HIV-1 Tg
rat in longitudinal studies on the progression of neurocognitive deficits through advancing
age.
PPI of the ASR has been promoted as a versatile experimental technique for the
evaluation of sensory system function (Ison et al., 1984; Wecker et al., 1985; Crofton &
Sheets, 1989) and temporal processing (e.g., Moran et al., 2013a; McLaurin et al., 2017a,
McLaurin et al., 2017b). The technique, popularized by Ison and Hammond (1971),
introduces a punctate prestimulus (i.e., light, tone) prior to a startling stimulus. Introduction
of the prestimulus 30 to 500 msec prior to the startling stimulus produces robust inhibition
of the ASR (Hoffman & Ison, 1980). The amplitude of the startle response can be used to
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determine whether the subject (i.e., rat, mouse, human) is able to detect the prestimulus
(Wecker et al., 1985), thus assessing the integrity of sensory system function. Additionally,
manipulation of the ISI (i.e., the time between the prestimulus and startle stimulus), as in
the present studies, allows for assessment of temporal processing.
Characteristics of PPI, including brevity (i.e., rodents: approximately 20-30
minutes, Fitting et al., 2006b; Moran et al., 2013a), repeatability (Braff et al., 1978;
Schwarzkoph et al., 1993), and ease of administration (i.e., no prior training, no invasive
procedures) make it an attractive method for the evaluation of sensory function (Ison et al.,
1984; Crofton & Sheets,1989). PPI has previously been used to assess the effect of toxicant
exposure on sensory system function. For example, Young and Fechter (1983) assessed the
effect of neomycin treatment on auditory system function. Results indicated not only that
neomycin treatment resulted in selective hearing loss, but also the sensitivity of PPI to
auditory system function (Young & Fechter, 1983). Additionally, Wecker and Ison (1986)
assessed the effect of inherited retinal degeneration on visual system function using PPI.
Across age, animals with inherited retinal degeneration failed to exhibit robust inhibition
to the visual prestimulus at any ISI, indicative of alterations in visual system function
(Wecker & Ison, 1986).
Temporal processing deficits, a potential elemental dimension of neurocognitive
impairment in HIV-1, have been previously observed in the HIV-1 Tg rat using crossmodal PPI (Moran et al., 2013a; McLaurin et al., 2017b; McLaurin et al., 2017c).
Specifically, a within-subject assessment from two to six months of age revealed a relative
insensitivity to the manipulation of ISI and a lack of perceptual sharpening with age in
HIV-1 Tg animals relative to control animals (Moran et al., 2013a). Alterations in the
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development of perceptual sharpening have also been reported in preweanling HIV-1 Tg
animals relative to controls (McLaurin et al., 2017c). Additionally, HIV-1 Tg and control
animals were assessed between nine and ten months of age, revealing the generality and
relative permanence of temporal processing deficits (McLaurin et al., 2017b). Accordingly,
the present study employed auditory and visual PPI to assess the integrity of the auditory
and visual sensory systems and the progression of temporal processing deficits in the HIV1 Tg rat through the majority of the animal’s functional lifespan.
Locomotor activity has been recognized as a state-of-the art technique used for the
assessment of gross motor movement (Pierce & Kalivas, 2007). The protocol employed in
the present study used an automated monitoring system to measure the number of photocell
interruptions within a test session (i.e., 60 minutes) as an index of motor behavior (Pierce
& Kalivas, 2007). Assessments of locomotor activity are commonly used as a preclinical
screening tool for motoric impairment in pharmacological studies (Robbins, 1977; Pierce
and Kalivas, 2007). For example, Booze and Mactutus (1990) used locomotor activity as
an assessment of the long-term effects of neonatal exposure to triethyl lead. No significant
differences in locomotor activity were observed at testing on PD 90, suggesting that
neonatal exposure to triethyl lead has no long-term effects on motor system function
(Booze & Mactutus, 1990). Additionally, locomotor activity has been used to examine the
effects of prenatal cocaine exposure (1 or 3 mg/kg) on locomotor and stereotyped behavior
following a cocaine challenge in adulthood (Peris et al., 1992). Animals prenatally exposed
to 3 mg/kg cocaine exhibited the most profound increases in locomotor and stereotyped
behavior following cocaine injections in adulthood, suggesting that cocaine in utero
behaviorally sensitized animals to subsequent cocaine exposure (Peris et al., 1992).
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Measures of novelty and habituation can be used to assess memory, including
episodic memory, in animal models (Eacott et al., 2005; Barker et al., 2007; Moran et al.,
2013b; Chao et al., 2016). Habituation, one of the simplest forms of learning characterized
by a decrease in response following repeated stimulation (Harris, 1943; Thompson &
Spencer, 1966; Rankin et al., 2009), allows for the assessment of learning and memory in
locomotor activity, both within sessions (intrasession) and between sessions (intersession;
review, Leussis & Bolivar, 2006). Significant alterations in intrasession habituation have
been reported in the HIV-1 Tg rat, assessed using three consecutive test sessions in
locomotor activity at 6, 7, and 11 months of age (Moran et al., 2013b). Profound deficits
in intrasession habituation were observed during the third test session at 7 and 11 months
in HIV-1 Tg animals compared to controls, suggestive of a deficit in long-term episodic
memory (Moran et al., 2013b). Alterations in intersession habituation have also been
reported in neonatal Sprague-Dawley rats stereotaxically injected with Tat1-86, a HIV-1
viral protein, compared to vehicle-treated controls (Moran et al., 2014b). Therefore, the
present study used locomotor activity to assess the integrity of the motoric system and the
progression of long-term episodic memory in the HIV-1 Tg rat through advancing age.
The aims of the present study were thus two-fold. First, to assess the integrity of
sensory and motor system function through advancing age in the HIV-1 Tg rat.
Determining the integrity of sensory and motor systems in the HIV-1 Tg rat through the
majority of the animal’s functional lifespan provides an opportunity to help establish the
applicability of the HIV-1 Tg rat in longitudinal studies of the progression of HAND.
Second, to establish the progression of neurocognitive deficits, including temporal
processing and long-term episodic memory, in the HIV-1 Tg rat, through the majority of
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the animal’s functional lifespan. The factor of biological sex was an integral component of
the experimental design. Understanding the progression of neurocognitive impairment, and
the effect of biological sex, heralds an opportunity for the development of an advantageous
model of progressive neurocognitive deficits in HIV-1 and establishes fundamental
groundwork for the development of neurorestorative treatments.
METHODS
Animals
Intact male and female Fischer (F344/N; Harlan Laboratories Inc., Indianapolis,
IN) HIV-1 Tg (male, n=37; female, n=33) and control rats (male, n=34; female, n=33) were
sampled from a total of 37 litters (HIV-1 Tg, N=20 litters; control N=17 litters). Crossmodal PPI and locomotor activity assessments were conducted every thirty days from PD
90 to PD 180 and every sixty days from PD 240 to PD 480.
Animals, housed with their biological dam, were delivered to the animal vivarium
between PD 7 and PD 9 across eleven months. Following weaning, which occurred at PD
21, animals were pair- or group-housed with animals of the same sex. Beginning at
approximately PD 60, animals were placed on food restriction (Pro-Lab Rat, Mouse,
Hamster Chow #3000) to maintain 85% body weight due to their participation in a
concurrently conducted signal detection task. Rodent food was again provided ad libitum
for the duration of the study following the successful completion of signal detection (PD
100-PD 277). Water was available ad libitum throughout the duration of the study.
Due to health issues, including significant weight loss (i.e., approximately 20%;
n=6) or tumors (n=4), some animals were euthanized prior to the completion of the study.
Specifically, two HIV-1 Tg animals (male n=1; female n=1) and one control animal (male,
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n=1) were euthanized prior to PD 420 and an additional five HIV-1 Tg animals (male n=3;
female n=2) and two control animals (male n=1; female n=1) were euthanized prior to PD
480.
Guidelines established by the NIH were used for the maintenance of animals in
AAALAC-accredited facilities. The targeted environmental conditions for the animal
vivarium were 21°± 2°C, 50% ± 10% relative humidity and a 12-h light:12-h dark cycle
with lights on at 0700 h (EST). The project protocol, under federal assurance (# A304901), was approved by the IACUC of the University of South Carolina.
Cross-Modal Prepulse Inhibition
Apparatus
An isolation cabinet (external dimensions: 10 cm-thick, double-walled, 81 x 81 x
116-cm) (Industrial Acoustic Company, INC., Bronx, NY), which provided 30 db(A) of
sound attenuation relative to the external environment, enclosed the startle platform (SRLab Startle Reflex System, San Diego Instruments, Inc., San Diego, CA), instead of the 1.9
cm thick ABS plastic or laminate cabinets offered with this system. Background noise of
70dB(A) was continuously delivered. All auditory prepulse and startle stimuli were
presented using a high-frequency loudspeaker of the SR-Lab system (model#40-1278B,
Radio Shack, Fort Worth, TX). A sound level meter (model #2203, Bruël & Kjaer,
Norcross, GA) was used to measure and calibrate the sound levels, with the microphone
placed inside the Plexiglas test cylinder. Visual prepulse stimuli were presented using a
white LED light (22 lux; Light meter model #840006, Sper Scientific, Ltd, Scottsdale, AZ).
The high-frequency loudspeaker of the SR-Lab system was mounted 30 cm above the
Plexiglas animal test cylinder and the white LED light was affixed on the wall in front of
the test cylinder. A piezoelectric accelerometer integral to the bottom of the cylinder
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converted the deflection of the test cylinder, resulting from the animal’s ballistic response
to the auditory stimulus, into analog signals. The response signals were digitized (12 bit A
to D, recorded at a rate of 2000 samples/sec) and saved to a hard disk. A SR-LAB Startle
Calibration System was used to calibrate the response sensitivities.
Procedure
Cross-modal PPI, used to assess auditory and visual sensory system function and
the progression of temporal processing, was conducted similar to our prior publications
(e.g., Moran et al., 2013a). In brief, a 30-minute test session, beginning with a 5-min
adjustment period, was conducted in the dark every 30 days from PD 90 to PD 180 and
every 60 days from PD 240 to PD 480. Six pulse-only ASR trials, with a fixed 10 second
ITI, were used for habituation at the beginning of the test session. An equal number of
auditory (85dB(A) white noise stimulus) and visual (22 lux) prepulse trials, totaling 72
trials, were presented using a counterbalanced order (i.e., ABBA) to control for ordereffects. ISIs (0, 30, 50, 100, 200, 4000 msec) were presented in 6-trial blocks according to
a Latin-square design with a variable ITI (15-25 sec). All prepulse stimuli and the auditory
startle stimulus (100 db(A)) had a 20 msec duration. The peak ASR amplitude values were
collected for analysis.
Locomotor Activity
Apparatus
Square (40 x 40 cm) activity monitors (Hamilton Kinder, San Diego Instruments,
San Diego, CA) were converted into round (~40 cm diameter) compartments using perspex
inserts. Infrared photocell (32 emitter/detector pairs) interruptions were used to detect free
movement; the sensitivity of the photocells was tuned by the manufacturer to maintain their
sensitivity with the additional layer of perspex.
39

Procedure
Motor system function and long-term episodic memory impairments were assessed
using locomotor activity every thirty days from PD 90 to PD 180 and every sixty days from
PD 240 to PD 480. A 60-minute test session was conducted between 700 and 1200h (EST)
under dim light conditions (<10 lux) in an isolated room. The number of photocell
interruptions within the 60-min test session were collected for analysis.
Statistical Analysis
ANOVA statistical techniques (SPSS Statistics 24, IBM Corp., Somer, NY) were
used for the analysis of all data. Individual observations were analyzed using litter means
and standard errors, dependent upon biological sex, to account for the nested design
(Denenberg, 1984; Wears, 2002).The mean series imputation method was used for all
censored data, either due to euthanization or an equipment malfunction, which occurred in
locomotor activity at PD 90 (control: n=1) and PD 150 (HIV-1 Tg: n=7; control: n=4).
Potential violations of compound symmetry were precluded by the use of orthogonal
decomposition of the repeated-measures factors or addressed, post-hoc, via the
conservative Greenhouse-Geisser df correction factor (Greenhouse & Geisser, 1959). Agedependent effects of the HIV-1 transgene were evaluated using tests of simple mains effects
and specific linear contrasts (Winer, 1971). Partial eta squared (ηp2) was used as a measure
of effect size. GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA) was used for all
regression analyses and to create all graphs. For all statistical tests, significance was set at
an alpha level of p≤0.05.
Specifically, for free-feeding body weight, a mixed-factor ANOVA was conducted
independently for each sex. Genotype (HIV-1 Tg vs. control) served as the betweensubject’s factor, while age served as the within-subjects factor. The peak ASR amplitude
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values, collected in cross-modal PPI, were analyzed for the assessment of the integrity of
auditory and visual system function. The progression of temporal processing was examined
using the area of inflection of the ASR amplitude response curve (McLaurin et al., 2016b).
Locomotor activity was assessed using the total number of photocell interruptions in a 60minute period, to establish the integrity of motoric system function, and the number of
photocell interruptions in 5-minute bins, to assess intrasession habituation, as an index for
long-term episodic memory. For cross-modal PPI and locomotor activity, a mixed-factor
ANOVA was performed, with genotype (HIV-1 Tg vs. control) and sex (male vs. female)
as the between-subject’s factors. As appropriate, age, time, ISI, and trial served as the
within-subjects factors.
RESULTS
Establishing the Integrity of Sensory and Motor System Function
Body Weight: Somatic Growth
Somatic growth, assessed using body weight, was examined by litter dependent
upon food access (i.e., food restriction vs. ad libitum) and sex. Regardless of sex and/or
food access, HIV-1 Tg animals weighed significantly less than control animals throughout
the duration of the experiment.
Male HIV-1 Tg and control animals exhibited a linear increase in growth (Figure
3.1), with no significant differences between genotype in the rate of growth [F(1,60)<1.0,
p≥0.05], while on food restriction due to a concurrently conducted signal detection task.
All male HIV-1 Tg and control animals completed the concurrently conducted signal
detection task by 6 months of age (PD 180), at which point food was subsequently available
ad libitum. During free-feeding, a one-phase association was the best fit for both HIV-1 Tg
and control animals (R2s≥0.97); however, significant differences were observed in the rate
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of growth [F(3,357)=1230, p≤0.001]. The overall ANOVA conducted on somatic growth
during free-feeding confirmed these observations, revealing a significant age x genotype
interaction [F(10,310)=70.0, pGG≤0.001, ηp2=0.693] with a prominent linear component
[F(1,31)=126.4, p≤0.001, ηp2=0.803]. Significant main effects of age [F(10,310)=607.1,
pGG≤0.001, ηp2=0.951] and genotype [F(1,31)=381.7, p≤0.001, ηp2=0.925] were also
observed.
Female HIV-1 Tg animals displayed an increase in weight according to a one-phase
association, while female control animals exhibited an increase in weight according to a
second order polynomial, during food restriction (Figure 3.1). All female HIV-1 Tg and
control animals completed the concurrently conducted signal detection task by
approximately 9 months of age (PD 277), at which point food was subsequently available
ad libitum. During free-feeding, a first-order polynomial was the best fit for both HIV-1
Tg and control animals (R2s≥0.98), however, significant differences were observed in the
rate of growth [F(1,252)=13.2, p≤0.001]. The rate of increase in body weight was
significantly slower in HIV-1 Tg animals (β1=3.97±1.07(95% CI)) relative to control
animals (β1=7.16±1.32(95% CI)). The overall ANOVA confirmed these observations,
revealing a significant age x genotype interaction [F(7,210)=22.8, pGG≤0.001, ηp2=0.432]
with a prominent linear component [F(1,30)=34.4, p≤0.001, ηp2=0.534]. Significant main
effects of age [F(7,210)=224.6, pGG≤0.001, ηp2=0.882] and genotype [F(1,30)=59.9,
p≤0.001, ηp2=0.666] were also observed.
Cross-Modal Prepulse Inhibition: Auditory System Function
Auditory PPI (Figure 3.2) provided strong evidence for the integrity of auditory
system function in both HIV-1 Tg and control animals through the majority of the animal’s
functional lifespan. Control animals exhibited maximal inhibition at the 100 msec ISI at all
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test sessions. In sharp contrast, the maximal inhibition was observed at multiple ISIs in
HIV-1 Tg animals dependent upon age (i.e., PD 90: 30 msec; PD 120-PD 240: 100 msec;
PD 300: 50 msec; PD 360-PD 420: 200 msec; PD 480: 50 msec). A significant increase in
ASR as a function of age was observed in control animals, but not in HIV-1 Tg animals.
However, both HIV-1 Tg and control animals exhibited robust inhibition to the auditory
prepulse during all test sessions, suggesting the integrity of auditory system function.
The overall ANOVA conducted on the peak ASR amplitude values confirmed these
observations, revealing a significant age x ISI x genotype interaction [F(40,2440)=11.3,
pGG≤0.001, ηp2=0.157] with a prominent linear-quadratic component [F(1,61)=52.2,
p≤0.001, ηp2=0.461], and a significant age x ISI x sex interaction [F(40,2440)=7.8,
pGG≤0.001, ηp2=0.113] with a prominent quadratic-quadratic component [F(1,61)=34.1,
p≤0.001, ηp2=0.359]. Significant two-way interactions included an age x sex interaction
[F(8,488)=10.3, pGG≤0.001, ηp2=0.144] with a prominent quadratic component
[F(1,61)=31.6, p≤0.001, ηp2=0.341], a significant age x genotype interaction
[F(8,488)=14.2, pGG≤0.001, ηp2=0.188] with a prominent linear component [F(1,61)=42.9,
p≤0.001, ηp2=0.413], a significant ISI x sex interaction [F(5,305)=77.9, pGG≤0.001,
ηp2=0.561] with a prominent quadratic component [F(1,61)=85.7, p≤0.001, ηp2=0.584], a
significant ISI x genotype interaction [F(5,305)=127.2, pGG≤0.001, ηp2=0.676] with a
prominent quadratic component [F(1,61)=139.1, p≤0.001, ηp2=0.695], and a significant
age x ISI interaction [F(40,2440)=29.3, pGG≤0.001, ηp2=0.324] with a prominent linearquadratic component [F(1,61)=113.5, p≤0.001, ηp2=0.651]. Significant main effects of age
[F(8,488)=42.7, pGG≤0.001, ηp2=0.412], ISI [F(5,305)=764.7, pGG≤0.001, ηp2=0.926], sex
[F(1,61)=91.4, p≤0.001, ηp2=0.600] and genotype [F(1,61)=124.9, p≤0.001, ηp2=0.672]
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were also observed. Further analyses were conducted to examine the locus of these
interactions.
The ASR at the point of maximal inhibition in auditory PPI was used to further
examine the significant age x ISI x genotype interaction (Figure A.1). A linear increase in
the ASR at the point of maximal inhibition, well-described using a global first-order
polynomial, was observed across age in both HIV-1 Tg and control animals (R2=0.70). No
significant differences in the rate of increase in the ASR at the point of maximal inhibition
were observed between genotypes [F(2,14)=3.2, p≥0.05]. The ASR at the point of maximal
inhibition increased at the same rate in HIV-1 Tg (β1=0.028±0.01 (95% CI)) and control
animals (β1=0.017±0.01 (95% CI)) suggesting the integrity of the auditory system. Thus,
both control and HIV-1 Tg animals displayed robust inhibition to the auditory prepulse,
albeit at different ISIs, at all test sessions, suggesting the integrity of auditory system
function through advancing age.
Cross-Modal Prepulse Inhibition: Visual System Function
Visual PPI revealed the integrity of visual system function in HIV-1 Tg and control
animals through the majority of the animal’s functional lifespan, illustrated in Figure 3.3.
Control animals, but not HIV-1 Tg animals, exhibited a significant increase in ASR as a
function of age. However, both HIV-1 Tg and control animals exhibited robust inhibition
to the visual prepulse at the 50 msec ISI at all test sessions, suggesting the integrity of
visual system function.
The overall ANOVA conducted on the peak ASR amplitude values confirmed these
observations, revealing significant higher-order interactions, including an age x ISI x
genotype x sex interaction with a prominent quadratic-quadratic component [F(1,61)=5.0,
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p≤0.029, ηp2=0.076], an age x genotype x sex interaction with a prominent quadratic
component [F(1,61)=4.9, p≤0.031, ηp2=0.074], an age x ISI x genotype interaction
[F(40,2440)=9.0, pGG≤0.001, ηp2=0.129] with a prominent linear-quadratic component
[F(1,61)=78.1, p≤0.001, ηp2=0.561], an age x ISI x sex interaction [F(40,2440)=4.3,
pGG≤0.001, ηp2=0.066] with a prominent quadratic-quadratic component [F(1,61)=38.6,
p≤0.001, ηp2=0.387], and an ISI x sex x genotype interaction [F(5,305)=4.4, pGG≤0.013,
ηp2=0.068] with a prominent quadratic component [F(1,61)=6.5, p≤0.013, ηp2=0.096].
Significant two-way interactions included, an age x sex interaction [F(8,488)=10.8,
pGG≤0.001, ηp2=0.151] with a prominent quadratic component [F(1,61)=37.0, p≤0.001,
ηp2=0.377], an age x genotype interaction [F(8,488)=13.4, pGG≤0.001, ηp2=0.180] with a
prominent linear component [F(1,61)=35.1, p≤0.001, ηp2=0.365], an ISI x sex interaction
[F(5,305)=60.9, pGG≤0.001, ηp2=0.500] with a prominent quadratic component
[F(1,61)=79.2, p≤0.001, ηp2=0.565], an ISI x genotype interaction [F(5,305)=149.5,
pGG≤0.001, ηp2=0.710] with a prominent quadratic component [F(1,61)=190.6, p≤0.001,
ηp2=0.758], and an age x ISI interaction [F(40,2440)=15.6, pGG≤0.001, ηp2=0.204] with a
prominent

quadratic-quadratic

Significant

main effects

component

[F(1,61)=113.8,

of age [F(8,488)=46.9,

p≤0.001,

pGG≤0.001,

ηp2=0.651].

ηp2=0.435], ISI

[F(5,305)=658.6, pGG≤0.001, ηp2=0.915], sex [F(1,61)=71.7, p≤0.001, ηp2=0.540] and
genotype [F(1,61)=108.2, p≤0.001, ηp2=0.640] were also observed.
Complementary analyses of the ASR at the point of maximal inhibition (i.e., 50
msec) in visual PPI were conducted to examine the significant age x ISI x genotype
interaction (Figure A.1). A linear increase in the ASR at the point of maximal inhibition
was observed as a function of age in both HIV-1 Tg and control animals, well-described
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using a first-order polynomial (R2s≥0.64). Significant differences in the rate of increase
between genotypes were observed [F(1,14)=14.5, p≤0.002]. The ASR at the point of
maximal inhibition increased faster in HIV-1 Tg animals (β1=0.14±0.03 (95% CI)) relative
to control animals (β1=0.07±0.03 (95% CI)), however, both HIV-1 Tg and control animals
exhibited robust inhibition (i.e., ≥55% inhibition) to the visual prestimulus at all test
sessions. Thus, visual PPI provides strong evidence for the integrity of visual system
function through advancing age in both HIV-1 Tg and control animals.
Locomotor Activity: Motor System Function
The mean number of photocell interruptions in a 60-minute locomotor activity test
session were used to assess motoric system function through advancing age in HIV-1 Tg
and control animals (Figure 3.4). A one-phase decay was the best fit for HIV-1 Tg and
control animals (R2s≥0.91), however, a significant difference was observed between the
best fit function [F(3,12)=41.1, p≤0.001]. Specifically, control animals, relative to HIV-1
Tg animals, exhibited a significantly greater mean number of photocell interruptions from
PD 90 to PD 180. No significant differences in the mean number of photocell interruptions
were observed between HIV-1 Tg and control animals at PD 240 or PD 300. At PD 360
and all subsequent test sessions, HIV-1 Tg animals displayed a significantly greater mean
number of photocell interruptions in comparison to controls. The repeated measures
ANOVA confirmed these observations, revealing a significant age x genotype interaction
[F(8,448)=20.5, pGG≤0.001, ηp2=0.251] with a prominent linear component [F(1,61)=96.9,
p≤0.001, ηp2=0.614], and a significant age x sex interaction [F(8,448)=2.2, pGG≤0.039,
ηp2=0.035] with a prominent quadratic component [F(1,61)=9.8, p≤0.003, ηp2=0.139].
Significant main effects of age [F(8,448)=102.4, pGG≤0.001, ηp2=0.627], and sex
[F(1,61)=10.5, p≤0.002, ηp2=0.147] were also observed. Therefore, neither HIV-1 Tg nor
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control animals exhibited any gross-motoric system impairments, evidenced using the
mean number of photocell interruptions, suggesting the integrity of motor system function
though advancing age.
Understanding the Progression of HIV-1 Associated Neurocognitive Disorders
Cross-Modal Prepulse Inhibition (Auditory): Temporal Processing
In auditory PPI, area of the inflection of the ASR response curve, a measure of PPI,
was used to establish the progression of temporal processing, illustrated in Figure 3.5. HIV1 Tg animals exhibited a profound alteration in the progression of temporal processing
relative to control animals. A segmental linear regression was the best fit for both HIV-1
Tg and control animals (R2s≥0.91). However, a leftward shift in maximal PPI was observed
in HIV-1 Tg animals relative to controls. Specifically, control animals exhibited a linear
increase in PPI through approximately PD 300, followed by a subsequent decrease. HIV-1
Tg animals displayed a leftward shift, with maximal peak inhibition observed at
approximately PD 270, followed by a subsequent decrease.

The overall ANOVA

confirmed these observations, revealing a significant age x genotype interaction
[F(8,488)=11.8, pGG≤0.001, ηp2=0.162] with a prominent linear component [F(1,61)=35.2,
p≤0.001, ηp2=0.366] and a significant age x sex interaction [F(8,488)=8.5, pGG≤0.001,
ηp2=0.123] with a prominent quadratic component [F(1,61)=31.9, p≤0.001, ηp2=0.343].
Significant main effects of genotype [F(1,61)=123.3, p≤0.001, ηp2=0.669], age
[F(8,488)=35.4, pGG≤0.001, ηp2=0.367], and sex [F(1,61)=85.1, p≤0.001, ηp2=0.583] were
also observed.
Separate analyses of each genotype were conducted to examine the locus of these
interactions (Figure 3.5). A segmental linear regression was the best fit for both male and
female control animals (R2s ≥0.90). Both male and female control animals exhibited
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maximal PPI at approximately PD 300, followed by a subsequent decrease. However, a
significant difference in the rate of temporal processing development from PD 90 to PD
300 was observed [F(1,12)=12.4, p≤0.004]. Specifically temporal processing development
was significantly greater in male control animals (β1=4815±1645) relative to female
control animals (β1=2387±367.5); no significant differences between males and females
were observed in the rate of temporal processing decline [F(1,12)=2.7, p≥0.05]. The overall
ANOVA for control animals confirmed these observations, revealing a significant age x
sex interaction [F(8,256)=4.5, pGG≤0.001, ηp2=0.122] with a prominent quadratic
component [F(1,32)=16.3, p≤0.001, ηp2=0.337]. Significant main effects of age
[F(8,256)=34.6, pGG≤0.001, ηp2=0.519] and sex [F(1,32)=80.3, p≤0.001, ηp2=0.715] were
also observed. For HIV-1 Tg animals, a segmental linear regression, with maximal PPI at
approximately PD 270, was the best fit for male HIV-1 Tg animals (R2=0.88). In sharp
contrast, female HIV-1 Tg animals failed to exhibit any significant development of
temporal processing, best fit using a horizontal line. The overall ANOVA for HIV-1 Tg
animals confirmed these observations, revealing a significant age x sex interaction
[F(8,232)=5.5, pGG≤0.001, ηp2=0.160] with a prominent quadratic component
[F(1,29)=16.7, p≤0.001, ηp2=0.366]. Significant main effects of age [F(8,232)=5.3,
pGG≤0.001, ηp2=0.154] and sex [F(1,29)=24.1, p≤0.001, ηp2=0.454] were also observed.
Thus, regardless of biological sex, HIV-1 Tg animals exhibited significant alterations in
the development of temporal processing, albeit alterations which are more profound in
female HIV-1 Tg animals.
Cross-Modal Prepulse Inhibition (Visual): Temporal Processing
In visual PPI (Figure 3.6), HIV-1 Tg rats exhibited a significant alteration in the
development of temporal processing, indexed using PPI, relative to controls. A segmental
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linear regression was the best fit for both HIV-1 Tg and control animals (R2s≥0.70). HIV1 Tg animals exhibited a significant leftward shift in maximal PPI relative to control
animals. Specifically, control animals exhibited a linear increase in PPI through PD 360,
followed by a subsequent decrease. In contrast, HIV-1 Tg animals displayed maximal PPI
at PD 300, followed by a subsequent decrease. The overall ANOVA on mean area of the
amplitude inflection curve confirmed these observations, revealing a significant age x
genotype interaction with a prominent linear component [F(1,61)=17.5, p≤0.001,
ηp2=0.223], a significant age x sex interaction [F(8,488)=4.4, pGG≤0.001, ηp2=0.068] with
a prominent linear component [F(1,61)=16.4, p≤0.001, ηp2=0.211], and a significant
genotype x sex interaction [F(1,61)=4.8, p≤0.032, ηp2=0.073]. Significant main effects of
genotype [F(1,61)=23.6, p≤0.001, ηp2=0.279], age [F(8,488)=10.3, pGG≤0.001, ηp2=0.145]
and sex [F(1,61)=69.9, p≤0.001, ηp2=0.534] were also observed.
Complementary analyses were conducted for each genotype to determine the locus
of these interactions (Figure 3.6). A segmental linear regression provided a well-described
fit for both male and female control animals (R2s≥0.82). Male control animals exhibited a
significant increase in PPI through PD 360, followed by a subsequent decrease. Female
control animals, however, exhibited rightward shift, with maximal PPI observed at PD
420, followed by a subsequent decrease. Differences in the rate of temporal processing
development were also observed, with female control animals exhibiting slower
development (β1=626.4±201.2) relative to male animals (β1=1852±874.8). The overall
ANOVA confirmed these observations, revealing a significant age x sex interaction
[F(8,256)=3.6, pGG≤0.003, ηp2=0.102] with a prominent linear component [F(1,32)=16.3,
p≤0.001, ηp2=0.338]. Significant main effects of age [F(8,256)=11.5, pGG≤0.001,
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ηp2=0.264] and sex [F(1,32)=103.0, p≤0.001, ηp2=0.763] were also observed. Male and
female HIV-1 Tg animals were also best fit using a segmental linear regression (R2s≥0.62).
Male HIV-1 Tg animals exhibited maximal PPI at approximately PD 300, while a
rightward shift, with maximal PPI at PD 420, was observed in female HIV-1 Tg rats.
Biological sex altered the rate of temporal processing development in HIV-1 Tg rats, with
slower development observed in female HIV-1 Tg rats (β1=201.8±127.1) relative to male
HIV-1 Tg rats (β1=1400±1097.5). The overall ANOVA confirmed these observations,
revealing a significant main effect of age with a prominent linear component
[F(1,29)=13.9, p≤0.001, ηp2=0.324] and sex [F(1,29)=12.3, p≤0.002, ηp2=0.297].
Locomotor Activity: Intrasession Habituation
The progression of intrasession habituation, used to assess long-term episodic
memory, is illustrated in Figure 3.7. A one-phase decay was the best fit for HIV-1 Tg and
control animals at all test sessions, however, significant differences between the best fit
line were observed. Specifically, at PD 90 and PD 120, control animals, compared to HIV1 Tg animals, exhibited a greater number of mean photocell interruptions, during the latter
half of the test session. In contrast, at PD 300 and all subsequent test sessions, HIV-1 Tg
animals displayed a greater number of mean photocell interruptions in the latter half of the
session relative to controls.
The overall ANOVA confirmed these observations, revealing a significant age x
time x genotype interaction [F(88,5368)=1.6, pGG≤0.025, ηp2=0.0.25] with a prominent
linear-quadratic component [F(1,61)=20.5, p≤0.001, ηp2=0.252]. Significant two-way
interactions included an age x genotype interaction [F(8,488)=20.5, pGG≤0.001, ηp2=0.252]
with a prominent linear component [F(1,61)=96.9, p≤0.001, ηp2=0.614], an age x sex
interaction [F(8,488)=2.2, pGG≤0.039, ηp2=0.035] with a prominent quadratic component
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[F(1,61)=9.8, p≤0.003, ηp2=0.139], a time x genotype interaction [F(11,671)=18.3,
pGG≤0.001, ηp2=0.231] with a prominent linear component [F(1,61)=38.4, p≤0.001,
ηp2=0.386], a time x sex interaction [F(11,671)=5.0, pGG≤0.002, ηp2=0.076] with a
prominent linear component [F(1,61)=10.6, p≤0.002, ηp2=0.148], and an age x time
interaction [F(88,5368)=8.6, pGG≤0.001, ηp2=0.124] with a prominent linear-linear
component [F(1,61)=221.5, p≤0.001, ηp2=0.784]. Significant main effects of age
[F(8,488)=102.4, pGG≤0.001, ηp2=0.627], time [F(11,671)=1408.1, pGG≤0.001, ηp2=0.958],
and sex [F(1,61)=10.5, p≤0.002, ηp2=0.147] were also observed. Thus, HIV-1 Tg animals
failed to exhibit intrasession habituation, evidenced by significantly greater activity in the
latter half of the test session, through advancing age, suggesting an impairment in longterm episodic memory.
DISCUSSION
Two interrelated goals were pursued to authenticate the utility of the HIV-1 Tg rat
for the study of progressive neurocognitive deficits, a sequelae of long-term HIV-1 viral
protein exposure (Vigorito et al., 2015). First, the integrity of auditory and visual sensory
system function, assessed using cross-modal PPI, and motoric system function, examined
using locomotor activity, was established. The integrity of sensory and motor systems in
the HIV-1 Tg rat confirms the utility of the HIV-1 Tg rat in longitudinal experimental
designs to determine the progression of HAND. Second, the progression of neurocognitive
impairments, including temporal processing and long-term episodic memory, in the HIV1 Tg rat were evaluated; the factor of biological sex was integral to the experimental design.
Regardless of sex, HIV-1 Tg animals, relative to controls, displayed significant alterations
in the development of auditory and visual PPI, suggesting a deficit in temporal processing.
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However, significant sex differences in the progression of temporal processing were
observed, with female HIV-1 Tg animals exhibited more pronounced deficits relative to
male HIV-1 Tg animals. An impairment in long-term episodic memory, evidenced by
significant alterations in intrasession habituation, was also observed in HIV-1 Tg animals
relative to controls. Understanding the progression of HAND heralds an opportunity for
the development of an advantageous model of neurocognitive deficits in HIV-1 and
establishes critical groundwork for the development of neurorestorative and/or
preventative treatments.
The integrity of sensory system function through advancing age in HIV-1 Tg and
control animals was assessed using cross-modal PPI. Robust inhibition to the presence of
auditory and visual prepulses was observed at all test sessions, confirming the integrity of
sensory system function in both HIV-1 Tg and control animals. Notably, the phenotypic
cataracts observed in the HIV-1 Tg rat do not prevent the animal from detecting brightness;
visual acuity, however, has not yet been systematically investigated in the HIV-1 Tg rat.
Robust inhibition to auditory, visual, and tactile prepulses have been previously observed
in HIV-1 Tg and control animals, albeit at younger ages (e.g., 2-6 months of age, Moran et
al., 2013a; 8-10 months of age, McLaurin et al., 2017a, McLaurin et al., 2017b). The
present study provides a longitudinal assessment through the majority of the animal’s
functional lifespan, providing strong evidence for the integrity of sensory system function
in the HIV-1 Tg rat.
Motoric system function was assessed using locomotor activity in HIV-1 Tg and
control animals through advancing age. From PD 90 to PD 180, control animals exhibited
a significantly greater number of mean photocell interruptions during the sixty-minute test
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session, consistent with previous reports of decreased motor movement in HIV-1 Tg
animals early (i.e., between 3-6 months) in development (June et al., 2009). No significant
differences in the number of photocell interruptions between HIV-1 Tg and control animals
were observed at PD 240 or PD 300. However, beginning at PD 360, and at all subsequent
test sessions, HIV-1 Tg animals exhibited a significantly greater number of mean photocell
interruptions relative to control animals. Thus, neither HIV-1 Tg nor control animals
displayed gross-motoric system impairments through advancing age, indicative of the
integrity of motor system function.
The overall health of HIV-1 Tg and control animals through advancing age was
also assessed using growth rate. HIV-1 Tg animals, regardless of sex, weighed significantly
less than control animals, but exhibited steady growth through PD 480 (approximately 16
months of age). The rate of growth, however, was significantly slower in male and female
HIV-1 Tg animals relative to their control counterparts. Previous observations have
reported no significant differences in the rate of growth, however, observations were
restricted to younger animals (e.g., Peng et al., 2010; Moran et al., 2012; Moran et al.,
2013b; Moran et al., 2014a; Roscoe et al., 2014). Early adulthood food restriction, as in the
present study, may have played a role in altering the growth trajectory of HIV-1 Tg
animals.
It is noteworthy that the observations in the present study (i.e., growth rates,
integrity of sensory system function, intact motoric system function), differ from those
reported in the original derivation of the HIV-1 Tg (Sprague-Dawley) rat, with transgene
expression on chromosomes 2 and 9 (Reid et al., 2001). Specifically, Reid et al. (2001)
reported relatively early wasting (i.e., 5-9 months of age), hind-limb paralysis, and AIDS
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related organ pathologies. However, the current derivation of the HIV-1 Tg (F344/N) rat,
used in the present study, is a healthier derivation of those originally described, with
transgene expression limited to chromosome 9. In the present study, HIV-1 Tg rats
exhibited no alterations in sensory system function (i.e., auditory or visual) or motor system
function through advancing age. The integrity of gustatory system function has also been
established using both one-bottle (Peng et al., 2010) and five-bottle (Bertrand et al., 2013)
sucrose taste preference tests, which revealed no significant differences between HIV-1 Tg
and control animals in sucrose consumption at any concentration. Thus, the present studies
provide strong evidence for the functional health of the HIV-1 Tg rat through the majority
of the animal’s functional lifespan, suggesting the utility of the HIV-1 Tg rat in studies of
the progression of neurocognitive deficits, including temporal processing and long-term
episodic memory, commonly observed in HAND.
Prominent alterations in the progression of temporal processing, indexed using the
area of inflection of the ASR amplitude response curve (McLaurin et al., 2016b), were
observed in HIV-1 Tg animals, regardless of sex, relative to controls using cross-modal
PPI. HIV-1 Tg animals displayed a significant leftward shift in the age at which maximal
PPI was observed in both auditory and visual PPI. Specifically, in auditory PPI, control
animals exhibited a significant increase in PPI as a function of age through approximately
PD 300, followed by a subsequent decrease. HIV-1 Tg animals, however, displayed
maximal PPI at approximately PD 270, followed by a subsequent decrease. In visual PPI,
control animals exhibited an increase in PPI as a function of age through PD 360, followed
by a subsequent decrease. In contrast, HIV-1 Tg animals displayed a significant leftward
shift, with maximal PPI observed at PD 300. The present study establishes, via longitudinal
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assessment, alterations in the progression of temporal processing through the majority of
the functional lifespan of the HIV-1 Tg rat.
Temporal processing deficits in the HIV-1 Tg rat may result from DAergic system
dysfunction, which has been implicated as a key target of HIV-1 infection. Alterations in
DA system function have previously been reported using multiple techniques in the HIV1 Tg rat, including immunofluorescence and Western blots (Webb et al., 2010; Moran et
al., 2012; Reid et al., 2016a), as well as [18F] fallypride PET (Lee et al., 2014). The serial
circuitry involved in PPI, established using lesioning (e.g., Fendt et al., 1994; Leitner &
Cohen, 1985) and electrical stimulation studies (Li et al., 1998; Li & Yeomans, 2000),
includes the brainstem and pedunculuopontine pathways. Alterations in the DAergic inputs
at multiple points within the serial circuitry mediating PPI have downstream effects,
ultimately altering startle response (Koch et al., 1999). The nucleus accumbens (Nac),
which receives DAergic inputs from the ventral tegmental area (VTA), may be a critical
loci for the regulation of PPI (Swerdlow et al., 1992). Specifically, the medial prefrontal
cortex (mPFC), which exhibits thinning in HIV-1 seropositive humans (Thompson et al.,
2005), may mediate DA release from the Nac via glutamateric projections (Koch et al.,
1999). Decreased DAergic activity in the prefrontal cortex (PFC) increases DA release in
the Nac (Koch et al., 1999); an effect which may be mediated by the glutamateric projection
from the PFC to the VTA (Taber & Fibiger, 1995).
Pharmacological and behavioral studies have also been used to establish the role of
DA in PPI (review, Geyer et al., 2001). Administration of DA agonists, including
apomorphine (e.g., Fitting et al., 2006b), SCH 39166 (e.g., Ellenbroek et al., 1996),
sulpiride (e.g., Ellenbroek et al., 1996), and amphetamine (e.g., Mansbach et al., 1998;
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Zhang et al., 2000), produced a marked decrease in PPI. Administration of apomorphine
subcutaneously in Sprague-Dawley rats stereotaxically injected with gp120, a HIV-1 viral
protein, produced significant alterations in PPI, evidenced by a decrease in startle response
amplitude and an insensitivity to the manipulation of ISI (Fitting et al., 2006b); results
which are comparable to temporal processing deficits observed in the HIV-1 Tg rat.
Significant reductions in PPI were also observed following local injections of either
SCH39166 or sulpiride into the mPFC (Ellenbroek et al., 1996). Examination of the
neurotransmitter adenosine, which may interact with DA in the CNS (Ferré et al., 1992),
provides additional evidence for the role of DA in the regulation of PPI (e.g., Hauber &
Koch, 1997). Thus, DA system dysfunction in the HIV-1 Tg rat may underlie alterations
in the progression of temporal processing deficits observed in the present study.
Profound alterations in the progression of intrasession habituation were observed
in the HIV-1 Tg rat in comparison to control animals, suggesting an impairment in longterm episodic memory. Beginning at PD 300 and at all subsequent test sessions, HIV-1 Tg
animals displayed significant deficits in intrasession habituation, evidenced by a higher
level of activity during the latter half of the session; a pattern compatible with impairment
in long-term episodic memory. Multiple experimental paradigms (e.g., locomotor activity,
rotarod, wheel running) have revealed alterations in both intrasession habituation (Moran
et al., 2013b) and intersession habituation (Chang et al., 2006; Reid et al., 2016b) in the
HIV-1 Tg rat. The present study, using a longitudinal experimental design, confirmed
robust alterations in intrasession habituation through the majority of the functional lifespan
of the HIV-1 Tg rat.
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Alterations in intrasession habituation may also result from DA system
dysfunction. Multiple pharmacological studies have provided evidence for the role of DA
in intrasession habituation (Carlsson, 1972; Giros et al., 1996, Wong et al., 2003).
Specifically, administration of apomorphine, a DA agonist, in rats produced decreased
intrasession habituation (Carlsson, 1972). DA transporter (Giros et al., 1996) and D1
receptor knockout mice (Wong et al., 2003) also exhibited decreased intrasession
habituation in locomotor activity. Additional studies are needed, however, to determine
whether alterations in intrasession habituation result from the effects of increased DA on
the motor system (Leussis & Bolivar, 2006). Notably, DA release may also be critical for
the formation of long-term episodic memories, commonly assessed in animal models using
intrasession habituation. Lisman and Grace (2005) proposed the hippocampus-VTA loop,
suggesting that DA release from the hippocampus may be vital for long-term episodic
memory encoding and retrieval. A pharmacological study found that infusion of a DA
antagonist into the rat hippocampus prior to encoding impairs long-term memory (Bethus
et al., 2010).
The assessment of sex differences was an integral component of the experimental
design, addressing the need for direct comparisons of neurocognitive deficits in males and
females in both clinical and preclinical studies (Maki & Martin-Thormeyer, 2009; Maki et
al., 2015). The factor of biological sex may moderate the progression of neurocognitive
deficits, including temporal processing, in the HIV-1 Tg rat. Female HIV-1 Tg animals,
compared to male HIV-1 Tg animals, exhibited more prominent deficits in temporal
processing. Specifically, in auditory PPI, female HIV-1 Tg animals failed to display any
significant development in temporal processing as a function of age. In visual PPI, female
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HIV-1 Tg animals, exhibited a slower development of PPI, relative to male HIV-1 Tg
animals. Sex differences in the progression of temporal processing extend those reported
in auditory gap-PPI, examined using an early, time-limited longitudinal experimental
design (McLaurin et al., 2016b), suggesting the generality and relative permanence of these
deficits. In sharp contrast, neither compelling nor consistent sex differences were observed
in the progression of intrasession habituation. Thus, biological sex may selectively
moderate the influence of the HIV-1 transgene on the progression of neurocognitive
deficits.
The present study provides a critical foundation for future studies examining the
progression of executive function and attention deficits, which are commonly altered in
HIV-1 seropositive individuals (Heaton et al., 2010; Heaton et al., 2011). For example,
signal detection tasks (McGaughy & Sarter, 1995), which rely on intact sensory and
motoric system function, can be used to assess sustained attention, as well as more complex
executive functions, including inhibition and flexibility. In signal detection, the presence
or absence of a stimulus (i.e., houselight, auditory tone) indicates the response an animal
must make (i.e., which lever to press) to receive a reinforcer. We have previously used the
signal detection task to assess cognitive functions in the HIV-1 Tg rat, reporting significant
deficits in sustained attention, flexibility and inhibition (Moran et al., 2014a). However, a
systematic evaluation of the progression of sustained attention deficits, and the effect of
biological sex, in the HIV-1 Tg rat is needed.
Establishing the integrity of auditory and visual system function, as well as motoric
system function, suggests the utility of the HIV-1 Tg rat for examining the progression of
HAND. Further, results of the present study substantiated significant alterations in the
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progression of temporal processing, which may underlie executive function and attentional
deficits commonly observed in the post-cART era (Heaton et al., 2010; Heaton et al., 2011).
Additionally, alterations in the progression of intrasession habituation, suggestive of an
impairment in long-term episodic memory, were observed. Results provide a strong
foundation for future studies assessing the progression of executive function deficits, and
the effect of biological sex, in the HIV-1 Tg rat using a longitudinal experimental design.
Understanding the progression of HAND, heralds an opportunity for the development of
an advantageous model of neurocognitive deficits in HIV-1 and establishes critical
groundwork for the development of neurorestorative treatments.

59

A

Male

500

Control
HIV-1 Tg

400
300
200

5

4

0

3

Weight (g 95% CI)

100

6

8

10

12

14

16

Age (Months)

B

Female

300
250
200
150
100
50

8

7

6

5

4

3

0
9 10 11 12 13 14 15 16

Age (Months)

Figure 3.1 Body Weight. Mean body weight is
illustrated for both males (A) and females (B) as a
function of genotype (HIV-1 Tg vs. control) and age
(±95% CI). HIV-1 Tg animals, regardless of sex,
weighed significantly less than control animals, but
exhibited steady growth through approximately 16
months of age. Notably, after a prior history of food
restriction, both male and female HIV-1 Tg animals
grew at a significantly slower rate relative to controls.
The x-axis break at 6 months for males and 9 months
for females indicates the point at which all animals were
again receiving food ad libitum.
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Figure 3.2 Auditory System Function. Mean peak ASR amplitude (±SEM) for auditory
PPI is illustrated for all test sessions as a function of genotype (HIV-1 Tg vs. Control).
Both HIV-1 Tg and control animals exhibited robust inhibition to the auditory prepulse at
all ages, albeit at different ISIs, suggesting the integrity of auditory system function through
the majority of the animal’s functional lifespan.
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Figure 3.3 Visual System Function. Mean peak ASR amplitude (±SEM) for visual PPI is
illustrated for all test sessions as a function of genotype (HIV-1 Tg vs. Control). Maximal
inhibition was observed at the 50 msec ISI for both HIV-1 Tg and control animals at all
test sessions. Robust inhibition to the visual prepulse was observed in both HIV-1 Tg and
control animals at all assessments, suggesting the integrity of visual system function
through the majority of the animal’s functional lifespan.
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Figure 3.4 Gross-Motoric System Function. Mean number of photocell
interruptions in a 60-minute locomotor activity test session are illustrated as
a function of genotype (HIV-1 Tg vs. control) and age (±95% CI). A onephase decay was the best fit for HIV-1 Tg and control animals, however,
significant differences in the fit of the function were observed [F(3,12)=41.1,
p≤0.001]. From PD 90 to PD 180, control animals exhibited a significantly
greater number of mean photocell interruptions relative to HIV-1 Tg
animals. However, beginning at PD 360 and all subsequent test sessions,
HIV-1 Tg animals, compared to controls, displayed a significantly greater
number of mean photocell interruptions. Results, therefore, suggest no grossmotoric impairments in either HIV-1 Tg or control animals through
advancing age.
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Figure 3.5 Progression of Temporal Processing: Auditory PPI. Auditory PPI,
assessed using mean area of the peak inflection curve, is illustrated as a function of
genotype (HIV-1 Tg vs. control) and age (±95% CI). (A) A segmental linear
regression was the best fit for HIV-1 Tg and control animals (R2s≥0.91). Temporal
processing in control animals was well-described using a segmental linear regression,
with maximal PPI observed at PD 300. In contrast, HIV-1 Tg animals displayed a
prominent leftward shift, with maximal inhibition observed at approximately PD 270.
(B) A segmental linear regression was the best fit for both male and female (R2s
≥0.90) control animals, with maximal PPI occurring at approximately PD 300.
However, female control animals exhibited a significantly slower rate of temporal
processing development from PD 90 to PD 300 compared to male control animals.
(C) A segmental linear regression, with maximal PPI at approximately PD 270,
provided a well-described fit for male HIV-1 Tg animals (R2=0.88). Female HIV-1
Tg animals, however, failed to exhibit any significant temporal processing
development as a function of age, best fit using a horizontal line. Thus, regardless of
sex, HIV-1 Tg animals displayed significant alterations in the progression of temporal
processing, assessed using auditory PPI, compared to control animals.
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Figure 3.6 Progression of Temporal Processing: Visual PPI. Visual PPI, assessed using
mean area of the peak inflection curve, is illustrated as a function of genotype (HIV-1 Tg
vs. control) and age (±95% CI). (A) A segmental linear regression was the best fit function
for both HIV-1 Tg and control animals (R2s≥0.70), A significant leftward shift in the point
of maximal inhibition was observed in HIV-1 Tg animals (PD 300) relative to control
animals (PD 360). (B) Significant alterations in the development of temporal processing
were observed in control animals dependent upon biological sex. Specifically, both male
and female control animals were best fit using a segmental linear regression (R2s ≥0.82).
Male control animals exhibited a significant increase in PPI through PD 360, followed by
a subsequent decrease. In contrast, a rightward shift, with maximal PPI observed at PD
420, was observed in female control animals. (C) Biological sex moderated the progression
of temporal processing deficits in HIV-1 Tg animals. A segmental linear regression
provided a well-described fit for both male and female HIV-1 Tg animals, with maximal
PPI observed at PD 300 and PD 420 respectively (R2s≥0.62). The factor of biological sex,
however, altered the rate of temporal processing development in HIV-1 Tg rats, with
slower development observed in female HIV-1 Tg rats relative to male HIV-1 Tg rats.
HIV-1 Tg animals, regardless of sex, exhibited profound alterations in the progression of
temporal processing, assessed using visual PPI, relative to control animals.
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Figure 3.7 Long-Term Episodic Memory. Mean number of photocell interruptions
during locomotor habituation trials across twelve 5-min trial blocks are illustrated at all test
sessions as a function of genotype (HIV-1 Tg, control; ±95% CI). Significant alterations in
intrasession habituation in the HIV-1 Tg rat were observed at PD 300 and all subsequent
test sessions, evidenced by a higher level of activity during the latter half of the session.
Alterations in intrasession habituation suggest an impairment in long-term episodic
memory in HIV-1 Tg animals.
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INTRODUCTION
HIV-1 remains a human health pandemic, with approximately 36.7 million
individuals living with the disease worldwide (UNAIDS, 2017). Older individuals (>50
years of age) account for approximately 30-50% of HIV-1 seropositive individuals in highresource countries (UNAIDS, 2013) following the great success of cART; a prevalence
that is expected to reach approximately 73% by 2030 (Smit et al., 2015). In the post-cART
era, milder forms of NCI have become a hallmark of HIV-1, afflicting between 40-70% of
HIV-1 seropositive individuals (Letendre et al., 2010; McArthur et al., 2010; Heaton et al.,
2011). Cross-sectional studies have provided a wealth of knowledge on HAND,
characterized by deficits in higher-order cognitive processes (e.g., attention, working
memory, executive function: Heaton et al., 2011; Cysique et al., 2004). However,
extrapolating cross-sectional findings to age-related disease progression is inferentially
fraught (Kraemer et al., 2000), heralding an examination of the progression of HAND using
a longitudinal experimental design.
Since the seminal call for animal models of HIV-1/AIDS (WHO, 1988), there has
been no extant in vivo animal model system available to provide a truly longitudinal study
of HAND. The HIV-1 Tg rat, originally developed by Reid et al. (2001), contains a gagpol deleted provirus regulated by the human viral promoter. HIV-1 Tg rats exhibit general
good health through advancing age, displaying steady growth rates (Peng et al., 2010;
Roscoe et al., 2014; Moran et al., 2013a), intact sensory (i.e., auditory, visual, gustatory)
and motor system function (Peng et al., 2010; McLaurin et al., 2018b), and a lifespan of
approximately 21 months of age (Peng et al., 2010). Cross-sectional studies have critically
tested the utility of the HIV-1 Tg rat as a model for NCI; multiple laboratories have reported
alterations in temporal processing (e.g., Moran et al., 2013a), sustained attention (e.g.,
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Moran et al., 2014a), learning (Vigorito et al., 2007; Moran et al., 2014a), and memory
(Repunte-Canonigo et al., 2014). A longitudinal assessment of NCI for the progression of
HAND, and associated neural mechanisms, in the HIV-1 Tg rat, however, remains a critical
knowledge gap.
Thus, in the present study, the HIV-1 Tg rat was used to establish the trajectory of
NCI, in the absence of sensory or motor system deficits (McLaurin et al., 2018b) and
comorbidities, across the functional lifespan. It was hypothesized that HIV-1 Tg rats,
relative to F344/N controls, would display progressive, sex-dependent expression of NCI
across the function lifespan; impairments that were associated with synaptic dysfunction
in pyramidal neurons from layers II-III of the mPFC and/or neuroinflammatory markers in
the hippocampus. A longitudinal experimental design was used to assess multiple
neurocognitive domains, including learning, sustained attention, flexibility and inhibition,
from approximately PD 60 through PD 600. Associated neural mechanisms, including
synaptic dysfunction in the mPFC and putative markers of neuroinflammation in the
hippocampus were also evaluated. The progression of HAND with age in the HIV-1 Tg rat
and associated synaptic dysfunction in the mPFC affords an instrumental model system for
the development of therapeutics and functional cure strategies.
METHODS
Experimental Design
The experimental design for all neurocognitive assessments and neuroanatomical
assessments is illustrated in Figure 4.1.
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Animals
Across 12 months, Fischer (F344/N; Harlan Laboratories Inc., Indianapolis, IN)
HIV-1 Tg (N=20 litters) and control (N=17 litters) rats were received at the animal
vivarium, between PD 7 and PD 9, housed with their biological dam. At approximately PD
21, animals were sampled from each litter (HIV-1 Tg: male, n=37, female, n=33; Control:
male n=34; female, n=33), weaned and pair- or group-housed with animals of the same sex
for the duration of experimentation.
During the original acquisition of signal detection, animals were placed on food
restriction, beginning at approximately PD 60, to maintain 85% body weight. After animals
successfully acquired the signal detection task (PD 100-PD 277), rodent food was again
provided ad libitum, including during all retest assessments. HIV-1 Tg and control animals
had ad libitum access to water throughout the duration of the study.
HIV-1 Tg and control animals were sacrificed following the successful completion
of the reversal task at approximately 20 months of age to assess synaptic dysfunction in
pyramidal neurons from layers II-III of the mPFC and putative markers of
neuroinflammation in the hippocampus. Due to health issues, including significant weight
loss (n=23), tumors (n=6), natural death (n=3) or other (n=4), some animals were
euthanized prior to 20 months of age.
Recommendations in the Guide for the Care and Use of Laboratory Animals of the
NIH were used for the maintenance of HIV-1 Tg and control animals in AAALACaccredited facilities. The targeted environmental conditions for the animal vivarium were
21°± 2°C, 50% ± 10% relative humidity and a 12-h light:12-h dark cycle with lights on at
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0700 h (EST). The IACUC at the University of South Carolina approved the project
protocol (Federal Assurance # D16-00028).
Phase 1: Original Acquisition
Apparatus
Sixteen operant chambers, located inside sound-attenuating chambers (Med
Associates, Inc., VT) were used to train animals in a signal detection task tapping sustained
attention. A pellet dispenser (45 mg), located between two retractable levers, and three
panel lights were located on the front wall of the operant chambers. Only the panel light
located above the pellet dispenser was used in the present experiment. A house light was
located at the top of the rear wall of the operant chamber. The house light, used for shaping,
and central panel light, used for signal presentation during the original acquisition of signal
detection and retest assessments, were incandescent (22 lux). PC and Med-PC for Windows
software (V 4.1.3; Med Associates, Inc., Fairfax, VT) controlled signal presentation, lever
operation, reinforcement delivery, and data collection.
Shaping
A standard shaping response protocol was used to train animals to lever-press at
approximately 2 months of age, described in detail by McLaurin et al. (2017d). All animals
met criteria in shaping (i.e., 60 reinforcers for 3 consecutive or 5 non-consecutive days),
indicating learning the operant response, prior to beginning the signal detection task.
Signal Detection
Following successful acquisition of shaping, all HIV-1 Tg (N=20 litters; male,
n=37, female, n=33) and control animals (N=17 litters; male n=34; female, n=33) were
trained in a signal detection task, tapping sustained attention.
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Three vigilance programs, initially described by McGaughy and Sarter (1995),
were employed. In brief, animals were trained to discriminate between signal (i.e., central
panel light illumination) and non-signal (i.e., no illumination) trials. In the first vigilance
program, consisting of 160 trials per session, termination of the stimulus light was
contingent upon a response. In the second vigilance program, consisting of 160 trials per
session, the length of the stimulus light was 1 sec. Correction trials, including up to three
repetitions of the trial, and force-choice trials were an integral component of the first two
vigilance programs, and occurred when an animal responded incorrectly. In the third
vigilance program, consisting of 162 trials per session, the length of the stimulus was
manipulated (i.e., 1000, 500, 100 msec) across trials using a block randomized
experimental design. Correction trials and force-choice trials were removed in the third
vigilance program. During the initial acquisition, no data was censored i.e., each and every
animal successfully acquired the signal detection task. A preliminary report of original
acquisition, on approximately half of the animals, was presented in McLaurin et al.
(2017d). Additional methodological details are presented in the Appendix B.
Phase 2: Retest Assessments
Apparatus
Throughout the retest assessments, HIV-1 Tg and control animals were assessed in
the operant chambers described above.
Procedure
After the successful completion of original acquisition, HIV-1 Tg and control
animals were assessed in the final vigilance program with varying signal durations every
60 days through approximately 18 months of age. Animals were given up to 60 days to
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successfully complete each retest assessment and were assessed in up to 6 retest
assessments.
Phase 3: 18 Month Assessment
Apparatus
At the 18 Month Assessment, HIV-1 Tg and control animals were assessed in the
operant chambers described above with a minor modification. An LED light bulb (11 lux),
instead of an incandescent light bulb, was used for signal presentation during the 18 month
acquisition and reversal assessment due to the short (i.e., 10 msec) signal duration times.
Procedure
After the successful completion of the 6th retest assessment or at 18 months of age,
HIV-1 Tg and control animals were challenged with two tasks. First, HIV-1 Tg (N=20
litters; male, n=29, female, n=29) and control animals (N=17 litters; male n=28; female,
n=31) were challenged for 5-consecutive days with shorter signal durations (i.e., 1000, 100,
10 msec). Second, HIV-1 Tg (N=20 litters; male, n=18, female, n=29) and control animals
(N=17 litters; male n=27; female, n=28) were assessed in a reversal task, tapping flexibility
and inhibition. Response contingencies were reversed from those originally learned in the
signal detection task. Animals were given up to 60 days to successfully complete the
reversal assessment or were sacrificed at approximately 20 months of age after 45 days in
the task.
Phase 4: Neuroanatomical Assessments
Synaptic Dysfunction
Preparation of Tissue. Animals were deeply anesthetized using sevoflurane (Abbot
Laboratories, North Chicago, IL) and transcardially perfused using methodology adapted
from Roscoe et al. (2014).
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DiOlistic Labeling. A DiOlisitc labeling technique, originally described by Seabold
et al. (2010), was used to visualize pyramidal neurons from layers II-III of the mPFC.
Methodology for the preparation of DiOlistic cartridges, preparation of Tefzel tubing, and
DiOlistic labeling is described in detailed by McLaurin et al. (2018a).
Pyramidal Neuron Dendritic Analysis and Spine Quantification. Pyramidal
neurons from layers II-III of the mPFC, located approximately 3.7 mm to 2.2 mm anterior
to Bregma (Paxinos & Watson, 2014), were analyzed. Z-stack images were obtained using
methodology previously reported (Roscoe et al., 2014) on three to four pyramidal neurons
from each animal [Control: N=17 litters, male, n=31, female, n=30; HIV-1 Tg: N=20 litters,
male, n=35, female, n=33].
The AutoNeuron and AutoSpine extension modules, available in Neurolucida 360
(MicroBrightfield, Williston, VT), were used for the analysis of spine parameters.
Selection criteria, including continuous dendritic staining, low background/dye clusters,
and minimal diffusion of the DiI dye into the extracellular space, were used for spine
analysis. Based on the selection criteria, one neuron from each animal was chosen for the
analysis of spine parameters. Neurons not meeting the selection criteria were not included
in the analysis, yielding Control, N=16 litters, male, n=26, female, n=20, and HIV-1 Tg
N=19 litters, male, n=28, female, n=27.
Spine Parameters. An observer-assisted automatic classification of dendritic spines
(i.e., thin, mushroom, stubby) was conducted using an algorithm in Neurolucida 360
(Rodriguez et al., 2008). The number of segments at each branch order, an assessment of
dendritic branching complexity, was examined for branch orders 1 through 10. A Sholl
analysis was conducted to evaluate neuronal complexity (i.e., the number of intersections
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at each successive radii) and dendritic spine connectivity (i.e., the number of dendritic
spines between each successive radii). Some animals were excluded due to processing
errors, yielding Control, N=16 litters, male, n=21, female, n=18, and HIV-1 Tg N=17
litters, male, n=26, female, n=23. Subsequently, dendritic spine morphology was assessed
using three parameters, including backbone length (µm), head diameter (µm), and volume
(µm3). Spine parameters were defined using well-accepted previously published results
(i.e., backbone length, 0.1 to 4.1 µm: Ruszczycki et al., 2012; head diameter, 0 to 0.825
µm: Konur et al., 2003; volume, 0.05 to 0.5 µm3: Hering & Sheng, 2001).
Neuroinflammatory Markers
The selection of the hippocampus for the assessment of neuroinflammation was
based on the publication of Fitting et al. (2008b; 2010), which displayed frank cell loss in
the hippocampus from viral protein exposure, maximizing the likelihood of detecting
neuroinflammation.
Total RNA isolation and cDNA synthesis. Total RNA was isolated from 30 mg of
hippocampal tissue using RNeasy FFPE kit (QIAGEN) according to manufacturer’s
protocol (Control: N=17 litters, male, n=31 female, n=30; HIV-1 Tg: N=20 litters, male
n=32, female n=30). The total RNA quality and quantity were assessed by a Nano drop
spectrophotometer (Thermo Scientific, USA). One µg of total RNA from each sample was
converted into cDNA by Cloned AMV first-strand cDNA synthesis kit (Invitrogen) for
real-time PCR. The 20 μl first-strand cDNA synthesis reaction mixture contained 1 μl
random-hexamer primer, 1 µg total sample RNA sample, 2 μl of 10 mM dNTP mix, 5x
cDNA synthesis buffer, 1 μl of 0.1 M DTT, 1 μl RNaseOUT, 1 µl cloned AMV RT and 1
µl DEPC-treated water. The following conditions were used: 65 °C for 5 min, 25 °C for 10
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min, 50 °C for 50 min and terminated at 85 °C for 5 min. The cDNA products were used
immediately for further analysis.
Multiplex PCR (mPCR). Initially, hippocampal samples were probed for the
expression of TNF-α, IL-1β, IL-6, NFκ-β and Iκ-β, and the internal control, GAPDH.
Cytokine primers, a PCR reaction buffer containing dNTPs and a positive control were
provided in a commercial mPCR kit from Maxibio Company (Rat Inflammatory
Cytokines–Set 2, Cat. No. MP-70207, San Francisco, CA, as previously employed by
Moran et al. (2014b). However, there was no significant expression of TNF-α, IL-1β, IL6, NFκ-β or Iκ-β in samples from HIV-1 Tg or F344/N control animals. Accordingly, we
pursued analysis via real-time PCR.
Real-time PCR. The neuroinflammation related cytokines (TNF-α, IL-1β, IL-6)
were quantified using a real-time PCR detection system and SsoAdvanced Universal
SYBR Green Supermix kit (BIO-RAD). In brief, the 20 μl reaction mixture contained 10
μl 2x SsoAdvanced universal SYBR Green supermix, 1 μl forward primer and reverse
primers (250 nM each), 1 μl template (100 ng) and 7 μl of DEPC-treated water. Reactions
were performed with the DNA Engine Opticon 2 system (M J Research, USA) using the
following cycling conditions: 30 sec at 95 °C and 40 cycles of 15 sec at 95 °C and 30 sec
at 58 °C. Animals failing to reach threshold after 40 cycles were considered to have
undetectable gene expression and accordingly these censored data were not included in the
figures or statistical analysis, yielding Control, N=8-15 litters, male, n=7-18, female, n=812, and HIV-1 Tg N=11-13 litters, male, n=6-14, female, n=9-15, dependent upon gene.
The data were analyzed using Intuitive Opticon Monitor TM software. Each primer,
including the corresponding GenBank numbers, are listed in Table B.1, and β-Actin was
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used as an internal control. The relative gene expression of each neuroinflammatory marker
(i.e., TNF-α, IL-1β, IL-6) was analyzed using the 2-ΔΔCt method to examine relative changes
in expression dependent upon genotype and biological sex (Livak & Schmittgen, 2001).
Statistical Analysis
Given the nested experimental design (i.e., pups within litter), figures, created using
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA), represent litter means and
standard errors, dependent upon biological sex (Denenberg, 1984; Wears, 2002).
ANOVA and regression techniques were used for the analysis of all data
(SAS/STAT Software 9.4, SAS Institute, Inc., Cary, NC; SPSS Statistics 24, IBM Corp.,
Somer, NY; GraphPad Software, Inc., La Jolla, CA). For all statistical analyses, litter was
used as the unit of analysis to preclude the violation of the assumption of independence,
leading to an inflation of Type 1 error rate (Holson & Pearce, 1992). Orthogonal
decomposition of the repeated-measures factors or the conservative Greenhouse-Geisser df
correction factor (pGG; Greenhouse & Geisser, 1959) were used to preclude potential
violations of sphericity. Effect size was assessed using ηp2. An alpha value of p≤0.05 was
considered significant for all statistical tests. Additional details on the statistical analyses
are available in the Appendix B.
Data Availability Statement
All relevant data are within the paper.
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RESULTS
Phase 1: Original Acquisition
The factor of biological sex was the driving factor for observed differences in
the temporal process of acquisition and sustained attention during the initial
acquisition of signal detection.
Temporal Process of Acquisition. All HIV-1 Tg and control animals were able to
successfully acquire the task, achieving 70% accuracy for 5 consecutive or 7 nonconsecutive days in each of the three vigilance programs. Profound sex differences were
observed in the temporal process of task acquisition, best fit using a sigmoidal doseresponse curve (Figure 4.2; R2s≥0.98). Female animals, independent of genotype, acquired
the task significantly slower than male animals (Main Effect: Sex [F(1,61)=101.1,
p≤0.001]). Presence of the HIV-1 transgene failed to significantly alter the temporal
process of initial acquisition of signal detection (Figure 4.2; p>0.05).
Signal Detection. The factor of biological sex (Figure 4.2) was the driving factor
for observed differences in sustained attention during the initial acquisition of signal
detection. Female animals, collapsed across genotype, displayed a decreased response rate,
as well as a prominent rightward shift in the loss of signal detection (i.e., where the number
of hits and misses intersect), relative to male animals (approximately 535 msec vs. 436
msec, respectively; Sex x Response Type x Duration Interaction [F(2,122)=74.0,
pGG≤0.0001, ηp2=0.548, Power=1.0]) with a prominent linear-linear component
[F(1,61)=87.2, p≤0.0001, ηp2=0.588, Power=1.0]. In sharp contrast, presence of the HIV1 transgene failed to alter signal detection during initial acquisition (Figure 4.2; Genotype
x Response Type x Duration Interaction [p>0.05]).
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Phase 2: Retest Assessments
HIV-1 Tg animals, independent of biological sex, exhibited a progressive
impairment in task acquisition across retest assessment.
Days to Criteria. HIV-1 Tg and control animals were retested every 60 days in the
final vigilance program, which manipulated signal duration length (1000, 500, 100 msec).
Completion of the retest assessment required animals to meet criteria of 70% accuracy for
5 consecutive or 7 non-consecutive days. To assess the progression of task acquisition
across retest assessments, the number of days required for 80% of the population sampled
to meet criteria was quantified (Figure 4.3). Control animals displayed a continuous
improvement in task acquisition across retest assessments, reaching asymptotic
performance at approximately 7 days. In sharp contrast, HIV-1 Tg animals exhibited an
improvement in task acquisition through retest session 2, followed by a progressive
decline. Assessment of the temporal process of acquisition at each individual retest
assessment (Figure B.1) revealed a significant main effect of genotype (p≤0.05) at all retest
assessments.
Despite the “savings” afforded by repeated testing, HIV-1 Tg animals
displayed a progressive, relative impairment in the detection of shorter signal
durations.
Signal Detection. Across retest assessments, genotype became the driving factor
for observed differences in sustained attention. Independent of genotype, HIV-1 Tg and
control animals exhibited a significant improvement in the detection of shorter signal
durations across retest assessments (Figure 4.4). However, HIV-1 Tg animals displayed a
progressive, relative impairment in the detection of shorter signal durations relative to

79

control animals (Genotype x Response Type x Duration x Retest Assessment Interaction
[F(8,488)=2.2, pGG≤0.05, ηp2=0.034, Power=0.763] with a prominent quadratic-quadratic
component [F(1,61)=7.3, p≤0.009, ηp2=0.106, Power=0.756]). Specifically, HIV-1 Tg
animals took significantly longer to reach the same level of performance (e.g., Loss of
Signal Detection at 10 msec: Control animals (Retest 1); HIV-1 Tg animals (Retest 5)) and
failed to improve to the level of control animals at any retest assessment.
Relative to genotype, the factor of biological sex played a less prominent role in
the progression of sustained attention (Sex x Response Type x Duration x Retest
Assessment Interaction with a prominent linear-linear component [F(1,61)=5.3, p≤0.025,
ηp2=0.080, Power=0.622]). Female animals, independent of genotype, failed to improve to
the same level of performance as male animals.
Phase 3: 18 Month Assessment
A more challenging signal detection task at 18 months of age, in combination
with a reversal task, tapping flexibility and inhibition, revealed marked
impairment, dependent upon task and biological sex, in HIV-1 Tg rats relative
to control animals.
Temporal Process of Acquisition. At 18 months of age, HIV-1 Tg and control
animals were challenged for 5 consecutive days with shorter signal durations (i.e., 1000,
100, 10 msec). The number of days HIV-1 Tg and control animals met criterion was
analyzed using a curve-fitting analysis. For male animals, independent of genotype, an
exponential growth equation provided a well-described fit (Figure 4.5; R2s≥0.98).
However, significant differences in the parameters of the function were observed
(F(2,15)=57.4, p≥0.001), indicating a shift in the distribution, with male HIV-1 Tg animals
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meeting criterion on fewer days relative to male control animals. In sharp contrast, a global,
exponential growth equation (R2≥0.96) provided a well-described fit for female HIV-1 Tg
and control animals (Figure 4.5), indicating no significant genotype differences in the
number of days meeting criterion during the 18 month acquisition.
Subsequently, animals were assessed in a reversal task, tapping flexibility and
inhibition. Presence of the HIV-1 transgene had a profound effect on the temporal process
of acquisition in reversal, dependent upon the factor of biological sex (Figure 4.5;
Genotype x Sex Interaction: [F(1,51)=4.8, p≤0.033]).
Complementary analyses were conducted for each sex to determine the locus of the
interaction. In male animals (Figure 4.5), presence of the HIV-1 transgene significantly
altered the temporal process of acquisition with male HIV-1 Tg animals acquiring the task
significantly slower than male control animals (Main Effect, Genotype: [F(1,26)=9.5,
p≤0.005]). In sharp contrast, presence of the HIV-1 transgene failed to significantly alter
the temporal process of acquisition in female animals (Figure 4.5; p>0.05).
Signal Detection. Assessment of signal detection data revealed a significant Task x
Response Type x Duration x Genotype x Sex interaction [F(2,108)=7.2, pGG≤0.002,
ηp2=0.117, Power=0.886] with a prominent linear-quadratic component [F(1,54)=10.0,
p≤0.003, ηp2=0.156, Power=0.874].
Male HIV-1 Tg animals revealed marked impairment in signal detection relative to
male control animals evidenced by a significant rightward shift in the loss of signal
detection during the 18 month acquisition (Figure 4.6). During the reversal assessment,
male control animals displayed a significant increase in both the number of hits and misses,
suggesting an overtraining reversal effect. No significant alterations in the number of hits

81

and/or misses was observed in the male HIV-1 Tg animals, suggesting that, despite
extensive training, there was no improvement in their performance during the reversal task.
In sharp contrast, at 18 months of age, female HIV-1 Tg animals displayed no
impairment in the detection of shorter signal durations relative to female control animals
(Figure 4.6). However, female HIV-1 Tg animals, relative to female control animals,
exhibited marked impairment in the reversal task evidenced by an inability to reliably
detect the signal at any duration assessed.
Phase 4: Neuroanatomical Assessments
Selective alterations in neuronal morphology were observed in pyramidal
neurons from layers II-III of the medial prefrontal cortex in HIV-1 Tg
animals, suggesting an alteration in dendritic branching complexity, but not
neuronal arbor complexity or dendrite length.
Branch Order. A centrifugal branch ordering method was utilized in Neurolucida
360 to automatically assign each dendrite with a branch order by counting the number of
segments traversed. Presence of the HIV-1 transgene had a profound effect on the number
of dendritic branches at each branch order (Figure 4.7; Genotype x Branch Order
Interaction [F(1,952)=10.1, p≤0.002]). Specifically, HIV-1 Tg animals exhibited an
increased relative frequency of dendritic branches at lower branch orders relative to
controls, suggesting an alteration in dendritic branching complexity.
Sholl Analyses. Subsequently, a Sholl analysis was conducted as a complementary
measure of neuronal arbor complexity, whereby the number of dendritic intersections
occurring every 10 µm from the soma were quantified in HIV-1 Tg and control animals.
Neither presence of the HIV-1 transgene nor the factor of biological sex influenced the
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number of intersections at successive radii (Figure 4.7; p>0.05) or the total dendrite length
(p>0.05; Control Male: 729.3 ± 83.1 µm, Control Female: 740.6 ± 49.7 µm; HIV-1 Tg
Male: 679.1 ± 81.0 µm; HIV-1 Tg Female: 758.4 ± 42.5 µm). Thus, HIV-1 Tg animals
exhibited selective alterations in the morphology of pyramidal neurons from layers II-III
of the mPFC, characterized by decreased dendritic branching complexity.
HIV-1 Tg animals displayed a profound shift in the distribution of dendritic
spines in pyramidal neurons from layers II-III of the medial prefrontal cortex,
supporting an alteration in synaptic connectivity.
Sholl analyses were subsequently utilized to determine where dendritic spines were
located on the neuron, assessed using spine type (i.e., Thin Spines, Stubby Spines,
Mushroom Spines), determined using an observer-assisted automatic classification system
in Neurolucida 360, genotype (i.e., HIV-1 Tg, Control), biological sex (i.e., Male, Female)
and radii as factors (Figure 4.8). HIV-1 Tg animals exhibited a prominent shift in the
distribution of dendritic spines dependent upon the factor of biological sex and spine type
(Genotype x Sex x Spine Type x Radii Interaction [F(2, 6265)=21.5, p≤0.001]). The effect
or lack of effect of biological sex on spine type is illustrated in Figure B.2.
Complementary analyses were conducted on each spine type to determine the locus
of these interactions. HIV-1 Tg animals displayed a prominent shift, with an increased
relative frequency of thin dendritic spines on more distal branches relative to control
animals (Genotype x Radii Interaction [F(1,2057)=83.1, p≤0.001]); the magnitude of
which was influenced by the factor of biological sex (Genotype x Sex x Radii Interaction
[F(1,2057)=19.1, p≤0.001]). In sharp contrast, an assessment of stubby dendritic spines
revealed a population shift with an increased relative frequency on more proximal branches
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in HIV-1 Tg animals relative to controls (Genotype x Radii Interaction [F(1,2057)=14.1,
p≤0.001]); an effect influenced by the factor of biological sex (Genotype x Sex x Radii
Interaction [F(1,2057)=27.3, p≤0.001]), whereby the effect was observed in female HIV1 Tg animals (Genotype x Radii Interaction [F(1,957)=50.9, p≤0.001]), but not male HIV1 Tg animals (Genotype x Radii Interaction: p>0.05). No significant differences in the
distribution of mushroom dendritic spines were observed (p>0.05).
A selective population shift in dendritic spine morphology was observed in
layers II-III pyramidal neurons of the medial prefrontal cortex dependent
upon presence of the HIV-1 transgene and biological sex.
Measurement of dendritic spine parameters, including backbone length, head
diameter, and volume (Figure B.3) revealed a selective population shift in dendritic spine
morphology in layers II-III pyramidal neurons of the mPFC dependent upon presence of
the HIV-1 transgene and biological sex. Male HIV-1 Tg animals exhibited a population
shift towards shorter dendritic spines with no observed alterations in head diameter or
volume. In sharp contrast, female HIV-1 Tg animals displayed a population shift towards
longer dendritic spines with decreased head diameter relative to female control animals; no
significant alterations in dendritic spine volume were revealed in female HIV-1 Tg animals
relative to female control animals. A generalized linear mixed effects model with a Poisson
distribution confirmed these observations, revealing a significant Genotype x Sex x Bin
interaction for both backbone length [F(1,1659)=37.2, p≤0.001] and head diameter
[F(1,1154)=68.2, p≤0.001]; an effect not observed for dendritic spine volume (p>0.05).
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There was no significant difference in neuroinflammation in the hippocampus
between HIV-1 Tg and control animals.
Three putative neuroinflammatory markers, including IL-1β, IL-6, and TNF-α,
were assessed in the hippocampus of HIV-1 Tg and control animals (Figure 4.9). Overall,
HIV-1 Tg and control animals, independent of biological sex, reaching threshold after 40
cycles, displayed low levels of gene expression. No significant genotype (p>0.05) or sex
(p>0.05) differences in gene expression, examined using the 2-ΔΔCt method, were observed.
Phase 5: Mechanistic Basis of Neurocognitive Impairment
Neurocognitive impairments across the functional lifespan explain significant
genotypic variance.
A DFA was utilized to determine whether neurocognitive assessments conducted
across the functional lifespan could classify animals based on genotype (Figure 4.10).
Variables included in the stepwise DFA represented alterations in sustained attention (Hits
and Misses at 1000, 500, and 100 msec during Original Acquisition and Retest 1-5; Hits
and Misses at 1000, 100, and 10 msec during the 18 Month Assessment), learning (Days
to Criteria during Original Acquisition, Days to Criteria at Retest 1-5, Number of Days
Meeting Criteria during the 18 Month Assessment), and flexibility and inhibition (Hits and
Misses at 1000, 100, and 10 msec during the Reversal Assessment).
HIV-1 Tg and control animals were maximally separated (canonical correlation of
0.70) by selecting seven variables corresponding to sustained attention (i.e.,Hits at 1000
msec during Original Acquisition, Hits at 500 msec during Retest 1, Misses at 1000 msec
during Retest 2, Misses at 100 msec during Retest 4, Hits at 1000 msec during Retest 5,
and Misses at 10 msec during the 18 Month Assessment) and learning (i.e., Days to Criteria
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during Retest 5). Animals were correctly classified for presence of the HIV-1 transgene
(jack-knifed classification) with 78.5% accuracy (Approximately of Wilks’ λ of 0.516,
χ2(7)=39.4, p≤0.001), accounting for approximately 61.6% of the genotypic variance.
Synaptic dysfunction, assessed in pyramidal neurons from layers II-III of the
medial prefrontal cortex, explains significant genotypic variance.
A DFA was utilized to determine whether synaptic dysfunction in pyramidal
neurons from layers II-III of the mPFC could classify animals based on genotype (Figure
4.10). Variables included in the stepwise DFA represented alterations in dendritic
branching complexity, dendritic spine connectivity, and dendritic spine morphology.
HIV-1 Tg and control animals were maximally separated (canonical correlation of
0.72) by selecting seven variables corresponding to dendritic spine connectivity (i.e.,
Relative Frequency of Thin Dendritic Spines at 150 µm; Relative Frequency of Stubby
Dendritic Spines at 40 µm, 110 µm, and 170 µm) and dendritic spine head diameter (i.e.,
Relative Frequency of Dendritic Spines within the 0.075 µm, 0.225 µm and 0.375 µm bin).
Animals were correctly classified for presence of the HIV-1 transgene (jack-knifed
classification) with 80.4% accuracy (Approximately of Wilks’ λ of 0.489, χ2(7)=32.5,
p≤0.001), accounting for approximately 64.6% of the genotypic variance.
DISCUSSION
Progressive NCI, including alterations in learning, sustained attention, flexibility,
and inhibition, were observed in the population of HIV-1 Tg rats sampled. During initial
acquisition, biological sex was the driving factor for observed differences in learning and
sustained attention. Across retest assessments, presence of the HIV-1 transgene became the
prominent factor underlying alterations in the temporal process of task acquisition, as well
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as sustained attention. Nevertheless, at 18 months of age, sex-dependent expression of NCI
were observed in HIV-1 Tg animals, relative to controls. Pyramidal neurons from layers
II-III of the mPFC revealed profound synaptic dysfunction in HIV-1 Tg animals relative to
controls; dysfunction that was characterized by alterations in dendritic branching
complexity, synaptic connectivity, and dendritic spine morphology. NCI across multiple
domains (i.e., learning, sustained attention) and synaptic dysfunction in the mPFC
independently identified the presence of the HIV-1 transgene with at least 78.5% accuracy,
accounting for at least 61.6% of the genotypic variance. Thus, even in the absence of
sensory or motor system deficits (McLaurin et al., 2018b) and comorbidities, HAND is a
neurodegenerative disease characterized by age-related disease progression; impairments
which may be due, at least partly, to synaptic dysfunction in the mPFC.
Located at the anterior pole of the mammalian brain, the PFC, recognized as an
anatomically complex brain region (Siddiqui et al., 2008), is organized in a laminar fashion
and comprised of three major subdivisions (i.e., mPFC, orbital PFC (oPFC) and lateral
PFC). Executive functions, including attention, flexibility, and inhibition, are the primary,
most basic function of the PFC (Fuster, 2008). Although executive functions cannot be
localized to any single subdivision of the PFC, the mPFC, oPFC, and lateral PFC each
exhibit some degree of functional specialization (Siddiqui et al., 2008; Fuster et al., 2008).
Specifically, the mPFC has been implicated as having a primary role in attention, including
pre-attentive processes (e.g., Ellenbroek et al., 1996) and sustained attention (e.g., Kim et
al., 2016), whereas the oPFC is involved in stimulus-reinforcement learning (e.g.,Rolls,
2004) and reversal (i.e., flexibility and inhibition; McAlonan & Brown, 2003).
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The utilization of a series of neurocognitive tasks across the functional lifespan
tapped multiple subdivisions of the PFC, revealing progressive NCI in the HIV-1 Tg rat.
At the genotypic level, HIV-1 Tg animals displayed a progressive, relative impairment in
tasks tapping both the mPFC (i.e., sustained attention) and the oPFC (i.e., stimulusreinforcement learning). Most notably, HIV-1 Tg animals also exhibited alterations in the
progression of PPI, a pre-attentive process tapping the mPFC (McLaurin et al., 2018b).
However, sex differences in the presentation of NCI at 18 months of age were dependent
upon the brain region tapped via neurocognitive assessments (i.e., mPFC vs. oPFC).
Specifically, male HIV-1 Tg animals exhibited significantly greater impairment, relative
to male control animals, in sustained attention and stimulus-reinforcement learning in the
reversal assessment, tasks tapping both the mPFC and oPFC. Female HIV-1 Tg animals,
however, displayed profound impairment, relative to female control animals, in flexibility
and inhibition, tasks predominantly associated with the oPFC. Elucidating the mechanisms
underlying sex-dependent expression of NCI is vital for the development of therapeutic
treatments and cure strategies.
The rich cortical and subcortical connections make the PFC ideally positioned to
serve as a central hub, integrating and relaying information from multiple afferent sources
(Miller & Cohen, 2001). Broadly, the PFC receives afferents from thalamic nuclei, the
limbic system, the frontal cortex, and other brain regions (e.g., hypothalamus, cerebellum,
mesencephalon; Fuster, 2008). Dense innervation from multiple neurotransmitter systems
to the PFC has also been well-established (Fuster, 2008); afferents which play a prominent
regulatory role across the PFC (Fuster, 2008) and are functionally involved in the control
of executive functions (for review, Robbins & Arnsten, 2009). Specifically, noradrenergic
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projections from the locus coeruleus (LC), DAergic afferents from the VTA, and
serotonergic projections from the raphe nuclei innervate the PFC.
Excitatory pyramidal neurons, characterized by a single apical dendrite, multiple
shorter dendrites, and thousands of dendritic spines are abundant throughout the PFC
(Spruston, 2008). A synaptic relationship between pyramidal neurons and the major
afferent systems is established via postsynaptic sites on dendritic shafts and spines; the vast
majority of which occur on dendritic spines (e.g., Hersch & White, 1981).
Morphologically, dendritic spines are classically characterized into three primary
categories (i.e., thin, stubby, mushroom; Peters & Kaiserman-Abramof, 1970). Thin spines,
the predominant spine type in both HIV-1 Tg and control animals, are characterized by a
long, thin neck and a small bulbous head, whereas the head volume to neck volume ratio
is higher in mushroom spines. In sharp contrast, stubby spines are devoid of a spine neck,
exhibiting an approximately equal head and neck volume ratio (Peters & KaisermanAbramof, 1970). Most notably, asymmetric excitatory synapses are primarily formed
between dendritic spine heads and presynaptic axons (e.g., Gray, 1959), however, some
dendritic spines receive additional input on their neck (Yuste, 2010). Thus, morphological
characteristics of dendritic spines, which are reflective of functionality and capacity for
structural change (Lai & Ip, 2013), and their distribution along the dendrite, may be
associated with synaptic dysfunction in the HIV-1 Tg rat.
Neuronal morphology, assessed using a branch order analysis, tapping dendritic
branching complexity, as well as the classical Sholl analysis, tapping neuronal arbor
complexity, revealed prominent alterations in HIV-1 Tg animals relative to controls
(Figure 4.11). In pyramidal neurons from layers II-III of the mPFC, assessed in the present
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study, HIV-1 Tg animals exhibited decreased dendritic branching complexity; an effect
independent of biological sex. No statistically significant genotypic differences were
observed in dendritic length, consistent with previous reports in younger HIV-1 Tg animals
(Festa et al., 2015) or neuronal arbor complexity. In sharp contrast, in medium spiny
neurons (MSNs) from the nucleus accumbens core subregion (NAcc), published results
suggest sex-dependent alterations in neuronal morphology (McLaurin et al., 2018c).
Specifically, female HIV-1 Tg animals, but not male HIV-1 Tg animals, displayed
profound alterations in dendritic branching complexity and neuronal arbor complexity
(McLaurin et al., 2018c). Morphological differences between pyramidal neurons,
characterized as polar neurons, and MSNs, characterized by a centrifugal morphology, may
underlie differences in branch order and Sholl analyses. Overall, results support alterations
in neuronal morphology in HIV-1 Tg rats independent of brain region assessed. However,
the comparison of results from branch order analyses with those from Sholl analyses
suggests that the two analytic measures may reflect different measures of neuronal
morphology.
HIV-1 Tg animals, independent of biological sex, exhibited a profound shift in the
distribution of dendritic spines along the apical dendrite, supporting a prominent alteration
in synaptic connectivity. Specifically, a preponderance of thin spines were observed on
more distal dendrites, extending into layer I of the mPFC, in HIV-1 Tg animals, relative to
controls. However, HIV-1 Tg animals, relative to controls, displayed an increased relative
frequency of stubby spines on more proximal dendrites; an effect which was most
prominent in female HIV-1 Tg rats. Notably, pyramidal neurons within layers II-III of the
mPFC express multiple monoamine receptors, including noradrenergic receptors (i.e.,
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primarily α1A, α1D), DAergic receptors (i.e., primarily D1) and serotonergic receptors (i.e.,
primarily 5-HT1A, 5-HT2A); receptor expression not observed within layer I of the mPFC
(Santana & Artigas, 2017). The preponderance of stubby spines, morphologically
characterized by the absence of a dendritic spine neck (Peters & Kaiserman-Abramof,
1970) and a smaller postsynaptic density (Schmidt & Eilers, 2009), on more proximal
dendrites suggests that HIV-1 Tg animals fail to receive afferent projections, and thus
neurotransmitter innervation, from the VTA, LC, and raphe nuclei (Figure 4.11); consistent
with neurotransmitter system alterations, specifically DAergic system dysfunction,
commonly reported in HIV-1 (e.g., Kumar et al., 2011; Gelman et al., 2012; Javadi-Paydar
et al., 2017; Bertrand et al., 2018). One previous study (Festa et al., 2015) and one
conference abstract (Festa et al., 2017) have also suggested alterations in dendritic spine
density in the mPFC in younger HIV-1 Tg animals; an effect which may also influence
synaptic connectivity. Thus, profound synaptic dysfunction was observed in HIV-1 Tg
animals, characterized by alterations in dendritic branching complexity, synaptic
connectivity (i.e., VTA-PFC-LC), and dendritic spine morphology, supporting a key neural
mechanism for expression of NCI in HAND.
Multiple animal systems are available to model components of neuroHIV, each
with their own advantages and constraints. Several major considerations of the prominent
animal species and their applicability to provide a biological system to model neuroHIV in
the post-cART era are highlighted in Figure 4.12. CNS infection occurs within two weeks
of HIV-1 infectivity in humans (Price et al., 1988; Valcour et al., 2012), leading to NCI
(e.g., Heaton et al., 2011; Cysique et al., 2004) and behavioral alterations (e.g., Apathy:
Kamat et al., 2012; Depression: Ciesla & Roberts, 2001). Selective NCI (e.g., selective
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attention appears relatively spared, Moran et al., 2014a) have been observed across
multiple domains in multiple prominent animals systems (e.g., HIV-1 Tg rat, pre-attentive
processes: Moran et al., 2013a; learning and memory: Vigorito et al., 2007, RepunteCanonigo et al., 2014; executive function: Moran et al., 2014a; SIV, spatial working
memory: Weed et al., 2004; Humanized Mice, memory: Boska et al., 2014; Tat Transgenic
Mice, spatial learning: Carey et al., 2012, Marks et al., 2016, reversal learning: Carey et
al., 2012). Examples of behavioral alterations, similar to those observed in HIV-1
seropositive individuals, include depressive-like behaviors (e.g., HIV-1 Tg rat: Nemeth et
al., 2014; Tat transgenic mice: Lawson et al., 2011, McLaughlin et al., 2017) and
motivational alterations (e.g., HIV-1 Tg rat: Bertrand et al., 2018). Furthermore, although
generally understudied, prominent sex differences in the expression of NCI have been
observed in HIV-1 seropositive individuals, with HIV-1 seropositive females displaying
more severe deficits relative to HIV-1 seropositive males (Royal et al., 2016; Maki et al.,
2018). Sex differences in the expression of NCI have been translationally modeled in the
HIV-1 Tg rat (McLaurin et al., 2016b; Rowson et al., 2016; McLaurin et al., 2017d), but
inconsistent results have been reported in other animal systems (e.g., Tat transgenic mice:
Hanh et al., 2015). Given the increased life expectancy of HIV-1 seropositive individuals
in the post-cART era, as well as the persistence of NCI, an in vivo biological system able
to provide a longitudinal study of HIV-1 is critical. HIV-1 seropositive individuals display
progressive NCI, with individuals exhibiting asymptomatic NCI at baseline having an
increased risk (i.e., two to six times) of developing symptomatic HAND (Grant et al.,
2014). The HIV-1 Tg rat, as demonstrated in the present study, displays age-related disease
progression in multiple neurocognitive domains across the functional lifespan. Thus, the
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present study further elucidates the advantages and constraints of the HIV-1 Tg rat
biological system to model neuroHIV in the post-cART era.
Despite the aforementioned strengths of the present study, a few caveats are
acknowledged. First, the neuronal analysis focused exclusively on pyramidal neurons from
layers II-III of the mPFC. Although the generalizability of synaptic dysfunction cannot be
directly assessed within the present study, observations across multiple brain regions (i.e.,
nucleus accumbens, mPFC; Roscoe et al., 2014; Festa et al., 2015; McLaurin et al., 2018a;
McLaurin et al., 2018c), ages (i.e., 4 months; 14-17 months; 20 months; Roscoe et al.,
2014; McLaurin et al., 2018a; McLaurin et al., 2018c) and in HIV-1 Tg rats following
psychostimulant exposure (i.e., methylphenidate; McLaurin et al., 2018a) suggests the
importance of further studies investigating synaptic dysfunction as a neural mechanism
underlying NCI in HAND. Second, neuroinflammatory markers were assessed exclusively
in the hippocampus and using only three cytokines (i.e., IL-1β, IL-6, and TNF-α). Despite
the utilization of two experimental methodologies and sufficient statistical power, no
significant differences in neuroinflammation in the hippocampus were suggested between
HIV-1 Tg and control animals; results consistent with those observed using [(18)F]DPA714 PET imaging and a profile of 24 neuroinflammatory markers in (3 and 9 month)
adult HIV-1 Tg animals (Lee et al., 2015) and following PD 1 stereotaxic injections of
HIV-1 viral proteins (i.e., Tat1-86, gp120; Moran et al., 2014b). However, this does not
preclude neuroinflammation in the adolescent brain, in other brain regions, or using other
methodology (e.g., ELISA, Royal et al., 2012). For example, results of the present study
are in contrast to those reported by Royal et al. (2012), which observed significant increases
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in the expression of INF-γ, TNF-α, and IL-β, assessed using ELISA, in brain lysates
prepared from the frontal cortex and subcortical white matter of the HIV-1 Tg rat.
Even in the absence of sensory or motor system deficits (McLaurin et al., 2018b)
and comorbidities, HAND is a neurodegenerative disease. NCI are characterized by agerelated disease progression across multiple neurocognitive domains, tapping two primary
subdivisions of the PFC. Most notably, alterations in sustained attention and learning
across the functional lifespan, account for approximately 61.6% of the genotypic variance
in NCI, independent of biological sex. Synaptic dysfunction in pyramidal neurons from
layers II-III of the mPFC, characterized by alterations in dendritic branching complexity,
synaptic connectivity, and dendritic spine morphology, supports a key, albeit not exclusive,
neural mechanism underlying HAND, accounting for approximately 64.6% of the
genotypic variance. Thus, the progression of HAND with age in the HIV-1 Tg rat and the
associated synaptic dysfunction affords an instrumental model system for the development
of therapeutics and functional cure strategies.
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Figure 4.1 Experimental Design. Schematic of the experimental design.
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Figure 4.2 Signal Detection: Original Acquisition. Initial acquisition of signal
detection. (A) Assessment of the temporal process of acquisition revealed a main
effect of sex (p≤0.001), with female animals, independent of genotype, acquiring
the signal detection operant task significantly slower than male animals. (B)
Genotype failed to alter the temporal process of acquisition during the original
acquisition phase (p>0.05). (C) Assessment of sustained attention during the initial
acquisition of signal detection revealed that female animals displayed a decreased
response rate, as well as a prominent rightward shift in the loss of signal detection
(i.e., the intersection of hits and misses; p≤0.001) relative to male animals. (D)
Presence of the HIV-1 transgene failed to alter sustained attention during initial
acquisition (p>0.05). Data are presented as cumulative frequencies with 95%
confidence intervals fit to the curve (A,B) or mean (X) ± SEM (C,D).
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Figure 4.3 Days to Criteria: Retest Assessments. The number of days at which
80% of the population sampled met criteria (±95% Confidence Intervals (CI)) is
illustrated as a function of genotype (HIV-1 Tg vs. control) and retest session.
Points and 95% CI were derived from the cumulative frequency curves presented
in Figure B.1. Control animals exhibited an improvement in performance as a
function of retest assessment, reaching asymptotic performance at approximately
7 days. In sharp contrast, HIV-1 Tg animals exhibited an initial improvement
through retest assessment 2, followed by a progressive decline.
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Figure 4.4 Signal Detection: Retest Assessments. Sustained
attention as a function of retest assessment. At each individual
retest session (i.e, Retest 1: A, Retest 2: B, Retest 3: C, Retest
4: D, Retest 5: E) HIV-1 Tg animals, independent of biological
sex, displayed an impairment in the detection of shorter signal
durations (1000, 500, 100 msec). Across retest sessions, HIV1 Tg animals displayed a progressive, relative impairment in
sustained attention (p≤0.05). Despite an improvement in the
detection of shorter signal durations as a function of retest
session, HIV-1 Tg animals failed to improve as quickly or to
the same magnitude as control animals. Data were
extrapolated to 10 msec using linear regression calculations to
demonstrate the point at which animals experiences a loss of
signal detection (i.e., the intersection of hits and misses). A
blue line indicates the point at which HIV-1 Tg animals
experienced a loss of signal detection. Data are presented as
mean ± SEM.
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Figure 4.5 Days to Criteria: 18 Month Acquisition and Reversal. Temporal
process of acquisition during the 18 month acquisition (A,B) and reversal (C,D)
task. During the 18 month acquisition task, HIV-1 Tg and control animals were
challenged for 5 consecutive days with shorter signal durations (i.e., 1000, 100,
10 msec). Male HIV-1 Tg animals (A) displayed a shift towards a decreased
number of days meeting criteria (i.e., 70% accuracy) relative to male control
animals (p≤0.001); a distribution shift not observed in female HIV-1 Tg animals
(B; p>0.05). The temporal process of acquisition in the reversal task was assessed
for HIV-1 Tg animals that had two months (i.e., 60 days) to acquire the task. Male
HIV-1 Tg animals took significantly longer to acquire the reversal task relative
to male control animals (C; p≤0.005); an impairment not observed in female HIV1 Tg animals (D; p>0.05). Data are presented as cumulative frequencies with 95%
confidence intervals fit to the curve.
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Figure 4.6 Signal Detection: 18 Month Acquisition and Reversal. Signal
detection data, presented as mean ± SEM, during the 18 month acquisition and
reversal task are illustrated as a function of genotype and sex. A significant Task x
Response Type x Genotype x Sex interaction [F(2,108)=7.2, pGG≤0.002,
ηp2=0.117] was observed. Male HIV-1 Tg (C) animals displayed a profound
impairment in the detection of shorter signals during 18 month acquisition task and
reversal task relative to male control (A) animals. Female HIV-1 Tg animals (D)
failed to exhibit a deficit in the detection of shorter signals during the 18 month
acquisition task relative to female control (B) animals. However, female HIV-1 Tg
animals exhibited prominent impairments in flexibility and inhibition, evidenced
by an inability to reliably detect the signal at any duration assessed during the
reversal task.
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Figure 4.7 Neuronal Morphology. Two assessments of neuronal morphology,
including a branch order analysis (A) and Sholl analysis (B) were conducted in
pyramidal neurons from the medial prefrontal cortex. Branch order analyses (A)
revealed an increased relative frequency of dendritic branches at lower branch orders
in HIV-1 Tg animals relative to controls. In sharp contrast, neither presence of the
HIV-1 transgene nor the factor of biological sex influenced the number of dendritic
intersections occurring every 10 µm from the soma, assessed using a Sholl analysis
(B). Thus, HIV-1 Tg animals exhibited selective alterations in the morphology of
pyramidal neurons from layers II-III of the mPFC, characterized by decreased
dendritic branching complexity. Data are illustrated as relative frequencies of the
entire dataset (A) or mean ± SEM (B).
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Figure 4.8 Synaptic Connectivity. The distribution of dendritic spines on pyramidal
neurons from the medial prefrontal cortex are illustrated as a function of spine type
(i.e., Thin: A, Stubby: B, Mushroom: C), genotype (HIV-1 Tg vs. control) and radii.
HIV-1 Tg animals exhibited a prominent distributional shift in the relative frequency
of thin spines (A), with an increased relative frequency on more distal branches,
relative to controls. In sharp contrast, HIV-1 Tg animals displayed an increased
relative frequency of stubby spines (B) on more proximal branches, relative to
controls. No genotypic alterations were observed in the distribution of mushroom
spines (C). Data are illustrated as relative frequencies of the entire dataset.
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Figure 4.9 Neuroinflammatory Markers. Three neuroinflammatory markers,
including IL-1β (A), IL-6 (B), and TNF-α (C), were assessed in the hippocampus
of HIV-1 Tg and control animals. Overall, HIV-1 Tg and control animals,
independent of biological sex, reaching threshold after 40 cycles, displayed low
levels of gene expression; levels which were dependent upon genotype or sex
(p>0.05). Data are presented as mean ± SEM.

103

A
12

Neurocognitive Impairment
Control
HIV-1 Tg

Frequency

9

6

3

0
-3.5

-2.1

-0.7

0.7

2.1

3.5

Discriminant Scores

B

Neuroanatomical Alterations

10

Frequency

8
6
4
2
0
-3.0

-2.0

-1.0

0.0

1.0

2.0

3.0

Discriminant Scores

Figure 4.10 Discriminant Function Analysis. A DFA
was utilized to determine whether neurocognitive
impairments (A) and synaptic dysfunction in the medial
prefrontal cortex (mPFC; B) could classify animals
based on genotype. Seven variables, corresponding to
alterations in learning and sustained attention, correctly
classified the presence of the HIV-1 transgene with
78.5% accuracy, accounting for 61.6% of the genotypic
variance in neurocognitive function (A). Seven
variables, corresponding to alterations in dendritic spine
connectivity and dendritic spine head diameter, correctly
classified the presence of the HIV-1 transgene with
80.4% accuracy, accounting for 64.6% of the genotypic
variance in synaptic dysfunction in the mPFC (B).
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Figure 4.11 Pyramidal Neuron Schematic. Dendritic spine connectivity in pyramidal
neurons of the medial prefrontal cortex is illustrated as a function of genotype (HIV-1 Tg
vs. control). Pyramidal neurons in HIV-1 Tg animals (B) displayed decreased dendritic
branching complexity, with a decreased relative frequency of higher order branches
relative to control animals (A) with no observed alterations in total dendrite length.
Control animals exhibited a preponderance of thin spines on more proximal branches,
receiving DAergic afferents from the VTA and noradrenergic innervation from the LC. In
sharp contrast, HIV-1 Tg animals displayed a preponderance of stubby spines on more
proximal branches. Morphological characteristics of stubby spines, including the absence
of a spine neck (Peters & Kaiserman-Abramof, 1970) and decreased PSD on the dendritic
spine head (Schmidt & Eilers, 2009) suggest that HIV-1 Tg animals failed to receive
appropriate DAergic afferents from the VTA or noradrenergic innervation from the LC.
Illustrated here is the reception of DAergic and noradrenergic afferents on the dendritic
spine neck, although other mechanisms are possible. Abbreviations: DA: Dopamine,
DAT: Dopamine Transporter, DA1 Receptor: Dopamine Receptor D1, VMAT2:
Vesicular Monoamine Transporter 2, NE: Norepinephrine, NET: Norepinephrine
Transporter, α1A Receptor: Alpha-1A Adrenergic Receptor, α1D Receptor: Alpha-1D
Adrenergic Receptor, NMDAR: NMDA Receptor, AMPAR: AMPA Receptor, VGLUT:
Vesicular Glutamate Transporter, mGLUR: Metabotropic Glutamate Receptor, EAAT2:
Excitatory Amino Acid Transporter 2.
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Figure 4.12 Prominent Animal Species to Study HIV-1. Several major considerations
of the prominent animal species and their applicability to provide a biological system to
model neuroHIV in the post-cART era are highlighted.
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CHAPTER 5
REMODELING NEURONAL CIRCUITRY VIA S-EQUOL AMELIORATES
NEUROCOGNITIVE IMPAIRMENTS CHARACTERISTIC OF HIV-1
ASSOCIATED NEUROCOGNITIVE DISORDERS
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INTRODUCTION
Neurodegenerative diseases, including AD and other dementias (43.8 million
individuals; GBD 2016 Dementia Collaborators, 2019), HAND (40-70% of the 37.9
million individuals with HIV-1; UNAIDS, 2019), and Parkinson’s disease (6.1 million
individuals; GBD 2016 Parkinson’s Disease Collaborators, 2018), afflict millions of
individuals worldwide. Despite differences in clinical symptomology, neurodegenerative
diseases share many histopathological features, including neuronal damage and glial
activation (Katsuno et al., 2018). Current therapeutics for neurodegenerative diseases,
however, remain inadequate due to their inability to modify disease progression (Barchet
& Amiji, 2009). The development of a neuroprotective and/or neurorestorative therapeutic
that penetrates the central nervous system and targets the salient histopathological features
of neurodegenerative diseases has the potential for great clinical significance.
Frontal-subcortical circuit dysfunction may underlie the NCI commonly observed
in neurodegenerative diseases, including AD (e.g., Zhao et al., 2015), HAND (e.g., Cole et
al., 2007), and Parkinson’s disease (e.g., Zgalijardi et al., 2006). Proposed by Alexander et
al. (1986), the frontal-subcortical circuits, which are modulated by neurotransmitter system
interactions, include five parallel segregated circuits linking regions of the prefrontal cortex
to the striatum, basal ganglia and thalamus (Alexander & Crutcher, 1990; Alexander,
1994). Executive dysfunction, which encompasses neurocognitive impairments in higherorder cognitive processes, is associated with alterations in the dorsolateral prefrontal circuit
(dlPFC; for review, Bonelli & Cummings, 2007). Excitatory glutamateric neurons,
originating in the dorsolateral prefrontal cortex, send projections to the dorsolateral head
of the caudate nucleus, which subsequently innervate the basal ganglia via the lateral
dorsomedial globus pallidus and rostrolateral substantia nigra pars reticulata. Inhibitory γ108

aminobutyric acid (GABA) fibers project from the basal ganglia to the ventral anterior and
mediodorsal thalamus; a brain region that then closes the circuit by sending glutamatergic
and excitatory fibers back to the dorsolateral prefrontal cortex.
Dendritic spines, serving as the primary site for excitatory synaptic transmission
(Uchizono, 1965), are dynamic structures that facilitate contact between two neurons.
Emerging from dendritic shafts, dendritic spines can be broadly divided into two
components: a spine head and spine neck. The dendritic spine head typically contains a
single type 1 asymmetric synapse, which is characterized by the presence of a protein rich
postsynaptic density (PSD; Gray, 1959). The dendritic spine neck, a thin membrane tube,
connects the head of the spine to the dendritic shaft. Morphological parameters of dendritic
spines fall along a continuum and may reflect functionality and capacity for structural
change (Lai and Ip, 2013). Indeed, strong linear relationships between dendritic spine
morphological parameters (i.e., total spine volume, head volume, neck length, neck
diameter) and PSD area (Harris and Stevens, 1988; Harris and Stevens, 1989; Arellano et
al., 2007), presynaptic vesicles (Harris and Stevens, 1989), as well as synaptic strength
(Araya et al., 2014) have been observed. Given the dynamic nature of dendritic spines (for
review, Yuste, 2010), and their functional significance, therapeutics targeted at restoring
synaptic efficacy may be key to ameliorating neurocognitive impairments resulting, at least
partly, from synaptic dysfunction (e.g., Lambert et al., 1998; Gelman et al., 2012; Phan et
al., 2017; McLaurin et al., 2019b).
Strong evidence supports the utility of the ovarian steroid estrogen (17β-estradiol)
to remodel neuronal circuitry at the synaptic level. Specifically, in healthy, control animals
17β-estradiol increases dendritic spine density (e.g., Khan et al., 2013; Hao et al., 2006;
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Tuscher et al., 2016; Wang et al., 2018), induces a morphological shift towards smaller,
thin dendritic spines (Hao et al., 2006), and enhances cholinergic and monoaminergic
neurotransmission (Kritzer & Kohama, 1998). Mechanistically, 17β-estradiol promotes the
growth and stability of new dendritic spines via the ERβ pathway (Wang et al., 2018)
supporting a key target for the development of novel therapeutics.
Phytoestrogens are plant-derived compounds that are structurally similar to 17βestradiol (Glazier & Bowman, 2001) and exhibit a selective affinity for ERβ (e.g., Kuiper
et al., 1998; Mueller et al., 2004). SE, the only enantiomer produced by humans (Setchell
et al., 2005), is the major metabolite produced by the gut microbiota following ingestion
of the soy derived phytoestrogen DAI (Setchell et al., 1984). Within the brain, SE
penetrates the CNS via the blood-brain barrier, distributing most significantly to the
prefrontal cortex in rats (Lund et al., 2001). Preclinical studies in the HIV-1 Tg rat, a
biological system promoted for the assessment of HAND, support the therapeutic efficacy
of SE for neurocognitive impairments (Moran et al., 2019; McLaurin et al., 2019a).
Furthermore, the translational relevance of SE for the treatment of neurocognitive
impairments is evidenced by its utilization in an ongoing clinical trial for AD (Ausio
Pharmaceuticls; NCT03101085). Despite the potential utility of SE for the treatment of
neurodegenerative diseases, the mechanism of SE action has not yet been fully elucidated.
Thus, the present study utilized the HIV-1 Tg rat as a biological system to model
key aspects of HAND, a neurodegenerative disease (Cohen et al., 2015; McLaurin et al.,
2019b), to critically test SE and the mechanism of SE action. The HIV-1 Tg rat, originally
reported by Reid et al. (2001), exhibits age-related, progressive neurocognitive
impairments (McLaurin et al., 2019b), in the absence of sensory or motor system deficits
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and comorbidities (McLaurin et al., 2018b). Prominent alterations in synaptic dysfunction
(Roscoe et al., 2014; McLaurin et al., 2018c; McLaurin et al., 2019b) have been repeatedly
observed in the HIV-1 Tg rat. Elucidating the neural mechanism underlying the therapeutic
effects of SE in HAND affords an opportunity to evaluate its therapeutic potential for other
neurodegenerative diseases characterized by synaptic dysfunction.
METHODS
Study Design
Research Objectives
The primary objective of the present study was to critically test the therapeutic
efficacy of SE for the treatment of neurocognitive impairments and to assess the
mechanism by which SE exerts its therapeutic effects. The guiding hypothesis of the
present study was that treatment with SE during the formative period would enhance
neurocognitive function in HIV-1 Tg animals to approximate controls by targeting synaptic
dysfunction.
The HIV-1 Tg rat, which has been promoted as an advantageous biological system
to model key aspects of HAND (for review, Vigorito et al., 2015) was utilized in the present
study. Developed by Reid et al. (2001), the non-infectious HIV-1 Tg rat contains a gag-pol
deleted provirus regulated by the natural HIV-1 promotor, LTR. F344/N controls, rather
than littermates, were used to assure the most developmentally appropriate and genetically
stable baseline. Given the recommendations from the National Institutes of Health, the
factor of biological sex was an integral component of the experimental design. HIV-1 Tg
and F344/N control animals were randomly assigned to treatment group (i.e., SE or
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placebo). Thus, the present study utilized a 2 (Genotype) x 2 (Biological Sex) x 2
(Treatment) experimental design.
Neurocognitive assessments were conducted to tap multiple neurocognitive
domains, including stimulus-response learning, sustained attention, selective attention, and
flexibility and inhibition. Given observations of synaptic dysfunction across multiple
neurodegenerative diseases (e.g. Lambert et al., 1998; Phan et al., 2017; McLaurin et al.,
2019b), a ballistic labeling technique was used to assess whether SE enhances synaptic
efficacy in pyramidal neurons from the mPFC; a brain region that partially resembles some
of the features associated with the primate anterior cingulate cortex and dlPFC (for review,
Ulyings et al., 2003; for review, Seamans et al., 2008). The sensitivity of the signal
detection operant task to DAergic and noradrenergic system function was assessed using
an in situ hybridization technique. Neuroanatomical assessments were conducted blind to
genotype, biological sex and/or treatment.
A statistical power analysis and an estimate of variance were calculated to
determine the number of animals needed for the proposed studies. A power analysis
suggested sample sizes of n=16 per group to detect sex (i.e., male, female) differences at
the 10-15% level. Based on our recent data variance with the proposed methods for the
assessment of the core components of executive function (Moran et al., 2014a; McLaurin
et al., 2019b), this sample size estimate should be adequate for detecting significant
differences with a power of 0.8 at p≤0.05 (Cohen et al., 2003).
Animals
Between PD 7 and PD 9, Fischer (F344/N; Harlan Laboratories Inc., Indianapolis,
IN) HIV-1 Tg (N=24 litters) and control (N=19 litters) animals, housed with their biological
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dam, were received at the animal vivarium. At approximately PD 24, animals were
randomly sampled from each litter (HIV-1 Tg: male, n=33, female, n=34; Control: male
n=38; female, n=34), weaned and pair- or group-housed with animals of the same sex for
the duration of experimentation. To control for independence of observations, the goal was
to select one rat for each treatment group from each litter (i.e., two male rats per litter and
two female rats per litter).
Beginning at approximately PD 28, HIV-1 Tg and control animals began daily
treatment with either SE or placebo (i.e., sucrose pellets (Bio-Serv, Inc., Flemington, NJ)).
SE, obtained from Cayman Chemical Company (Ann Arbor, MI), was incorporated into
sucrose pellets by Bio-Serv, with each pellet containing 0.2 mg SE.
Animals were randomly assigned to either the SE or placebo group (Control: SE,
n=35 (male, n=18, female, n=17), Placebo, n=37 (male, n=20, female, n=17); HIV-1 Tg:
SE, n=35 (male, n=17, female, n=18), Placebo, n=32 (male, n=16, female, n=16)). HIV-1
Tg and control animals treated with SE received a daily oral dose of 0.2 mg of SE; a dose
which was previously established as the most effective dose using a dose-response
experimental design (Moran et al., 2019). Furthermore, the dose selected yielded a daily
amount of 0.25-1.0 mg/kg SE; an amount equivalent to a 2.5-10 mg dose in a 60 kg human
(Cf., most elderly Japanese have a daily isoflavone intake of 30-50 mg, Akaza, 2012).The
placebo group received a sucrose pellet. Treatment was administered daily after the
completion of neurocognitive testing to promote the long-term remodeling of neuronal
circuitry (e.g., Bertrand et al., 2014, Bertrand et al., 2015). HIV-1 Tg and control animals
were treated through PD 90.
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HIV-1 Tg and control animals were sacrificed following the successful completion
of either the assessment of selective attention (i.e., 5 days in the task) or the assessment of
flexibility and inhibition (i.e., 70% accuracy for 5 consecutive or 7 non-consecutive days
or 60 days in the task). Brains from animals sacrificed following the assessment of selective
attention were processed for RNA in situ hybridization to assess dopamine D1 and
norepinephrine α2 receptor expression in the PFC. Animals were selected for RNA in situ
hybridization based on the number of days to criterion in the signal detection operant task
with the goal of reflecting the spectrum (i.e., animals completing the task early, middle,
and late) of cognitive function observed in HIV-1 Tg and control animals. Brains from
animals sacrificed following the assessment of flexibility and inhibition were utilized to
examine synaptic dysfunction in pyramidal neurons from layers II-III of the mPFC.
Recommendations in the Guide for the Care and Use of Laboratory Animals of the
NIH were used for the maintenance of HIV-1 Tg and control animals in AAALACaccredited facilities. The targeted environmental conditions for the animal vivarium were
21°± 2°C, 50% ± 10% relative humidity and a 12-h light:12-h dark cycle with lights on at
0700 h (EST). The IACUC at the University of South Carolina approved the project
protocol (Federal Assurance # D16-00028).
Neurocognitive Assessments
Apparatus
Thirty-two operant chambers, located inside sound-attenuating chambers (Med
Associates, Inc., VT) were used to assess animals in a series of tasks tapping multiple
neurocognitive domains, including stimulus-response learning, sustained attention,
selective attention, and flexibility and inhibition. The front wall of the operant chamber
included a pellet dispenser (45 mg), located between two retractable levers, and three panel
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lights. The present experiment utilized only the panel light (LED, 11 lux) located above
the pellet dispenser for signal presentation. The top of the rear wall of the operant chamber
included a house light (incandescent, 5.5 lux), which was utilized for shaping. Signal
presentation, lever operation, reinforcement delivery, and data collection were controlled
using PC and Med-PC for Windows software (V 4.1.3; Med Associates, Inc., Fairfax, VT).
Shaping
A standard shaping response protocol was used to train animals to lever-press at
approximately 2 months of age, described in detail by McLaurin et al. (2017d) with minor
modifications. All animals were assessed in the shaping response protocol for 45 days prior
to beginning the signal detection operant task.
Sustained Attention: Signal Detection Operant Task
After 45 days in shaping, all HIV-1 Tg (SE, n=35 (male, n=17, female, n=18),
Placebo, n=32 (male, n=16, female, n=16) and control (SE, n=35 (male, n=18, female,
n=17), Placebo, n=37 (male, n=20, female, n=17)) animals were trained in a signal
detection operant task, tapping sustained attention.
The signal detection operant task, initially described by McGaughy and Sarter
(1995), included a series of four tasks. In brief, animals were trained to discriminate
between signal (i.e., central panel light illumination) and non-signal (i.e., no illumination)
trials. In the first program, consisting of 160 trials per session, the stimulus light was
terminated after an animal made a response. In the second program, consisting of 160 trials
per session, the length of the stimulus light was 1 sec. Integral to the first two programs
were correction trials, which included up to three repetitions of the trial, and forced-choice
trials; trials which occurred when an animal responded incorrectly. In the third and fourth
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programs, each consisting of 162 trials per session, the length of the stimulus was
manipulated (i.e., 1000, 500, 100 msec and 1000, 100, 10 msec, respectively) across trials
using a block randomized experimental design. Correction trials and forced-choice trials
were removed from the third and fourth programs.
HIV-1 Tg and control animals were trained on each program until achieving at least
70% accuracy on five consecutive, or seven non-consecutive, test sessions. Accuracy was
calculated using the following equation:
𝐻𝑖𝑡𝑠 + 𝐶𝑜𝑟𝑟𝑒𝑐𝑡 𝑅𝑒𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠
𝐻𝑖𝑡𝑠 + 𝐶𝑜𝑟𝑟𝑒𝑐𝑡 𝑅𝑒𝑗𝑒𝑐𝑡𝑖𝑜𝑛 + 𝑀𝑖𝑠𝑠𝑒𝑠 + 𝐹𝑎𝑙𝑠𝑒 𝐴𝑙𝑎𝑟𝑚𝑠
Selective Attention: Visual Distractor Task
After the successful completion of the signal detection operant task, HIV-1 Tg (SE,
n=35 (male, n=17, female, n=18), Placebo, n=32 (male, n=16, female, n=16) and control
(SE, n=35 (male, n=18, female, n=17), Placebo, n=37 (male, n=20, female, n=17)) animals
were challenged for five consecutive days in a visual distractor task, tapping selective
attention. During the visual distractor task, the signal detection operant task with varying
signal durations (1000, 100, 10 msec) was divided into three trial blocks, each containing
54 trials. During the second trial block, a 1.5 sec visual distractor stimulus was presented
at the beginning of each trial. The visual distractor stimulus onset and offset was 1 sec
prior to and 0.5 sec after the signal onset (center panel light), for a 1.5 sec total duration.
The house light was used as the visual distractor, with an intensity of 5.5 lux measured
from the center of the chamber at the level of the animal’s height.
Flexibility and Inhibition: Reversal Task
Subsequently, HIV-1 Tg (SE, n=25 (male, n=11, female, n=14), Placebo, n=23
(male, n=12, female, n=11) and control (SE, n=24 (male, n=11, female, n=13), Placebo,
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n=24 (male, n=13, female, n=12)) animals were challenging in a reversal task, tapping
flexibility and inhibition. During the reversal task, response contingencies learned during
the signal detection operant task were reversed. Animals were given at least 60 days to
successfully complete the reversal assessment.
Neuroanatomical Assessments
RNA in situ hybridization
A novel RNA in situ hybridization technique was used to evaluate dopamine (DA)
receptor and norepinephrine (NE) receptor expression in the mPFC (Control: SE, n=6
(male, n=3, female, n=3), Placebo, n=6 (male, n=3, female, n=3); HIV-1 Tg: SE, n=6
(male, n=3, female, n=3), Placebo, n=6 (male, n=3, female, n=3). Specifically, DA receptor
expression was assessed using D1-alpha subtype receptor probe (Rn-Drd1α) and NE
receptor expression was examined using the alpha-2 NE receptor probe (Rn-Adra2a).
Methodology for RNA in situ hybridization was described in detail by Li et al.
(2018), with minor modifications for the present study. In brief, fresh frozen brain sections
were obtained and 30 µm sections were cut from the mPFC (approximately 3.7 mm to 2.2
mm anterior to Bregma (Paxinos & Watson, 2014). Sections were mounted onto slides and
allowed to dry. Brain sections were pretreated and incubated for 30 minutes. Subsequently,
3 drops (90 µL) of the Rn-Drd1α probe and Rn-Adra2a probe were added to the brain
sections. Next, amplification steps were performed using the Amp 1-FL, Amp 2-FL, Amp
3-FL, and Amp 4-FL reagents. Slides were cover-slipped and stored in the dark until Zstack images were obtained using confocal microscopy.
RNA Analysis and Quantification. A Nikon TE-2000E confocal microscope,
utilizing Nikon’s EZ-C1 software (version 3.81b), was used to acquire z-stack images at
the 60x objection (n.a.=1.4) from the mPFC. Two images were obtained for each animal.
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Both the Rn-Drd1α probe and Rn-Adra2a probe exhibited a “discrete dots” staining
pattern (Li et al., 2018). Given the observed staining pattern, a cell region was defined and
fluorescent signals were quantified by counting the number of dots per cell which were
used for the assignment of a cell score ranging from 1 to 9, whereby higher categories
reflect a greater number of mRNA molecules within the cell.
Synaptic Dysfunction
Preparation of Tissue. Sevoflurane (Abbot Laboratories, North Chicago, IL) was
used to deeply anesthetize animals for transcardial perfusion. Methodology for transcardial
perfusion is reported in Roscoe et al. (2014).
DiOlistic Labeling. Pyramidal neurons from layers II-III of the mPFC were
visualized using a DiOlisitc labeling technique, originally described by Seabold et al.
(2010). Methodology for the preparation of DiOlistic cartridges, preparation of Tefzel
tubing, and DiOlistic labeling is described in detail by McLaurin et al. (2018a).
Pyramidal Neuron Dendritic Analysis and Spine Quantification. Analyses were
conducted on pyramidal neurons from layers II-III of the mPFC, including both the anterior
cingulate cortex and infralimbic cortex. Specifically, neurons were located approximately
3.7 mm to 2.2 mm anterior to Bregma (Paxinos & Watson, 2014). Z-stack images were
obtained using methodology previously reported (Roscoe et al., 2014) on three to four
pyramidal neurons from each animal [Control: SE, n=28 (male, n=15, female, n=13),
Placebo, n=30 (male, n=16, female, n=14); HIV-1 Tg: SE, n=28 (male, n=13, female,
n=15), Placebo, n=24 (male, n=11, female, n=13)].
Spine analyses, conducted using the AutoNeuron and AutoSpine extension models
in Neurolucida 360 (MicroBrightfield, Williston, VT), were completed on neurons meeting
selection criteria (e.g., continuous dendritic staining, low background/dye clusters, and
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minimal diffusion of the DiI dye into the extracellular space; Li et al., 2020). Based on the
selection criteria, one neuron from each animal was chosen for the analysis of spine
parameters. Neurons not meeting the selection criteria were not included in the analysis,
yielding Control: SE, n=25 (male, n=14, female, n=11), Placebo, n=27 (male, n=15,
female, n=12); HIV-1 Tg: SE, n=25 (male, n=12, female, n=13), Placebo, n=22 (male,
n=10, female, n=12).
Neuronal and Spine Parameters. Analyses were conducted to assess neuronal
morphology (i.e., Sholl analysis) and dendritic spine morphology. The classical Sholl
analysis (Sholl, 1953) was utilized to count the number of intersections at each successive
radii (10 μm) as a method to evaluate neuronal complexity. Dendritic spine morphology
was assessed using three parameters, including the backbone length (µm), head diameter
(µm), and neck diameter (µm). Spine parameters were defined using well-accepted
previously published results [i.e., volume, 0.05 to 0.85 µm: Hering & Sheng, 2001;
backbone length, 0.4 to 4.0 µm: Ruszcycki et al., 2012; head diameter, 0 to 1.2 µm: Konur
et al., 2003; neck diameter, 0 to 1.0 µm].
Statistical Analysis
Data were analyzed using ANOVA and regression techniques (SAS/STAT
Software 9.4, SAS Institute, Inc., Cary, NC; SPSS Statistics 26, IBM Corp., Somer, NY;
GraphPad Software, Inc., La Jolla, CA). Statistical significance was established at an alpha
criterion of p≤0.05. A priori planned comparisons were conducted to establish the presence
of neurocognitive impairment (i.e., Control Placebo vs. HIV-1 Tg Placebo) and the
magnitude of the SE effect (i.e., HIV-1 Tg Placebo vs. HIV-1 Tg SE and/or Control
Placebo vs. HIV-1 Tg SE).
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The temporal process of acquisition (i.e., the number of days to meet criterion)
during the acquisition of the signal detection operant task, under additional attentional
demands, and during reversal acquisition was analyzed using a curve-fitting analysis, fit
with a 95% CI, to directly assess functional form (GraphPad Software, Inc., La Jolla, CA,
USA). Additionally, the number of days meeting criterion during the visual distractor task
was analyzed using a curve-fitting analysis, fit with a 95% CI (GraphPad Software, Inc.,
La Jolla, CA, USA).
The response profile and signal duration data during the acquisition of the signal
detection operant task and under additional attentional demands were analyzed using a
mixed-factor ANOVA (SPSS Statistics 26, IBM Corp., Somer, NY). Additionally, the
response profile and signal duration data from the reversal task were assessed by
conducting a mixed-factor ANOVA with a compound symmetry covariance structure
(SAS/STAT Software 9.4, SAS Institute, Inc., Cary, NC). with genotype (HIV-1 Tg vs.
control), sex (male vs. female), and treatment (SE vs. placebo) serving as betweensubject’s factors, as appropriate. Response type (correct rejections, hits, misses and false
alarms) and signal duration (e.g., 1000, 500, 100 msec) served as the within subject’s
factors, as appropriate. During the acquisition of the signal detection operant task and under
additional attentional demands, signal detection data was analyzed for the first five days in
the task. For the reversal task, when an animal met criteria, the first five consecutive or
seven non-consecutive days that an animal achieved 70% accuracy were included. In the
reversal assessment, if an animal failed to meet criteria, but had completed 60 days in the
task, the seven days with the highest percent accuracy were included in the analysis.
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The number of false alarms during each trial block were analyzed using a repeatedmeasures ANOVA (SPSS Statistics 26, IBM Corp., Somer, NY) to validate the assessment
of selective attention in the visual distractor task. For task validation, all animals
independent of genotype, sex and/or treatment, were included in the analysis. The response
profile for non-signal trials (i.e., false alarms and correct rejections) was also examined
using a repeated-measures ANOVA (SPSS Statistics 26, IBM Corp., Somer, NY), with the
number of responses during the first and second trial block serving as the dependent
variable. Signal duration data from the visual distractor task were analyzed for only trial
block two (i.e., when the distractor was present) using a mixed-modal ANOVA (SPSS
Statistics 26, IBM Corp., Somer, NY).
Simple linear regression analyses were conducted to examine the relationship
between the mean cell score, reflecting DA (Drd1α) and NE (Adra2a) receptor expression
in the mPFC, and the number of days to meet criterion in the signal detection operant task.
The number of days to acquisition included performance across all four vigilance
programs.
Dendritic branching complexity was assessed to evaluate neuronal morphology by
examining branch orders one through fifteen. A curve-fitting analysis, fit with a 95% CI,
to directly assess functional form (GraphPad Software, Inc., La Jolla, CA, USA), was
conducted on the cumulative frequency of branch order. The number of dendritic spines at
each radii and dendritic spine morphology were analyzed using a generalized linear mixed
effects model with a Poisson distribution and an unstructured covariance pattern
(SAS/STAT Software 9.4, SAS Institute, Inc., Cary, NC). Between subject’s factors
included genotype, sex, and treatment, as appropriate. Within subjects’ factors included
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radii and bin, as appropriate. Analyses were conducted on the number of dendritic spines
in each bin.
RESULTS
Neurocognitive Assessments
Neurocognitive impairments, including alterations in temporal processing,
attention, memory, and executive function (e.g., Cysique et al., 2004; Garvey et al., 2009;
Heaton et al., 2011), are a hallmark of HIV-1 in the post-cART era; deficits which have
been translationally modeled in the HIV-1 Tg rat (e.g., Vigorito et al., 2007; Moran et al.,
2013a; Moran et al., 2014a; Repunte-Canonigo et al., 2014; McLaurin et al., 2019b).
Therefore, in the present study, it was hypothesized that HIV-1 Tg animals would exhibit
selective neurocognitive impairments across multiple neurocognitive domains, including
stimulus-reinforcement learning, sustained attention, selective attention, and flexibility and
inhibition. To critically test the hypothesis, a priori planned comparisons between HIV-1
Tg animals treated with placebo and control animals treated with placebo were conducted.
Presence of the HIV-1 Transgene
Signal Detection Operant Task: 1000, 500, 100 msec. Beginning at approximately
two months of age, HIV-1 Tg and control animals were trained in a signal detection operant
task, containing three vigilance programs, originally described by McGaughy and Sarter
(1995). The task, tapping sustained attention, required HIV-1 Tg and control animals to
attend to a randomly presented stimulus (i.e., illumination of the central panel) across 160162 testing trials. The presence or absence of the stimulus indicated which response to
make (i.e., which lever to press) to receive a reinforcer (i.e., sucrose pellet). On each trial,
the animal may emit one of four response choices (i.e., hits, misses, correct rejections, false
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alarms). Hits and correct rejections, indicative of the ability to attend to the stimulus, were
rewarded with a reinforcer. Misses, reflecting a lapse of attention, and false alarms,
indicative of failure of response inhibition, were not rewarded. Furthermore, the third
vigilance program systematically manipulated the signal duration (i.e., 1000, 500, 100
msec), which afforded an opportunity to assess the temporal components of sustained
attention.
All HIV-1 Tg and control animals treated with placebo, independent of biological
sex, were able to successfully acquire the task, achieving 70% accuracy for five
consecutive or seven non-consecutive test sessions. Presence of the HIV-1 transgene failed
to significantly alter the temporal process of acquisition (p>0.05), best fit using a sigmoidal
dose response curve (Figure 5.1; R2s≥0.99). Results support, therefore, no prominent
genotypic deficits in stimulus-reinforcement learning during the initial task acquisition.
Sustained attention was assessed by averaging the performance of each animal
across their first five days in the third vigilance program. Presence of the HIV-1 transgene
failed to significantly alter the response profile (i.e., number of correct rejections, hits,
misses, and false alarms; Figure 5.1; p>0.05). Investigating the temporal components of
sustained attention, however, revealed profound impairments in HIV-1 Tg animals treated
with placebo relative to their control counterparts (Figure 5.1; Genotype x Response Type
x Duration with a prominent linear-quadratic component, [F(1,65)=5.3, p≤0.03,
ηp2=0.075]). A pronounced rightward shift in the loss of signal detection (i.e., where the
number of hits and misses intersect), was observed in HIV-1 Tg animals treated with
placebo relative to control animals treated with placebo (approximately 720 msec vs. 420
msec, respectively). Thus, HIV-1 Tg animals displayed a prominent deficit in the
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perception of time, a potential elemental dimension of HAND (e.g., Chao et al., 2004;
Matas et al., 2010; Moran et al., 2013a), in sustained attention.
Signal Detection Operant Task: 1000, 100, 10 msec. After successfully acquiring
the first three vigilance programs, HIV-1 Tg and control animals were challenged with a
fourth vigilance program that included shorter signal durations (1000, 100, 10 msec) to
increase attentional load.
All HIV-1 Tg and control animals treated with placebo, independent of biological
sex, were able to successfully acquire the fourth vigilance program, achieving 70%
accuracy for five consecutive or seven non-consecutive test sessions. A one-phase
association provided a well-described fit for both control and HIV-1 Tg animals treated
with placebo (Figure 5.1; R2s≥0.97). Under increased attentional demands, however, HIV1 Tg animals treated with placebo exhibited profound deficits in stimulus-reinforcement
learning, evidenced by a significantly slower rate (i.e., K) of learning [F(1,38)=17.5,
p≤0.001].
The effects of an increased attentional load on sustained attention were assessed by
averaging the performance of each animal across their first five days in the fourth vigilance
program. Presence of the HIV-1 transgene failed to significantly alter the response profile
(Figure 5.1; p>0.05) or temporal components of sustained attention (Figure 5.1; p>0.05)
under increased attentional demands. Thus, HIV-1 Tg animals treated with placebo
displayed a prominent deficit in stimulus-reinforcement learning, but not sustained
attention, when challenged with an increased attentional load.
Visual Distractor Task: 1000, 100, 10 msec. After successfully acquiring all four
vigilance programs, HIV-1 Tg and control animals completed five test sessions in a visual
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distractor task to assess selective attention. During the second trial block (i.e., Trials 54108), a 1.5 second visual distractor was presented at the beginning of each trial.
A curve-fitting analysis was utilized to examine the number of days HIV-1 Tg and
control animals treated with placebo met criterion. A global first-order polynomial
provided a well-described fit for HIV-1 Tg and control animals treated with placebo
(Figure 5.1; R2s≥0.98), supporting no prominent genotypic deficits in stimulusreinforcement learning during the visual distractor task.
To validate the assessment of selective attention in all animals, independent of
genotype, biological sex and/or treatment, the relative frequency of false alarms during
each trial block were examined (Figure 5.1). During the second trial block (i.e., when the
distractor was present), a dramatic increase in the relative frequency of false alarms was
observed relative to either the first or third trial blocks (Main Effect, Trial Block
[F(2,262)=171.0, pGG≤0.001]); results which support the assessment of selective attention.
Examination of the relative frequency of false alarms and correct rejections in HIV-1 Tg
and control animals treated with placebo during the first and second trial blocks (Figure
5.1) provided additional support for the assessment of selective attention (Trial Block x
Response Type, [F(1,65)=120.7, pGG≤0.001]) and absence of any genotypic effect
(p>0.05). Furthermore, no significant genotypic differences in the temporal components of
selective attention (p>0.05) were observed during the second trial block of the visual
distractor task. Thus, there was no evidence for any prominent deficits in selective attention
in the HIV-1 Tg rat.
Reversal Task: 1000, 100, 10 msec. After completing the visual distractor task, a
subset of HIV-1 Tg and control animals were challenged with a reversal task, tapping
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flexibility and inhibition. Response contingencies were reversed from those originally
learned in the signal detection operant task. Animals completed the reversal task by either
meeting criteria (i.e., 70% accuracy for five consecutive or seven non-consecutive test
sessions) or completing at least 60 test sessions.
Presence of the HIV-1 transgene significantly altered the temporal process of
acquisition in the reversal task supporting a prominent deficit in stimulus-reinforcement
learning (Figure 5.2). Independent of genotype, a first-order polynomial provided a welldescribed fit for the cumulative proportion of placebo-treated animals successfully
acquiring the task (R2s≥0.97). Significant differences, however, were observed in the fit of
the first-order polynomial [F(2,33)=6.7, p≤0.01] reflecting the decreased proportion of
HIV-1 Tg animals treated with placebo successfully acquiring the task (i.e., 47.8%) relative
to their control counterparts (i.e., 64%) .
Flexibility and inhibition were assessed by averaging an animal’s best
performances, based on percent accuracy, during the first 60 days in the reversal task.
Presence of the HIV-1 transgene significantly altered the response profile (Figure 5.2)
dependent upon the factor of biological sex (Genotype x Sex x Response Type,
[F(3,129)=2.9, p≤0.04]). Specifically, male HIV-1 Tg animals treated with placebo
exhibited an increased number of correct rejections and misses relative to male control
animals treated with placebo. In sharp contrast, female HIV-1 Tg animals treated with
placebo displayed no deficits in flexibility and inhibition.
Consistent with alterations in the observed response profile, HIV-1 Tg animals
treated with placebo exhibited prominent deficits in the temporal components of flexibility
and inhibition (Figure 5.2), dependent upon the factor of biological sex (Genotype x Sex x

126

Response Type, [F(1, 43)=15.5, p≤0.001]). Independent of signal duration, male HIV-1 Tg
animals treated with placebo exhibited an increased number of misses relative to male
control animals treated with placebo; an effect that led to HIV-1 Tg animals treated with
placebo to be unable to reliably detect the signal at any duration assessed. Male control
animals, however, displayed a loss of signal detection at approximately 520 msec. Thus,
although deficits in stimulus-reinforcement learning in the reversal task were independent
of biological sex, only male HIV-1 Tg animals displayed alterations in flexibility and
inhibition.
Therapeutic Efficacy of S-Equol
Given the marked neurocognitive impairments in HAND, a neuroprotective and/or
neurorestorative therapeutic may be advantageous in the post-cART era. To evaluate the
magnitude of the SE effect, two a priori planned comparisons were conducted, 1) By
comparing HIV-1 Tg animals treated with placebo and HIV-1 Tg animals treated with SE
and 2) By comparing control animals treated with placebo and HIV-1 Tg animals treated
with SE.
Signal Detection Operant Task: 1000, 500, 100 msec. Independent of biological
sex, treatment with SE enhanced the temporal components of sustained attention in HIV-1
Tg animals (Figure 5.3; Genotype x Treatment x Response Type x Duration interaction
with a prominent linear-quadratic component [F(1,131)=5.7, p≤0.02, ηp2=0.042]). A loss
of signal detection was observed at approximately 720 msec in HIV-1 Tg animals treated
with placebo, approximately 570 msec in HIV-1 Tg animals treated with SE, and
approximately 420 msec in control animals treated with placebo.

127

Subsequently, a priori comparisons were conducted to evaluate the magnitude of
the SE effect. Sustained attention in HIV-1 Tg animals treated with SE was statistically
indistinguishable from either HIV-1 Tg animals treated with placebo (Treatment x
Response Type x Duration, p>0.05) or control animals treated with placebo (Genotype x
Response Type x Duration, p>0.05). Treatment with SE, therefore, precluded the
development of a statistically significant deficit in the temporal components of sustained
attention in the HIV-1 Tg rat.
Signal Detection Operant Task: 1000, 100, 10 msec. Treatment with SE failed to
preclude the development of profound deficits in the temporal process of acquisition of the
fourth vigilance program, requiring an increased attentional load.
All HIV-1 Tg and control animals, independent of treatment and/or biological sex,
were able to successfully acquire the fourth vigilance program, achieving 70% accuracy
for five consecutive or seven non-consecutive test sessions. A one-phase association
provided a well-described fit for HIV-1 Tg animals treated with SE, HIV-1 Tg animals
treated with placebo, and control animals treated with placebo (Figure 5.3; R2s≥0.97).
Under increased attentional demands, however, HIV-1 Tg animals treated with SE
exhibited no statistically significant improvement in the rate (i.e., K) of learning relative to
HIV-1 Tg animals treated with placebo (p>0.05) and a significantly slower rate of learning
relative to control animals treated with placebo [F(1,40)=16.7, p≤0.001]. Thus, treatment
with SE during the formidable period (i.e., PD 28-90) failed to prevent the development of
deficits in the temporal process of acquisition under increased attentional demands.
Reversal Task: 1000, 100, 10 msec. Treatment with SE failed to preclude the
development of profound deficits in the temporal process of acquisition in the reversal task.
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Despite SE treatment, only 40% of the HIV-1 Tg animals were able to successfully acquire
the reversal task, well-described by a segmental linear regression (R2≥0.98; Figure 5.3).
Thus, treatment with SE during the formidable period (i.e., PD 28-90) failed to prevent
deficits in the temporal process of acquisition in the reversal task.
In sharp contrast, treatment with SE enhanced the temporal components of
flexibility and inhibition in male HIV-1 Tg animals (Figure 5.3; Genotype x Treatment x
Response Type, [F(1, 43)=5.9, p≤0.02]). Independent of signal duration, male HIV-1 Tg
animals treated with SE exhibited an increased number of hits relative to either male HIV1 Tg or male control animals treated with placebo; an effect that led to a robust leftward
shift in the loss of signal detection. Specifically, a loss of signal detection was observed at
approximately 190 msec in male HIV-1 Tg animals treated with SE, and approximately
520 msec in male control animals treated with placebo. Male HIV-1 Tg animals treated
with placebo failed to reliably detect the signal at any duration assessed.
Subsequently, a priori comparisons were conducted to evaluate the magnitude of
the SE effect. Comparison of HIV-1 Tg animals treated with SE and HIV-1 Tg animals
treated with placebo revealed a statistically significant treatment x response type
interaction [F(1,21)=7.4, p≤0.01]; a result reflecting the increased number of hits observed
in HIV-1 Tg animals treated with SE. Furthermore, comparison of HIV-1 Tg animals
treated with SE and control animals treated with placebo revealed a main effect of genotype
[F(1,22)=8.4, p≤0.01], but no statistically significant interactions (p>0.05); a main effect
reflecting, again, the increased responding exhibited by HIV-1 Tg animals treated with SE.
Thus, treatment with SE, increased responding in HIV-1 Tg animals, producing a robust
shift in the temporal components of flexibility and inhibition.
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Neuroanatomical Assessments
In Situ Hybridization: Dopamine and Norepinephrine Receptor Expression
A subset of HIV-1 Tg and control animals were sacrificed after the completion of
the visual distractor task to evaluate DA (Drd1α) and NE (Adra2a) receptor expression in
the mPFC. Animals were selected based on the number of days to criterion in the four
vigilance programs comprising the signal detection operant task to reflect the spectrum of
cognitive function observed in HIV-1 Tg and control animals.
The signal detection operant task is sensitive to both DA (Figure 5.4) and NE
(Figure 5.4) receptor expression. For DA, a segmental linear regression provided a welldescribed fit for the relationship between the number of days to criterion and mean cell
score, revealing a regression coefficient (r) of 0.679. The relationship between the number
of days to criterion and mean cell score for NE was also described by a segmental linear
regression, revealing a regression coefficient (r) of 0.845. The number of days to criterion,
therefore, explained 46.1% of the variance in the mean cell score for Drd1α and 71.4% of
the variance in the mean cell score for Adra2a. A linear increase in mean cell score was
observed for both DA and NE when animals needed more than 121 days to acquire the
signal detection operant task, supporting suboptimal neurotransmitter system function.
Presence of the HIV-1 Transgene: Synaptic Dysfunction
Additional HIV-1 Tg and control animals were sacrificed after the completion of
the reversal task to evaluate synaptic dysfunction in pyramidal neurons from layers II-III
of the mPFC. A ballistic labeling technique was utilized to visualize pyramidal neurons,
which were subsequently analyzed using sophisticated neuronal reconstruction software.
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Neuronal Morphology. Dendritic branching complexity was examined using a
centrifugal branch ordering method, which assigned each dendrite with a branch order by
counting the number of segments traversed. Branch orders one through fifteen were
analyzed using regression analyses.
Presence of the HIV-1 transgene significantly altered the branch order distribution
in pyramidal neurons (Figure 5.5). Independent of genotype, a sigmoidal dose-response
curve provided a well-described fit for the cumulative frequency of the number of dendrites
at each branch order in placebo-treated animals (R2s≥0.99). However, significant
differences were observed in the fit of the sigmoidal dose-response curve [F(4,22)=33.6,
p≤0.01], supporting a prominent alteration in dendritic branching complexity. Notably,
deficits in dendritic branching complexity occurred in the absence of any statistically
significant differences in total dendrite length (p>0.05).
Excitatory Synapses. HIV-1 Tg animals treated with placebo, independent of
biological sex, had a decreased number of dendritic spines dependent upon distance from
the soma (Figure 5.5; Radii x Genotype, [F(1,3606)=55.7, p≤0.001]), relative to control
animals treated with placebo. A cubic-polynomial provided a well-described fit for the
number of dendritic spines, independent of genotype (R2s≥0.96); albeit statistically
significant differences in the fit of the function were observed [F(4,36)=5.1, p≤0.002].
Furthermore, HIV-1 Tg animals treated with placebo exhibited a population shift towards
decreased dendritic spine volume relative to control animals treated with placebo (Figure
5.5; Genotype x Bin, [F(15, 675)=2.9, p≤0.001]). HIV-1 Tg animals treated with placebo,
therefore, may have fewer and weaker synapses, relative to their control counterparts.
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Dendritic Spine Morphology. Presence of the HIV-1 transgene produced a
selective, sex-dependent population shift in dendritic spine morphology. Four parameters,
including dendritic spine backbone length, dendritic spine head diameter, and dendritic
spine neck diameter, were examined. Measurements of dendritic spine backbone length
[F(18, 810)=29.4, p≤0.001], head diameter [F(12, 540)=8.1, p≤0.001], and neck diameter
[F(10, 450)=11.2, p≤0.001], however, were dependent upon presence of the HIV-1
transgene and the factor of biological sex (i.e., Genotype x Sex x Bin interaction).
Complementary analyses were conducted independently for each sex.
Male HIV-1 Tg animals treated with placebo exhibited a population shift towards
decreased dendritic spine backbone length (Figure 5.5) and increased neck diameter
(Figure 5.5) relative to their control counterparts (Genotype x Bin: Backbone Length,
[F(18, 414)=12.2, p≤0.001]; Neck Diameter: [F(10,230)=2.1, p≤0.03]). No statistically
significant alterations in dendritic spine head diameter were observed in male animals
(p>0.05). Morphological characteristics of dendritic spines in male HIV-1 Tg animals
treated with placebo, therefore, suggest a population shift towards ‘stubby’ spines.
In sharp contrast, female HIV-1 Tg animals treated with placebo displayed a
population shift towards increased dendritic spine backbone length (Figure 5.5) with
decreased neck (Figure 5.5) and head diameter (Figure 5.5) relative to female control
animals treated with placebo (Genotype x Bin: Backbone Length, [F(18, 396)=19.4,
p≤0.001]; Head Diameter, [F(12,264)=10.9, p≤0.001]; Neck Diameter, [F(10,220)=13.4,
p≤0.001]). Morphological characteristics of dendritic spines in female HIV-1 Tg animals
treated with placebo, therefore, suggest a population shift towards ‘thin’ spines.
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Independent of biological sex, however, dendritic spines in HIV-1 Tg animals were
indicative of a more immature phenotype relative to their control counterparts.
Therapeutic Efficacy of S-Equol: Synaptic Dysfunction
Profound synaptic dysfunction, characterized by alterations in dendritic branching
complexity, synaptic connectivity and dendritic spine morphology, was observed in HIV1 Tg animals treated with placebo supporting a key neural mechanism underlying HAND
in the post-cART era. Given the therapeutic effects of SE on HIV-1 Tg animals, SE may
exert its effects by remodeling neuronal circuitry at the synaptic level. To evaluate the
magnitude of the SE effect on synaptic dysfunction, two a priori planned comparisons were
conducted, 1) By comparing HIV-1 Tg animals treated with placebo and HIV-1 Tg animals
treated with SE and 2) By comparing control animals treated with placebo and HIV-1 Tg
animals treated with SE.
Neuronal Morphology. Alterations in the branch order distribution in pyramidal
neurons was mitigated in HIV-1 Tg animals by treatment with SE during the formative
period (Figure 5.6). Dendritic branching complexity, examined by evaluating the
cumulative frequency of the number of dendrites at each branch order, in HIV-1 Tg animals
treated with placebo was well-described by a sigmoidal dose-response curve (R2≥0.99).
More notably, however, dendritic branching complexity in control animals treated with
placebo and HIV-1 Tg animals treated with SE was best fit using a global sigmoidal doseresponse curve (R2≥0.99). HIV-1 Tg animals treated with SE during the formative period,
therefore, exhibited a shift in dendritic branching complexity that was statistically
indistinguishable from control animals treated with placebo.
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Synaptic Contacts. HIV-1 Tg animals treated with SE exhibited long-term
alterations in the number of dendritic spines dependent upon distance from the soma
(Figure 5.6; Genotype x Treatment x Radii, [F(1,7286)=11.8, p≤0.001]). Independent of
genotype and/or treatment, a cubic-polynomial provided a well-described fit for the
number of dendritic spines (R2s≥0.96).
Subsequently, a priori comparisons were conducted to evaluate the magnitude of
the SE effect. Comparison of HIV-1 Tg animals treated with SE and HIV-1 Tg animals
treated with placebo revealed a statistically significant treatment x radii interaction
[F(1,3458)=405.3, p≤0.001]. Additionally, comparison of HIV-1 Tg animals treated with
SE and control animals treated with placebo also revealed a statistically significant
genotype x radii interaction [F(1,3828)=208.8, p≤0.001]. Specifically, HIV-1 Tg animals
treated with SE exhibited an increased number of dendritic spines on more distal radii
relative to either HIV-1 Tg animals treated with placebo or control animals treated with
placebo.
Furthermore, treatment with SE significantly altered the distribution of dendritic
spine volume in HIV-1 Tg animals (Figure 5.6; Genotype x Treatment x Bin, [F(15,
1365)=2.3, p≤0.004]). Despite a shift towards increased dendritic spine volume in HIV-1
Tg animals treated with SE, the distribution of dendritic spine volume was statistically
indistinguishable from HIV-1 Tg animals treated with placebo (Treatment x Bin, p>0.05).
Most critically, however, the distribution of dendritic spine volume was also statistically
indistinguishable from control animals treated with placebo (Genotype x Bin, p>0.05);
results which support a shift towards increased dendritic spine volume in HIV-1 Tg animals
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treated with SE. Thus, HIV-1 Tg animals treated with SE may have stronger synapses
relative to HIV-1 Tg animals treated with placebo.
Dendritic Spine Morphology. Treatment with SE during the formative period led to
long-term modifications in dendritic spine morphology in HIV-1 Tg animals;
morphological changes that are consistent with population shifts towards more mature
spines. The overall linear mixed effects model with a Poisson distribution revealed a
statistically significant genotype x sex x treatment x bin interaction for backbone length
[F(18, 1638)=13.2, p≤0.001], head diameter [F(12, 1092)=20.1, p≤0.001] and neck
diameter [F(10, 910)=17.9, p≤0.001]. Subsequently, an a priori contrast between HIV-1
Tg animals treated with placebo and HIV-1 Tg animals treated with SE was conducted,
revealing that SE produced a statistically significant population shift in the morphological
parameters of dendritic spines (Treatment x Sex x Bin interaction: Backbone Length [F(18,
774)=26.0, p≤0.001]; Head Diameter [F(12,516)=35.6, p≤0.001]; Neck Diameter
[F(10,430)=40.3, p≤0.001]).
Male HIV-1 Tg animals treated with SE exhibited a population shift towards
increased dendritic spine backbone length (Figure 5.6) and decreased neck diameter
(Figure 5.6) relative to HIV-1 Tg animals treated with placebo (Treatment x Bin: Backbone
Length, [F(18, 360)=5.0, p≤0.001]; Neck Diameter: [F(10,200)=3.2, p≤0.001]). Treatment
with SE during the formative period, therefore, shifted the morphological characteristics
of dendritic spines in male HIV-1 Tg animals, suggesting a population shift from ‘stubby’
spines to ‘thin’ spines.
SE treatment during the formative period also led to long-term changes in dendritic
spine morphology in female HIV-1 Tg animals, evidenced by decreased dendritic spine
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backbone length (Figure 5.6) and increased head (Figure 5.6) and neck (Figure 5.6)
diameter relative to female HIV-1 Tg animals treated with placebo (Treatment x Bin:
Backbone Length, [F(18, 414)=30.4, p≤0.001]; Head Diameter [F(12,276)=48.9,
p≤0.001]; Neck Diameter: [F(10,230)=56.9, p≤0.001]). Morphological characteristics of
dendritic spines in female HIV-1 Tg animals treated with SE, therefore, suggest a
population shift towards ‘mushroom’ spines. Thus, independent of biological sex, dendritic
spines in HIV-1 Tg animals treated with SE were shifted towards a more mature phenotype
relative to HIV-1 Tg animals treated with placebo; results which support the utility of SE
to remodel neuronal circuitry at the synaptic level in HIV-1 Tg animals.
DISCUSSION
Treatment with SE during the formative period (i.e., PD 28 to PD 90) precluded the
development of neurocognitive impairments in the HIV-1 Tg rat by remodeling neuronal
circuitry at the synaptic level. HIV-1 Tg animals treated with placebo exhibited prominent
neurocognitive deficits, dependent upon the factor of biological sex, in sustained attention,
stimulus-response learning, and flexibility and inhibition. Treatment with SE during the
formative period served as a neuroprotective therapeutic, selectively precluding the
development of neurocognitive impairments in the HIV-1 Tg rat, independent of biological
sex; effects which persisted despite the cessation of treatment. Neuronal circuitry in the
HIV-1 Tg rat was remodeled by treatment with SE, evidenced by profound long-term
modifications in dendritic branching complexity, synaptic efficacy, and dendritic spine
morphology in pyramidal neurons from layers II-III of the mPFC. Results support SE as
an efficacious neuroprotective therapeutic for HAND; a therapeutic approach that exerts
its effects by targeting synaptic dysfunction. Understanding the mechanism of SE action in
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HAND affords an opportunity to evaluate its therapeutic potential for other diseases
characterized by synaptic dysfunction.
Tapping multiple neurocognitive domains afforded an opportunity to assess the
effect of HIV-1 viral proteins, biological sex, and/or SE treatment on the three major
subdivisions (i.e., mPFC, oPFC and lateral PFC) of the PFC. Additionally, as evidenced
by in situ hybridization, stimulus-reinforcement learning, one neurocognitive domain
tapped in the present study, in the signal detection operant task is also sensitive to DA and
NE receptor expression; an effect that was independent of genotype, sex and/or treatment.
HIV-1 Tg animals treated with placebo exhibited prominent deficits, characterized by sexdependent expression of neurocognitive impairments, in tasks tapping both the mPFC (i.e.,
sustained attention, Kim et al., 2016) and oPFC (i.e., stimulus-response learning, Rolls,
2004; flexibility and inhibition, McAlonan & Brown, 2003); results which replicate and
extend those previously reported (e.g., Moran et al., 2014a; McLaurin et al., 2019b).
However, the lateral PFC, which plays a primary role in selective attention (Kam et al.,
2018), appears relatively spared. Most notably, treatment with SE prevented the
development of neurocognitive impairments in the temporal components of both sustained
attention (mPFC) and flexibility and inhibition (oPFC). Treatment with SE, however, was
unable to preclude deficits in stimulus-response learning under increased attentional
demands or in the acquisition of the reversal task.
A series of cross-sectional studies in the HIV-1 Tg rat (Moran et al., 2019;
McLaurin et al., 2019a) have assessed multiple factors (i.e., dose, age, neurocognitive
domains, biological sex) to optimize treatment conditions and improve the therapeutic
efficacy of SE for HAND. First, a dose-response experimental design in ovariectomized
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female HIV-1 Tg animals revealed a linear relationship between SE dose (0, 0.05 mg, 0.1
mg, 0.2 mg) and sustained attention, with the most efficacious dose at 0.2 mg SE,
approximating controls (Moran et al., 2019). Second, investigating the efficacy of SE at
multiple ages (i.e., 6-8 months of age, Moran et al., 2019; 2-3 months of age, McLaurin et
al., 2019a; PD 28, present study) afforded an opportunity to evaluate whether SE served as
a neuroprotective and/or neurorestorative therapeutic. SE is most efficacious when utilized
as a neuroprotective therapeutic, evidenced by the preclusion of NCI in all HIV-1 Tg
animals, independent of biological sex, in the present study. However, SE may also serve
as a neurorestorative therapeutic, albeit with decreased efficacy (i.e., 40%; Moran et al.,
2019). Third, the therapeutic efficacy of SE generalizes across multiple neurocognitive
domains, including preattentive processes, stimulus-response learning (albeit under select
conditions, Moran et al., 2019; McLaurin et al., 2019a), sustained attention, selective
attention, and flexibility and inhibition; a generalizability which supports the utility of SE
to more broadly target frontal-subcortical circuits and neurotransmitter systems. Finally, as
demonstrated in the present study, SE serves as a neuroprotective therapeutic for both male
and female HIV-1 Tg animals, despite the presence of endogenous hormones.
Glutamatergic pyramidal neurons are characterized by a pyramidal shaped soma,
one large apical dendrite, several shorter basal dendrites, and thousands of dendritic spines
(for review, Spruston, 2008).

The function of glutamatergic pyramidal neurons is

modulated by multiple neurotransmitter systems, whereby the soma and axon receive
inhibitory GABA inputs, whereas dendrites and dendritic spines receive excitatory (e.g.,
glutamatergic, dopaminergic, noradrenergic) inputs (Spruston, 2008). Specifically,
glutamatergic afferents establish synaptic contact on the dendritic spine head, while
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DAergic and noradrenergic afferents are targeted at the dendritic spine neck (Freund et al.,
1984). Morphological changes in dendritic spines, therefore, may be indicative of
alterations in synaptic neurotransmission, and ultimately neuronal circuits.
Synaptic dysfunction, characterized by alterations in neuronal and dendritic spine
morphology, may be a key histopathological feature underlying neurocognitive
impairments observed in neurodegenerative diseases (e.g., Lambert et al., 1998; Phan et
al., 2017; McLaurin et al., 2019b). In the present study, HIV-1 Tg animals treated with
placebo, independent of biological sex, exhibited altered dendritic branching complexity
and weaker synapses, evidenced by decreased dendritic spine volume (Kasai et al., 2003;
Hayashi & Majewska, 2005), relative to control animals treated with placebo; alterations
which likely reflect deficits in glutamatergic synaptic transmission. First, the blockade of
glutamate receptors (i.e., AMPA- or NMDA-type) leads to profound decreases in dendritic
arbor growth (Rajan & Cline, 1998; Sin et al., 2002; Haas et al., 2006). Second, the PSD,
which is strongly correlated with dendritic spine volume (Freire, 1978; Arellano et al.,
2007), is comprised of glutamate receptors, signaling proteins, and cytoskeletal elements
(for review, Sheng & Hoogenraad, 2007). Dendritic spines with large PSDs express a
greater number of glutamate receptors (for review, Kasai et al., 2003). Most critically,
strong evidence suggests that HIV-1 viral proteins induce alterations in glutamatergic
synaptic transmission both in vitro (e.g., Patton et al., 2000; Wang et al., 2003; Askenova
et al., 2009; Gupta et al., 2010; Aksenov et al., 2012; Melendez et al., 2016) and in vivo
(Melendez et al., 2016).
Sex-dependent morphological changes in dendritic spines from pyramidal neurons
of layers II-III of the mPFC provide additional evidence for synaptic dysfunction in HIV-
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1 Tg rats treated with placebo. Male HIV-1 Tg animals treated with placebo exhibited a
population shift towards shorter dendritic spines with increased neck diameter relative to
male control animals treated with placebo. The absence of a dendritic spine neck in male
HIV-1 Tg animals supports the failure to receive either DAergic afferents from the VTA
or noradrenergic projections from the LC. In female HIV-1 Tg animals treated with
placebo, a population shift towards longer dendritic spines with decreased head diameter
and decreased neck diameter was observed relative to female control animals treated with
placebo. The decreased head diameter in female HIV-1 Tg animals may reflect a smaller
PSD, supporting alterations in neurotransmitter release. Notably, neurotransmitter system
dysfunction is well recognized consequence of HIV-1 infection; a finding that has been
reported in clinical (e.g., Kumar et al., 2011; Gelman et al., 2012) and preclinical (Sinharay
et al., 2017; Denton et al., 2019) studies.
Treatment with SE, however, remodeled neuronal circuitry by ameliorating
synaptic dysfunction in the HIV-1 Tg rat. Independent of biological sex, SE mitigated
deficits in dendritic branching complexity and strengthened synapses, evidenced by a shift
towards increased dendritic spine volume, in HIV-1 Tg animals. Furthermore, sexdependent long-term modifications in dendritic spine morphology were observed in HIV1 Tg animals after SE treatment during the formative period. Specifically, male HIV-1 Tg
animals treated with SE displayed a population shift towards longer dendritic spines with
decreased neck diameter relative to male HIV-1 Tg animals treated with placebo; a
population shift towards parameters consistent with ‘thin’ spines (Peters & KaisermanAbramof, 1970). Additionally, enhanced DAergic and noradrenergic neurotransmission
may also underlie the prevention of neurocognitive deficits in male HIV-1 Tg animals
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treated with SE; a plausible hypothesis given evidence for increased noradrenergic and
DAergic activity in the PFC following estrogen treatment (Kritzer, 2000; Jacome et al.,
2010). In female HIV-1 Tg animals, SE induced a population shift towards shorter dendritic
spines with increased head diameter and increased neck diameter relative to female HIV-1
Tg animals treated with placebo; a shift towards parameters consistent with ‘mushroom’
spines (Peters & Kaiserman-Abramof, 1970). Thus, treatment with SE during the formative
period produced long-term remodeling in the neuronal circuit, evidenced by modifications
to neuronal morphology and dendritic spine morphology; modifications which support
enhanced synaptic transmission.
The rigor and reproducibility crisis in the behavioral and biomedical sciences
stems, at least in part, from concern regarding the failure to effectively translate preclinical
studies into the clinic. A multitude of factors, including poor experimental design (Collins
& Tabak, 2014), low statistical power (Button et al., 2013), and inappropriate statistical
analyses (Collins & Tabak, 2014) contribute to the reproducibility challenges in preclinical
research. In light of these concerns, the present study was designed to target the key aspects
of translational relevance. First, the biological system utilized to model key aspects of
HAND, which resembles HIV-1 seropositive individuals on cART, the dose of SE, which
yields a daily amount less than the daily isoflavone intake of most elderly Japanese
individuals (i.e., 30-50 mg; Akaza, 2012), and the inclusion of biological sex, reflect the
clinical population of interest. Second, animals were sampled using methods that provide
an opportunity to control for independence of observations; an assumption that underlies
many common statistical techniques (e.g., t-tests, ANOVA). Violating the independence
of observation assumption results in spuriously significant effects, evidenced by inflated
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type I error rates (e.g., Haseman & Hogan, 1975; Holson & Pearce, 1992; Aarts et al.,
2014). Finally, as discussed above, the present study replicates and extends a series of
cross-sectional in vivo studies (Moran et al., 2019; McLaurin et al., 2019a). Each study has
uniquely demonstrated the therapeutic efficacy of SE, and now the mechanism of SE
action, for the treatment of neurocognitive impairments in HAND.
Despite the aforementioned strengths of the present study, a few caveats are
acknowledged. First, although the long-term modifications in both neurocognitive function
and synaptic efficacy support a disease modifying therapeutic, there remains a critical need
to test this hypothesis using a longitudinal experimental design. Second, the present study
utilized a biological system modeling key aspects of HAND to assess the therapeutic
efficacy of SE, and its mechanism of action. Although SE targets one of the
histopathological features (i.e., synaptic dysfunction), characteristic of multiple
neurodegenerative diseases, and is being assessed in ongoing clinical trial for AD (Ausio
Pharmaceuticls; NCT03101085), additional studies are required to test its therapeutic
potential for other neurodegenerative diseases. Finally, to date, the duration of SE treatment
has not been systematically manipulated. Treatment of 0.2 mg SE for 62 days, as in the
present study, selectively precluded the development of neurocognitive impairments and
led to long-term modifications in synaptic efficacy. However, given the increased lifespan
of HIV-1 seropositive individuals (Romley et al., 2014; Teeraananchai et al., 2017), longer
treatment durations may be more efficacious.
In conclusion, treatment with SE during the formative period (i.e., PD 28 to PD 90)
prevented the development of neurocognitive impairments in the HIV-1 Tg rat by
remodeling neuronal circuitry at the synaptic level. SE, which crosses the blood-brain
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barrier, distributes most significantly to the PFC, and ameliorates synaptic dysfunction in
the HIV-1 Tg rat, may serve as a neuroprotective or neurorestorative therapeutic to modify
the progression of HAND; a hypothesis which needs to be critically tested via a
longitudinal experimental design. Most critically, however, elucidating the neural
mechanism underlying the therapeutic effects of SE in HAND affords an opportunity to
evaluate its therapeutic potential for other neurodegenerative diseases characterized by
synaptic dysfunction.
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Figure 5.1 Genotypic Neurocognitive Impairments. Presence of the HIV-1 transgene on
neurocognitive function was assessed by comparing HIV-1 Tg animals treated with
placebo and control animals treated with placebo. In the signal detection operant task,
tapping sustained attention, HIV-1 Tg animals did not display any statistically significant
alterations in the number of days to meet criterion (A) or the response profile (B). However,
HIV-1 Tg animals exhibited a prominent rightward shift in the loss of signal detection
relative to their control counterparts, supporting a deficit in the temporal components of
sustained attention (C). Under increased attentional demands (i.e., shorter signal
durations), HIV-1 Tg animals exhibited a profound deficit in the temporal process of
acquisition (D), but no alterations in response profile (E) or the temporal components of
sustained attention (F). In the visual distractor task, tapping selective attention, HIV-1 Tg
animals displayed no alterations in the number of days at criterion (G) or selective attention
(I), despite strong evidence for validation of the task (H).
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Reversal Task: 1000, 100, 10 msec
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Figure 5.2 Flexibility and Inhibition. Presence of the HIV-1 transgene on flexibility
and inhibition was assessed by comparing HIV-1 Tg animals treated with placebo
and control animals treated with placebo. HIV-1 Tg animals displayed prominent
deficits in stimulus-reinforcement learning during the acquisition of reversal (A),
with a decreased proportion of HIV-1 Tg animals treated with placebo successfully
acquiring the task (i.e., 47.8%) relative to their control counterparts (i.e., 64%). Male
HIV-1 Tg animals treated with placebo, but not female HIV-1 Tg animals treated
with placebo, exhibited alterations in the response profile (B) and temporal
components of flexibility and inhibition (C).
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Figure 5.3 Therapeutic Efficacy of S-Equol. Therapeutic efficacy of SE for
the marked impairments in neurocognitive function. Treatment with SE
enhanced the temporal components of sustained attention in HIV-1 Tg animals
(A); an enhancement which made them statistically indistinguishable from either
HIV-1 Tg animals treated with placebo or control animals treated with placebo.
However, SE failed to ameliorate deficits in stimulus-reinforcement learning
under increased attentional demands (B,C) or in the acquisition of the reversal
task (D, E). In male HIV-1 Tg animals, SE enhanced the temporal components
of flexibility and inhibition (G); an effect which resulted from a dramatic
increase in the number of hits relative to other groups (F).
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Figure 5.4 In situ Hybridization. In situ hybridization
assessing dopamine (Drd1α) and norepinephrine (Adra2a)
receptor expression in the medial prefrontal cortex. A
segmental linear regression provided a well-described fit for
the relationship between the number of days to criterion and
mean cell score for both DA (correlation coefficient, r,
0.679) and NE (r, 0.845). Results support, therefore, the
sensitivity of the signal detection operant task to alterations
in Drd1α and Adra2a receptor expression.
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Figure 5.5 Genotypic Synaptic Dysfunction. Presence of the HIV-1 transgene
on synaptic dysfunction was assessed by comparing pyramidal neurons from
layers II-III of the mPFC in HIV-1 Tg animals treated with placebo and control
animals treated with placebo. Independent of biological sex, HIV-1 Tg animals
treated with placebo exhibited significant alterations in dendritic branching
complexity (A), a decreased number of dendritic spines dependent upon
distance from the soma (B), and a prominent population shift towards decreased
dendritic spine volume (C) relative to control animals treated with placebo.
Male HIV-1 Tg animals, relative to male control animals, displayed a
population shift towards decreased dendritic spine backbone length (D) and
increased neck diameter (E). In sharp contrast, female HIV-1 Tg animals
exhibited a population shift towards increased dendritic spine backbone length
(F) with decreased neck diameter (G) and head diameter (H).
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Figure 5.6 Remodeled Neuronal Circuitry. Therapeutic efficacy of S-Equol (SE) for the
prominent alterations in synaptic function in pyramidal neurons from layers II-III of the
mPFC. Independent of biological sex, treatment with SE mitigated the alterations in
dendritic branching complexity (A), increased the number of dendritic spines on more
distal radii (B), and produced a prominent shift towards increased dendritic spine volume
(C) in HIV-1 Tg animals. In male HIV-1 Tg animals, treatment with SE produced a
population shift towards increased dendritic spine backbone length (D) and decreased neck
diameter (E) relative to male HIV-1 Tg animals treated with placebo. Female HIV-1 Tg
animals treated with SE, relative to female HIV-1 Tg animals treated with placebo,
displayed a population shift towards decreased dendritic spine backbone length (F) and
increased neck diameter (G) and increased head diameter (H).
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CHAPTER 6
S-EQUOL PARTIALLY RESTORES THE DEVELOPMENTAL TRAJECTORY
OF NEUROCOGNITIVE FUNCTION IN THE HIV-1 TRANSGENIC RAT
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INTRODUCTION
PHIV, which afflicts approximately 1.7 million children (<15 years of age)
worldwide (UNAIDS, 2019), continues to be a public health concern. cART, the primary
treatment regimen for HIV-1, suppresses viral replication in the periphery (Markowitz et
al., 1995), but poorly penetrate the blood-brain barrier (Gimenez et al., 2004; Letendre et
al., 2008). Due to the ineffective treatment of HIV-1 in the CNS, chronic neurologic
impairments are a commonly reported consequence of PHIV (Franklin et al., 2005;
Paramesparan et al., 2010). Although early initiation of cART has a beneficial effect on
neurocognitive development (e.g., Laughton et al., 2012; Crowell et al., 2015), HIV-1
seropositive children continue to perform below their HIV-uninfected peers (Lowick et al.,
2012). There remains, therefore, a critical need to develop neuroprotective therapeutics that
penetrate the CNS and alter the developmental trajectory of chronic neurological
impairments.
Isoflavones, including DAI and genistein, are a subclass of flavonoids that act as
phytoestrogens by selectively binding to ERβ (Casanova et al., 1999; Mersereau et al.,
2008). Equol, which can exist in either the R- or S- conformation, is a metabolite produced
by the gut microbiota following the ingestion of DAI (Setchell et al., 1984). Relative to its
precursor (i.e., DAI), SE, the only enantiomer produced by humans (Setchell et al., 2005),
has a slower clearance rate, higher bioavailability, and stronger, selective affinity for ERβ
(Setchell & Clerici, 2010). Notably, cells containing ERβ mRNA or immunoactivity are
widely dispersed throughout the brain (e.g., Li et al. 1997; Shughrue et al. 1997; Zhang et
al. 2002; Gonzalez et al. 2007) and have been observed in brain regions (e.g., PFC,
hippocampus) commonly associated with higher-order cognitive functioning (Sweatt,
2004; Fuster, 2008). Furthermore, activation of ERβ, via either phytoestrogens or soy
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isoflavones, has been associated with enhancements in a variety of cognitive functions,
including memory (e.g., File et al., 2001; Henderson et al., 2012), sustained attention (e.g.,
Duffy et al., 2003), and flexibility and planning (e.g., File et al., 2001; File et al., 2005);
although inconsistencies in the literature may reflect the inability of most (i.e., 70-75%) of
the Western population to convert DAI to SE (Rowland et al., 2000; Setchell & Cole,
2006). Therefore, utilization of the metabolite SE, rather than the parent compound, may
afford the most direct and efficacious target for the development of novel therapeutics for
neurocognitive dysfunction.
A series of three independent cross-sectional studies in the HIV-1 Tg rat support
SE as a neuroprotective and/or neurorestorative therapeutic for NCIassociated with HIV-1
(Moran et al., 2019; McLaurin et al., 2019a; Chapter 5). The systematic manipulation of
SE dose (i.e., 0, 0.05, 0.1, 0.2 mg) revealed a linear dose response, with 0.2 mg SE serving
as the most efficacious dose for the mitigation of sustained attention deficits (Moran et al.,
2019). Furthermore, the efficacy of SE generalizes across neurocognitive domains (i.e.,
preattentive processes, stimulus-reinforcement learning, sustained attention, selective
attention, and flexibility and inhibition), and the factor of biological sex. Soy isoflavones
and their derivatives (i.e., SE) have also been implemented as effective therapeutics for
cognitive dysfunction associated with other neurodegenerative diseases, including AD
(e.g., Bagheri et al., 2011) and Sanfilippo syndrome (Piotrowska et al., 2008). However,
extrapolating cross-sectional findings to disease progression is inferentially fraught
(Kraemer et al., 2000), necessitating the use of a longitudinal experimental design to
critically test if and/or how SE modifies the progression of chronic neurological
impairment.
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Chronic neurological impairments associated with PHIV are characterized by
alterations in executive function, preattentive processing, and long-term episodic memory
(e.g., Koekkoek et al., 2008; Ruel et al., 2012; Moran et al., 2014b; McLaurin et al., 2017c).
Specifically, deficits in preattentive processing are recognized as one of the most sensitive
neurocognitive measures for HIV-1 disease (Koekkoek et al., 2008). Alterations in
preattentive processes generalize across species (e.g., HIV-1 seropositive humans,
Minassian et al., 2013; HIV-1 transgenic (Tg) rat, Moran et al., 2013a; gp120 and Tat
transgenic mice, Henry et al., 2014; Paris et al., 2015), age (e.g., McLaurin et al., 2017a;
McLaurin et al., 2017b), the factor of biological sex (e.g., McLaurin et al., 2016b;
McLaurin et al., 2018b) and are sensitive to treatment with SE (McLaurin et al., 2019a).
Alterations in preattentive processing mediate, at least partially, deficits in higher-order
cognitive processes (i.e., stimulus-reinforcement learning, sustained attention, long-term
episodic memory; McLaurin et al., 2019e) across the functional lifespan; results which
demonstrate the componential relationship between neurocognitive functions impaired by
HIV-1 viral proteins. Furthermore, PPI, an assessment of preattentive processing, has been
heralded as a diagnostic and prognostic biomarker for HAND (for review, McLaurin et al.,
2019c). Therefore, critically testing the effect of SE on the progression of preattentive
processes may reflect its potential for modifying progressive neurological impairments in
PHIV.
Introduced and popularized by Hoffman and Ison (e.g., Hoffman & Searle, 1965;
Ison & Hammond, 1971), PPI of the ASR is a translational experimental paradigm
commonly used to assess preattentive processing. The brief PPI experimental paradigm
relies upon the addition or removal of a salient prestimulus (i.e., tone, light, gap in
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background noise) and a startling stimulus; a prestimulus that, when presented 30 to 500
msec before the starting stimulus, produces a dramatic reduction in ASR (Hoffman & Ison,
1980). Utilization of the classical ISI approach, which systematically manipulates the time
interval between the salient prestimulus and startling stimulus, establishes the shape of the
ISI function, affording an opportunity to infer preattentive processing (McLaurin et al.,
2019d). Notably, when the classical ISI approach is employed PPI has high test-retest
reliability (Braff et al., 1978); an important consideration when conducting a longitudinal
experimental design.
Thus, the aims of the present study were twofold. First, to assess whether SE alters
somatic growth, the integrity of sensory system function and/or the integrity of grossmotoric function. Evaluating the functional health of HIV-1 Tg and control animals six
months after the cessation of SE treatment provides an opportunity to establish the longterm safety of SE treatment. Second, to evaluate if and/or how SE modifies the progression
of preattentive processing in the HIV-1 Tg rat. The HIV-1 Tg rat, which expresses 7 of the
9 HIV-1 genes constitutively throughout development, affords a biological system to
model key aspects of chronic neurological impairments in PHIV (for review, Vigorito et
al., 2015). Three experimental paradigms, including auditory PPI, visual PPI, and auditory
gap-PPI, were conducted every 30 days from PD 60 to PD 210 to assess preattentive
processing. Development of an efficacious therapeutic that modifies the progression of
chronic neurological impairment resulting from PHIV has the potential for great clinical
significance.
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METHODS
Animals
Fischer (F344/N; Envigo, Indianapolis, IN) HIV-1 Tg (N=24 litters) and control
animals (N=19 litters) were procured at the animal vivarium, housed with their biological
dam, between PD 7 and PD 9. HIV-1 Tg (male, n=33, female, n=34) and F344/N control
(male n=38; female, n=34) animals were randomly sampled from each litter. The goal was
to select only one rat of each sex was selected for each treatment to control for
independence of observation, an assumption underlying many traditional statistical
techniques (i.e., ANOVA). After weaning, which occurred at approximately PD 24,
animals were pair- or group-housed with animals of the same sex for the duration of
experimentation.
AAALAC-accredited facilities were utilized to maintain HIV-1 Tg and control
animals throughout the duration of experimentation using guidelines provided by the Guide
for the Care and Use of Laboratory Animals of the NIH. The targeted environmental
conditions for the animal vivarium were 21°± 2°C, 50% ± 10% relative humidity and a 12h light:12-h dark cycle with lights on at 0700 h (EST). The project protocol was approved
by the IACUC at the University of South Carolina under federal assurance (# D16-00028).
S-Equol
HIV-1 Tg and control animals were treated daily with either SE or placebo (i.e.,
sucrose pellets (Bio-Serv, Inc., Flemington, NC) during the formative period (i.e.,
approximately PD 28 to PD 90). SE (Cayman Chemical Company, Ann Arbo, MI), was
incorporated into sucrose pellets by Bio-Serve, with each pellet containing 0.2 mg SE.
Animals were randomly assigned to receive either SE or placebo (Control: SE,
n=35 (male, n=18, female, n=17), Placebo, n=37 (male, n=20, female, n=17); HIV-1 Tg:
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SE, n=35 (male, n=17, female, n=18), Placebo, n=32 (male, n=16, female, n=16)). A doseresponse experimental design (Moran et al., 2019) previously established 0.2 mg of SE as
the most efficacious dose for the treatment of sustained attention in the HIV-1 Tg rat.
Translationally, the dose utilized yielded a daily amount of 0.25-1.0 mg/kg SE; an amount
equivalent to a 2.5-10 mg dose in a 60 kg human (Cf., most elderly Japanese have a daily
isoflavone intake of 30-50 mg, Akaza, 2012).Therefore, HIV-1 Tg and control animals
assigned to the SE treatment group received a daily oral dose of 0.2 mg of SE. The placebo
group received a sucrose pellet. Treatment was administered daily after the completion of
neurocognitive testing to promote the long-term remodeling of neuronal circuitry (e.g.,
Bertrand et al., 2014, Bertrand et al., 2015).
Cross-Modal Prepulse Inhibition
Apparatus
The startle chambers utilized to conduct cross-modal PPI has been previously
reported (McLaurin et al., 2018b). In brief, a startle platform (SR-Lab Startle Reflex
System, San Diego Instruments, Inc., San Diego, CA) was enclosed within an isolation
cabinet (external dimensions: 10 cm-thick, double-walled, 81 x 81 x 116-cm) (Industrial
Acoustic Company, INC., Bronx, NY), to provide sound attenuation (30 db(A)) relative to
the external environment. A SR-Lab system high-frequency loudspeaker (model#401278B, Radio Shack, Fort Worth, TX), mounted 30 cm aboe the Plexiglas animal test
cylinder, was used to present continuous background noise (22dB(A)), auditory prepulse
stimuli (85 db(A), duration: 20 msec) and the startle stimulus (100 db(A), duration: 20
msec). A 22 lux white LED light, affixed on the wall in front of the test cylinder, was
utilized to present visual prepulse stimuli (duration: 20 msec). A piezoelectric
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accelerometer, attached to the bottom of the Plexiglas animal test cylinder, converted the
deflection of the test cylinder, resulting from animal’s response to the startle stimulus, into
analog signals. Response signals were digitized (12 bit A to D, recorded at a rate of 2000
samples/sec) and saved to a hard disk. Two individual startle apparatuses were used
throughout the duration of experimentation.
Procedure
Cross-modal PPI was conducted on PD 20, prior to weaning, as a baseline
measurement. Subsequently, the developmental trajectory of temporal processing was
assessed by utilizing repeated measurements of cross-modal PPI every 30 days from PD
60 to PD 210 (Control: SE, n=35 (male, n=18, female, n=17), Placebo, n=37 (male, n=20,
female, n=17); HIV-1 Tg: SE, n=35 (male, n=17, female, n=18), Placebo, n=32 (male,
n=16, female, n=16)). A final cross-modal PPI assessment was conducted at PD 270
(Control: SE, n=29 (male, n=13 female, n=16), Placebo, n=29 (male, n=15, female, n=14);
HIV-1 Tg: SE, n=27 (male, n=11, female, n=16), Placebo, n=28 (male, n=14, female,
n=14)) to examine the integrity of auditory and visual sensory system function. The
protocol used to conduct cross-modal PPI is reported by McLaurin et al. (2018b).
In brief, cross-modal PPI was conducted using a 30-minute test session that began
with a 5-min acclimation period (70 dB(A) background white noise). The session began
with six pulse-only ASR trials with a fixed 10 sec intertrial interval. The 72 test trials,
which included an equal number of visual and auditory prepulse trials, were presented in a
counterbalanced order (i.e., ABBA) to control for order-effects. Six interstimulus intervals
(i.e., 0, 30, 50, 100, 200, and 4000 msec), affording an opportunity to evaluate the shape
of the function, were presented in 6-trial blocks according to a Latin-square design. Control
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trials (i.e., 0, 4000 msec ISIs) were included to provide a reference ASR within cross-modal
PPI. During the test trials, the ITI was variable from 15 sec to 25 sec. Mean peak ASR
amplitude values were collected for analysis. All test sessions were conducted in the dark.
Auditory Gap Prepulse Inhibition
Apparatus
Auditory gap-PPI was conducted using the startle apparatus described above.
Procedure
A baseline assessment of auditory gap-PPI was conducted on PD 21, prior to
weaning. Subsequently, a longitudinal experimental design was utilized to assess whether
alterations, resulting from presence of HIV-1 viral proteins, biological sex, and/or
treatment with SE, in the developmental trajectory of temporal processing generalize
across experimental paradigms. Repeated measurements of auditory gap-PPI were
conducted every 30 days from PD 60 to PD 210. At PD 270, a final auditory gap-PPI
assessment was conducted to examine the integrity of auditory system function. Sample
sizes reported for cross-modal PPI (above) reflect those utilized for auditory gap-PPI.
Assessments of auditory gap-PPI were always conducted after cross-modal PPI. The
protocol used to conduct auditory gap-PPI is reported by McLaurin et al. (2016b).
In brief, a 20-min test session, beginning with a 5-min acclimation period (70 dB(A)
background white noise) was utilized to conduct auditory gap-PPI. After the acclimation
period, six pulse-only ASR trials, with a fixed 10 sec ITI, were presented. Six trial blocks,
interdigitated using a Latin-square experimental design, were utilized for the presentation
of the 36 test trials. A 20-msec gap in background noise served as the prestimulus. The
systematic manipulation of the time interval (i.e., ISIs 0, 30, 50, 100, 200, and 4000 msec)
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between the prestimulus and auditory startle stimulus afforded a critical opportunity to
evaluate the shape of the function. Control trials (i.e., 0, 4000 msec ISIs) were included to
provide a reference ASR within auditory gap-PPI. During the test trials, the ITI was
variable from 15 sec to 25 sec. Mean peak ASR amplitude values were collected for
analysis. All test sessions were conducted in the dark.
Locomotor Activity
Apparatus
Perspex inserts were utilized to convert square (40 x 40 cm) activity monitors
(Hamilton Kinder, San Diego Instruments, San Diego, CA) into round (~40 cm diameter)
compartments. Free movement was detected throughout the test sessions by interruptions
of infrared photocells (32 emitter/detector pairs). Notably, the sensitivity of the infrared
photocells was tuned by the manufacturer to work with the additional layer of perspex.
For the assessment of gross motoric movement, the total number of photocell interruptions
within the 60-min test session were calculated. To assess habituation, as a measurement of
long-term episodic memory, the total number of photocell interruptions were binned into
five-min intervals.
Procedure
Locomotor activity was conducted at PD 270 to examine the integrity of grossmotoric system function (Control: SE, n=29 (male, n=13 female, n=16), Placebo, n=29
(male, n=15, female, n=14); HIV-1 Tg: SE, n=27 (male, n=11, female, n=16), Placebo,
n=26 (male, n=13, female, n=13)). Locomotor activity consisted of a 60-min test session
conducted between 700 and 1200h (EST) under dim light conditions (<10 lux) in an
isolated room.
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Statistical Analysis
ANOVA and regression techniques were used to statistically analyze all data (SPSS
Statistics 26, IBM Corp., Somer, NY; GraphPad Software, Inc., La Jolla, CA). Given
potential violations of sphericity inherent in repeated-measures experimental designs,
planned orthogonal contrasts and/or the post-hoc Greenhouse-Geisser df correction factor
(Greenhouse & Geisser, 1959) were applied. An alpha criterion of p≤0.05 was considered
statistically significant for all analyses.
Early alterations in preattentive processing were analyzed using a mixed-factor
ANOVA (SPSS Statistics 26, IBM Corp., Somer, NY) with the mean peak ASR amplitude
serving as the dependent variable. Genotype (HIV-1 Tg vs. Control) and biological sex
(Male vs. Female) served as between subjects factors. Furthermore, ISI (0, 30, 50, 100,
200, and 4000) and trial (1 to 6) were included in the analysis as within subjects factors.
Body weight and sensory function at PD 270 were also analyzed using a mixedfactor ANOVA (SPSS Statistics 26, IBM Corp., Somer, NY). A univariate ANOVA
utilized to evaluate gross-motoric system function at PD 270, where the mean number of
photocell interruptions served as the dependent variable. Genotype, biological sex, and
treatment (SE vs. Placebo) served as between subjects factors. ISI, trial, and age served as
within subjects factors, as appropriate.
The area of the inflection of the ASR amplitude response curve (McLaurin et al.,
2016b), a measure of PPI, was calculated to assess the developmental trajectory of
preattentive processes. Regression analyses (GraphPad Software, Inc., La Jolla, CA) and
mixed-model ANOVA techniques (SPSS Statistics 26, IBM Corp., Somer, NY) were used
to conduct a priori planned comparisons. Specifically, planned comparisons were
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conducted to establish the absence of an SE effect on the progression of preattentive
processes in control animals (i.e., Control Placebo vs. Control SE). When there was no
statistically significant treatment effect in control animals, subsequent analyses were
conducted on all control animals, collapsed across treatment. Additionally, planned
comparisons were conducted 1) to establish the how the HIV-1 transgene altered the
developmental trajectory of preattentive processes (i.e., Control Placebo vs. HIV-1 Tg
Placebo) and 2) to evaluate if and to what extent SE enhanced the progression of
preattentive processes (i.e., HIV-1 Tg Placebo vs. HIV-1 Tg SE and/or Control Placebo vs.
HIV-1 Tg SE). Between subjects’ factors included genotype, biological sex, and treatment.
Age was included as a within subjects’ factor.
RESULTS
Early Neurocognitive Impairments
HIV-1 Tg animals exhibited early neurocognitive impairments in preattentive
processing; impairments which were dependent upon the factor of biological sex, sensory
modality (i.e., auditory, visual) and experimental paradigm (i.e., cross-modal PPI, gapPPI).
In auditory PPI (Figure 6.1), HIV-1 Tg animals, independent of biological sex,
displayed a relative insensitivity to the manipulation of ISI relative to control animals.
Maximal inhibition for both HIV-1 Tg and control animals was observed at the 100 msec
ISI. However, HIV-1 Tg animals exhibited a relatively flatter ISI function relative to
control animals. The overall mixed-model ANOVA, conducted on the mean peak ASR
amplitude, confirmed these observations, revealing a statistically significant genotype x
ISI interaction with a prominent cubic component [F(1,135)=7.0, p≤0.009, ηp2=0.05].
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Male HIV-1 Tg animals, but not female HIV-1 Tg animals, exhibited a relative
insensitivity to the manipulation of ISI in visual PPI (Figure 6.1). Independent of biological
sex, both HIV-1 Tg and control animals displayed maximal inhibition at the 50 msec ISI.
However, male HIV-1 Tg animals exhibited a relatively flatter ISI function relative to male
control animals. The overall mixed-model ANOVA, conducted on the mean peak ASR
amplitude, confirmed these observations, revealing a statistically significant genotype x
sex x ISI interaction with a prominent cubic component [F(1,135)=4.2, p≤0.05, ηp2=0.030].
No statistically significant impairments in preattentive processing were observed in
auditory gap-PPI (Figure 6.1). Independent of biological sex, HIV-1 Tg and control
animals displayed significant inhibition following the presentation of a 20 msec gap in
background noise with maximal inhibition observed at the 30 msec ISI. A downward mean
shift in the mean peak ASR amplitude curve was observed in HIV-1 Tg animals relative to
control animals, evidenced by a statistically significant main effect of genotype
[F(1,137)=11.0, p≤0.001, ηp2=0.075]. However, HIV-1 Tg animals failed to exhibit an
impairment in preattentive processing, per se, in gap-PPI (Genotype x ISI interaction,
p>0.05); results which are consistent with those previously reported at PD 18 (McLaurin
et al., 2017c).
Body Weight: Somatic Growth
Body weight (Figure 6.2), an assessment of somatic growth, was measured weekly
in HIV-1 Tg and control animals from 4 weeks of age (i.e., PD 28) through 40 weeks of
age (i.e., PD 280). HIV-1 Tg animals, independent of biological sex, weighed significantly
less than control animals throughout the duration of the experiment.

A one-phase

association provided a well-described fit for HIV-1 Tg and control animals, independent
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of biological sex and/or treatment (R2s≥0.99). Significant differences, however, were
observed in the rate of growth, evidenced by a statistically significant genotype x age
interaction (Male: [F(36, 2376)=78.0, p≤0.001, ηp2=0.542] with a prominent linear
component [F(1, 66)=271.9, p≤0.001, ηp2=0.805]; Female: [F(36, 2268)=18.5, p≤0.001,
ηp2=0.227] with a prominent linear component [F(1, 63)=53.8, p≤0.001, ηp2=0.461]). Most
critically, however, treatment with SE did not alter the growth trajectory of either HIV-1
Tg or control animals, independent of biological sex, evidenced by the failure to observe a
statistically significant main effect of treatment (p>0.05) or any statistically significant
higher-order interactions with treatment (p>0.05).
Integrity of Sensory and Motor System Function: Postnatal Day 270
Sensory System Function
Cross-modal PPI and auditory gap-PPI assessed at PD 270 to evaluate the integrity
of sensory auditory and visual system function in HIV-1 Tg and control animals following
treatment with SE during the formative period.
Robust inhibition to the presentation of either an auditory prepulse (Figure 6.3) or
a gap in background noise (Figure 6.3) was observed, independent of genotype, biological
sex, and/or treatment, at PD 270, supporting the integrity of auditory system function. In
auditory PPI (Figure 6.3), control animals, independent of treatment, and HIV-1 Tg
animals treated with SE exhibited maximal inhibition at the 200 msec ISI. In contrast, HIV1 Tg animals treated with placebo displayed a prominent leftward shift in the point of
maximal inhibition (i.e., 50 msec ISI). In auditory gap PPI (Figure 6.3), both HIV-1 Tg and
control animals displayed maximal inhibition at the 50 msec ISI.
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The integrity of visual system function was evidenced by robust inhibition to the
presentation of a 20 msec visual prepulse, independent of genotype, biological sex, and/or
treatment, at PD 270 (Figure 6.3). Both HIV-1 Tg and control animals, independent of
treatment, displayed robust inhibition to the visual prepulse at the 50 msec ISI, supporting
the integrity of visual system function.
However, across all three experimental paradigms (i.e., auditory PPI, auditory gap
PPI, visual PPI), profound deficits in temporal processing were observed at PD 270 in HIV1 Tg animals; deficits that were not precluded by treatment with SE during the formative
period. Specifically, HIV-1 Tg animals, independent of experimental paradigm, exhibited
a relative insensitivity to the manipulation of ISI, evidenced by a relatively flatter ISI
function compared to control animals. The overall mixed-model ANOVA, conducted on
the mean peak ASR amplitude, confirmed these observations, revealing a statistically
significant genotype x ISI interaction (Auditory PPI: [F(5,525)=78.2, pGG≤0.001,
ηp2=0.427] with a prominent quadratic component [F(1, 105)=99.0, p≤0.001, ηp2=0.485];
Auditory Gap PPI: [F(5,525)=51.5, pGG≤0.001, ηp2=0.329] with a prominent quadratic
component [F(1, 105)=93.0, p≤0.001, ηp2=0.470] ;Visual PPI: [F(5,525)=52.8, pGG≤0.001,
ηp2=0.335] with a prominent quadratic component [F(1, 105)=71.4, p≤0.001, ηp2=0.405].
A statistically significant sex x ISI interaction (Auditory PPI: [F(10,525)=19.6, pGG≤0.001,
ηp2=0.158] with a prominent quadratic component [F(1,105)=25.2, p≤0.001, ηp2=0.193];
Auditory Gap PPI: [F(5,525)=18.3, pGG≤0.001, ηp2=0.148] with a prominent quadratic
component [F(1, 105)=33.7, p≤0.001, ηp2=0.243] ;Visual PPI: [F(5,525)=13.8, pGG≤0.001,
ηp2=0.116] with a prominent quadratic component [F(1,105)=24.5, p≤0.001, ηp2=0.189])
was also observed. There was not a statistically significant main effect of treatment and/or
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any higher-order interactions between genotype and treatment (p>0.05) for any of the
experimental paradigms.
Notably, in auditory gap-PPI, a statistically significant genotype x sex x ISI
interaction was also observed [F(5,525)=4.9, pGG≤0.003, ηp2=0.044]. The statistically
significant three-way interaction reflects sex differences in temporal processing, but not
the integrity of auditory system functioning. Treatment with SE during the formative
period, therefore, has no adverse effects on sensory system function. Furthermore, despite
the strong evidence for intact sensory system function, prominent alterations in temporal
processing persist.
Motor System Function
Gross motoric system function was examined using the mean number of photocell
interruptions in a 60 minute locomotor activity test session at PD 270. All animals,
independent of genotype, biological sex, and/or treatment exhibited significant motor
movement during the test session (Figure 6.3). HIV-1 Tg animals, collapsed across
biological sex and treatment, displayed a statistically significantly greater number of
photocell interruptions relative to control animals (Main Effect, Genotype [F(1,103)=6.8,
p≤0.01, ηp2=0.062]). There was not a statistically significant main effect of treatment
and/or any higher-order interactions between genotype and treatment (p>0.05). Thus,
treatment with SE during the formative period had no adverse effect on gross motoric
system function.
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Preattentive Processing
The progression of preattentive processing was established by evaluating the area
of the inflection of the ASR response curve (McLaurin et al., 2016b). Planned comparisons
were utilized to statistically test a priori hypotheses (detailed above).
Auditory Prepulse Inhibition
In auditory PPI, treatment with SE during the formative period had neither
beneficial nor adverse effects on the progression of preattentive processing in control
animals (Figure 6.4). Independent of treatment, a global one-phase association afforded a
well-described fit (R2≥0.98) for control animals. The planned comparison was examined
using a mixed-modal ANOVA, which failed to reveal a statistically significant main effect
of treatment or any higher-order interactions with treatment (p>0.05) in control animals.
HIV-1 Tg animals treated with placebo exhibited prominent alterations in the
progression of preattentive processing in auditory PPI relative to control animals (Figure
6.4). A segmental linear regression, with maximal PPI at PD 120, afforded a well-described
fit for HIV-1 Tg animals treated with placebo (R2≥0.90) whereas a one-phase association
provided the best fit for control animals (R2≥0.99); observations which were confirmed by
conducting a planned comparison revealing a statistically significant genotype x age
interaction [F(5, 325)=3.6, pGG≤0.01, ηp2=0.052] with a prominent linear component [F(1,
65)=17.9, p≤0.001, ηp2=0.216].
Despite the prominent genotype effect, treatment with SE during the formative
period failed to mitigate deficits in the progression of preattentive processing in HIV-1 Tg
animals (Figure 6.4). Specifically, independent of treatment, a global segmental linear
regression (R2≥0.82), with maximal PPI observed at PD 120, provided the best fit for the
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progression of preattentive processing in HIV-1 Tg animals. Neither a statistically
significant main effect of treatment nor any higher-order interactions with treatment
(p>0.05) were observed in HIV-1 Tg animals. Therefore, SE was unable to mitigate the
profound effect of the HIV-1 transgene on the developmental trajectory of preattentive
processing in auditory PPI.
Visual Prepulse Inhibition
In visual PPI, treatment with SE during the formative period had neither beneficial
nor adverse effects on the progression of preattentive processing in control animals (Figure
6.5); results which were consistent with observations in auditory PPI. Specifically, a global
segmental linear regression (R2≥0.70), with maximal PPI at PD 120, provided a welldescribed fit for the preattentive processing in control animals.
Presence of the HIV-1 transgene significantly altered the developmental trajectory
of preattentive processing in visual PPI (Figure 6.5). A segmental linear regression
provided the best fit for both HIV-1 Tg animals treated with placebo (R2≥0.97) and control
animals collapsed across treatment (R2≥0.82). HIV-1 Tg animals treated with placebo,
however exhibited a prominent rightward shift in the point of maximal PPI relative to
control animals (PD 150 vs. PD 120, respectively); a shift which supports an alteration in
the development of preattentive processing (Figure 6.5).
Treatment with SE during the formative period enhanced the progression of
preattentive processes in HIV-1 Tg animals (Figure 6.5). Independent of treatment, a
segmental linear regression provided the best fit in HIV-1 Tg animals (R2s≥0.97).
However, HIV-1 Tg animals treated with SE exhibited a prominent leftward shift in the
point of maximal inhibition relative to HIV-1 Tg animals treated with placebo (PD 120 vs.
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PD 150, respectively); a shift which supports a significant effect of SE in HIV-1 Tg
animals. The magnitude of the SE effect was evaluated by comparing HIV-1 Tg animals
treated with SE and control animals; an examination which revealed maximal inhibition at
PD 120 independent of genotype. After PD 120, however, HIV-1 Tg animals treated with
SE exhibited a significant decrease in PPI, whereas control animals displayed no significant
change in PPI. Treatment with SE during the formative period, therefore, was able to alter
the developmental trajectory of visual PPI; albeit only through PD 120.
Auditory Gap Prepulse Inhibition
In auditory gap-PPI, treatment with SE during the formative period had neither
beneficial nor adverse effects on the development of preattentive processing in control
animals (Figure 6.6); results which were consistent with observations in both auditory and
visual PPI. A global segmental linear regression (R2≥0.94), with a change in the rate of
preattentive processing development at PD 120, provided a well-described fit for the
progression of preattentive processing in control animals. Neither a statistically significant
main effect of treatment or any higher-order interactions with treatment (p>0.05) were
observed when the planned comparison was evaluated using a mixed-modal ANOVA.
HIV-1 Tg animals treated with placebo displayed profound alterations in the
development of preattentive processes in auditory gap-PPI (Figure 6.6). A first-order
polynomial provided the best fit for HIV-1 Tg animals treated with placebo (R2≥0.97),
whereas a segmental linear regression afforded a well-described fit for control animals
(R2≥0.99); results which were confirmed by planned comparisons, revealing a statistically
significant genotype x age interaction with a prominent linear component [F(1,100)=5.1,
p≤0.03, ηp2=0.049].
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Treatment with SE ameliorated, at least partially, alterations in the progression of
preattentive processing in HIV-1 Tg animals (Figure 6.6). A segmental linear regression,
with maximal PPI observed at approximately PD 135 was the best fit for HIV-1 Tg animals
treated with SE (R2≥0.99). The progression of preattentive processing in HIV-1 Tg animals
treated with placebo, however, was well-described using a first-order polynomial
(R2≥0.97). Planned comparisons revealed a statistically significant treatment x age
interaction with a prominent quadratic component [F(1, 63)=5.5, p≤0.02, ηp2=0.080],
supporting these observations. Evaluation of the magnitude of the SE effect (i.e., HIV-1
Tg animals treated with SE vs. Control animals) revealed that a segmental linear regression
provided the best fit for both HIV-1 Tg animals treated with SE (R2≥0.99) and control
animals (R2≥0.99). However, beginning at approximately PD 135, HIV-1 Tg animals
treated with SE exhibited a decline in preattentive processing. In sharp contrast, control
animals continued to display significant development of preattentive processing through
PD 210. Although there was a statistically significant effect of SE in HIV-1 Tg animals,
the progression of preattentive processing was still significantly different from controls
(Genotype x Age interaction [F(5,515)=2.3, pGG≤0.05, ηp2=0.022] with a prominent linear
component [F(1,103)=9.8, p<0.002, ηp2=0.087]). Thus, treatment with SE enhances the
developmental trajectory of preattentive processing in HIV-1 Tg animals; albeit not to the
level of controls.
DISCUSSION
Treatment with SE during the formative period (i.e., PD 28 to PD 90) selectively
restored, albeit only partially, the developmental trajectory of preattentive processes in the
HIV-1 Tg rat. Selective early alterations in preattentive processes, characterized by a
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relative insensitivity to the manipulation of ISI, were observed in HIV-1 Tg animals
relative to control animals. Treatment with SE had no adverse long-term effects on somatic
growth, sensory system function or gross-motoric system function in either HIV-1 Tg or
control animals supporting the safety of 0.2 mg SE.

Prominent alterations in the

development of preattentive processes were observed in HIV-1 Tg animals, independent
of experimental paradigm; results which are consistent with previous reports (e.g., Moran
et al., 2013a; McLaurin et al., 2016b; McLaurin et al., 2018b). However, the developmental
trajectory of preattentive processes in HIV-1 Tg animals was partially restored in visual
PPI and auditory gap-PPI by treatment with SE. In auditory PPI, treatment with SE failed
to alter the progression of preattentive processes. Utilization of a longitudinal experimental
design afforded a critical test of SE as a novel therapeutic to modify the progressive chronic
neurological impairments revealing its therapeutic benefits and opportunities for
improvement.
Selective, early alterations in preattentive processes were revealed across a series
of PPI experimental paradigms. A relative insensitivity to the manipulation of ISI was
observed in HIV-1 Tg animals, independent of biological sex, in auditory PPI, but not
auditory gap-PPI; results which replicate those previously reported (McLaurin et al.,
2017c). Furthermore, male, but not female, HIV-1 Tg animals exhibited prominent
alterations in visual PPI relative to their control counterparts reflecting early sex
differences in neurocognitive impairments. Notably, in clinical studies of HIV-infected
children, sex differences in HIV RNA levels and CD4 parameters have been observed in
the presence (European Collaborative Study, 2002; Foca et al., 2006) and absence (Ruel et
al., 2011) of cART. The effect of biological sex on chronic neurological impairments in
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PHIV, however, remains understudied with the exception of a few recent manuscripts
(McLaurin et al., 2016b; Bangirana et al., 2017). Presence of early deficits in preattentive
processes, independent of biological sex, however, highlights the critical need for an
adjunctive therapeutic to alter the progression of chronic neurological impairments.
Critically testing the long-term effects of a novel therapeutic on somatic growth,
sensory system function and gross-motoric system function is integral to evaluating its
potential utility. Although presence of the HIV-1 transgene slowed the rate of somatic
growth, independent of biological sex, treatment with SE had no adverse effects. Six
months after the cessation of SE (i.e., PD 270), there was no evidence for any long-term
genotype and/or treatment effects on auditory system function, visual system function or
gross-motoric system function in either HIV-1 Tg or control animals. Specifically, robust
inhibition to the presentation of either an auditory or visual prepulse was observed in PPI;
an experimental paradigm that has been promoted for the evaluation of sensory system
function (Ison, 1984; Wecker et al., 1985; Crofton & Sheets, 1989). Locomotor activity
was also conducted to index motor behavior (Pierce & Kalivas, 2007) revealing a
significantly greater motor activity in HIV-1 Tg animals, independent of treatment, relative
to controls. Additionally, previous studies report no evidence for adverse peripheral effects,
assessed using uterine weight, following SE treatment in either HIV-1 Tg or control
animals (Moran et al., 2019). Results of the present study, therefore, demonstrate both the
functional health of the HIV-1 Tg rat, replicating previous reports (McLaurin et al., 2018b),
and the safety of the SE as an innovative therapeutic.
Treatment with SE during the formative period (i.e., PD 28 to PD 90) restored,
albeit only partially, the developmental trajectory of preattentive processes in the HIV-1
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Tg rat in both visual PPI and auditory gap-PPI. Specifically, in visual PPI, HIV-1 Tg
animals treated with placebo exhibited a significant rightward shift in the age at which the
point of maximal PPI was observed relative to control animals (i.e., PD 150 vs. PD 120,
respectively). HIV-1 Tg animals treated with SE, however, displayed a prominent leftward
shift in the age at which the point of maximal PPI was observed (i.e., PD 120); a shift
approximating the one observed in control animals. In auditory gap-PPI, the rate of
preattentive processing development is significantly slower in HIV-1 Tg animals treated
with placebo relative to control animals. Treatment with SE, however, significantly
increased the rate of preattentive processing development in HIV-1 Tg animals; albeit not
to the level of controls. The failure to observe restoration in the development of preattentive
processes after PD 120 in either visual PPI or auditory PPI may be due to the cessation of
SE treatment at PD 90. A longer treatment duration may be necessary for long-term
modifications in disease progression, reflecting an opportunity for further therapeutic
improvement.
Treatment with SE, however, was unable to alter the progression of preattentive
processes in auditory PPI. Specifically, independent of treatment, control animals exhibited
significant development of preattentive processes throughout the duration of
experimentation. HIV-1 Tg animals, however, displayed an increased in preattentive
processing through PD 120, but failed to exhibit any significant development at later
assessments. Notably, the neural circuits mediating and/or regulating auditory PPI, visual
PPI, and auditory gap-PPI have key differences which may explain the selective therapeutic
efficacy of SE.

172

The serial neural circuit mediating PPI has been well-established by lesioning (e.g.,
Leitner & Cohen, 1985) and electrical stimulation (e.g., Li & Yeomans, 2000) studies.
Initially, acoustic prepulse stimuli are relayed to the IC, whereas visual prepulse stimuli
are relayed to the SC. Subsequently, sensory input projects to the PPTg, which triggers
acetylcholine projections to the caudal pontine reticular nucleus activating motor neurons
and eliciting a startle response (Fendt et al., 2001; Koch & Schnitzler, 1997).
Additional brain regions (e.g., mPFC, Nac, lateral globus pallidus (LGP)) and
neurotransmitter systems (e.g., DA, GABA) are involved in the regulation of PPI,
evidenced by pharmacological manipulations (e.g., Ellebroek et al., 1996; Japha & Koch,
1999; Pothuizen et al., 2005) and c-Fos induction (e.g., Takahasi et al., 2007; MorenoPaublete et al., 2017). Specifically, c-Fos induction studies have revealed that auditory PPI
and auditory gap-PPI are uniquely regulated by the LGP and auditory cortex, respectively
(Moreno-Paublete et al., 2017). Within the LGP, which has significantly lower DA levels
in HIV-1 seropositive individuals (Kumar et al., 2009), inhibitory GABAergic neurons
project to the PPTg, playing a key regulatory role in PPI (Takahasi et al., 2007). In contrast,
excitatory neurons project from the auditory cortex to the PPTg (Schofield & Motts, 2009).
Auditory PPI, therefore, may be regulated by inhibitory neurons, whereas auditory gapPPI is more likely regulated by excitatory neurons; regulatory differences that may underlie
the selective therapeutic efficacy of SE.
Mechanistically, SE may remodel neuronal circuitry at the synaptic level by
modifying neuronal morphology and dendritic spines, leading to subsequent enhancements
in neurotransmission (Chapter 5). At the broadest level, strong evidence supports the utility
of 17β-estradiol to increase dendritic spine density (e.g., Khan et al. 2013; Hao et al. 2006;

173

Tuscher et al. 2016; Wang et al., 2018), produce a robust shift in the morphological
characteristics of dendritic spines (Hao et al., 2006) and enhance excitatory
neurotransmission (Kritzer & Kohama, 1998); effects which occur via the ERβ pathway
(Wang et al., 2018). In sharp contrast, 17β-estradiol reduces the efficacy of GABAergic
inhibition (Mukherjee et al., 2017). In the context of HIV-1, estrogenic compounds block
neurotoxic effects (Kendall et al., 2005), attenuate oxidative stress (Wallace et al., 2006)
and prevent loss of DA transporter function (Wallace et al., 2006) induced by HIV-1 viral
proteins (i.e., Tat, gp120). More specifically, SE prevents synapse loss (Bertrand et al.,
2015) and enhances synaptic efficacy (Chapter 5) resulting from the presence of HIV-1
viral proteins.
Thus, in conclusion, the present study utilized a longitudinal experimental design
to critically test SE as a novel therapeutic to modify the progressive chronic neurological
impairments. Assessments of functional health, including somatic growth, sensory system
function, and gross-motoric system function support the long-term safety of 0.2 mg SE.
Furthermore, treatment with SE during the formative period selectively restored, albeit
only partially, the developmental trajectory of preattentive processes in the HIV-1 Tg rat,
supporting its potential as a therapeutic to modify progressive chronic neurological
impairments commonly observed in PHIV. Long-term modifications in disease
progression may require a longer duration of treatment, affording a key opportunity for
improvement.
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Figure 6.1 Early Neurocognitive Impairments. Mean peak ASR (±
SEM) is illustrated as a function of genotype (HIV-1 Tg vs. Control).
Early alterations in preattentive processes are evidenced by a relative
insensitivity to the manipulation of ISI in auditory PPI (A), independent
of biological sex. Male (B), but not female (C), HIV-1 Tg animals
displayed prominent early alterations in visual PPI. There was no
evidence for any early alterations in preattentive processes in auditory
gap prepulse inhibition (D).
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Figure 6.2 Somatic Growth. Mean body weight
(±95% CI), a measure of somatic growth, is
illustrated for males (A) and females (B) as a
function of genotype (HIV-1 Tg vs. control),
treatment (SE vs. placebo) and age. Independent of
biological sex, HIV-1 Tg animals exhibited a
slower rate of growth relative to control animals.
Treatment with SE did not alter the growth
trajectory of either HIV-1 Tg or control animals.
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Figure 6.3 Sensory and Motor System Function. Integrity of sensory and grossmotoric system function was assessed at PD 270, six months after the cessation of SE
treatment. Both HIV-1 Tg and control animals, independent of treatment, exhibited
robust inhibition to the presentation of an auditory prepulse (A), a gap in background
noise (B), and a visual prepulse (C) supporting the integrity of sensory system
function. Locomotor activity (D) supported the integrity of gross-motoric system
function, evidenced by significant motor movement, independent of genotype,
biological sex, and/or treatment, during the test session.
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Figure 6.4 S-Equol: Auditory PPI. Auditory PPI, examined using mean area of
the peak inflection curve (±95% CI), is illustrated as a function of genotype (HIV1 Tg vs. control), treatment (SE vs. placebo) and age. (A) Treatment with SE had
no beneficial or adverse effects on the progression of preattentive processes in
control animals, evidenced by a global one-phase association (R2≥0.98). (B)
Preattentive processes in control animals was well-described using a one-phase
association(R2≥0.99), whereas a segmental linear regression, with maximal PPI at
PD 120, provided the best fit for HIV-1 Tg animals treated with placebo (R2≥0.90);
results supporting a prominent alteration in the development of preattentive
processes in HIV-1 Tg animals treated with placebo. (C) Treatment with SE failed
to mitigate deficits in the developmental trajectory of preattentive processing in
HIV-1 Tg animals, evidenced by a global segmental linear regression (R2≥0.82).
Thus, SE was unable to mitigate the profound effect of the HIV-1 transgene on the
developmental trajectory of preattentive processing in auditory PPI.
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Figure 6.5 S-Equol: Visual PPI. Visual PPI, examined using mean area of the peak
inflection curve (±95% CI), is illustrated as a function of genotype (HIV-1 Tg vs.
control), treatment (SE vs. placebo) and age. (A) Treatment with SE had no
beneficial or adverse effects on the progression of preattentive processes in control
animals, evidenced by a global segmental linear regression (R2≥0.70), with maximal
PPI at PD 120. (B) Although preattentive processes in both HIV-1 Tg and control
animals were well-described by a segmental linear regression (R2≥0.97 and R2≥0.82,
respectively), HIV-1 Tg animals displayed a prominent rightward shift in the point
of maximal PPI relative to control animals (PD 150 vs. PD 120, respectively). (C)
Treatment with SE enhanced the developmental trajectory of preattentive processes
in HIV-1 Tg animals, evidenced by a prominent leftward shift in the point of
maximal inhibition in HIV-1 Tg animals treated with SE relative to HIV-1 Tg
animals treated with placebo (PD 120 vs. PD 150, respectively). (D) Both HIV-1 Tg
animals treated with SE and control animals exhibited maximal inhibition at PD 120.
However, after PD 120, HIV-1 Tg animals treated with SE displayed a significant
decrease in PPI, whereas control animals displayed no significant change in PPI.
Thus, treatment with SE during the formative period was able to partially restore the
developmental trajectory of visual PPI in HIV-1 Tg animals.
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Figure 6.6 S-Equol: Auditory Gap-PPI. Auditory gap-PPI, assessed using mean
area of the peak inflection curve (±95% CI), is illustrated as a function of genotype
(HIV-1 Tg vs. control), treatment (SE vs. placebo) and age. (A) Treatment with
SE had no beneficial or adverse effects on the progression of preattentive
processes in control animals, evidenced by a global segmental linear regression
(R2≥0.94), with a change in the rate of preattentive processing development at PD
120. (B) HIV-1 Tg animals treated with placebo displayed a prominent alteration
in the developmental trajectory of preattentive processes. Specifically, a first-order
polynomial provided a well-described fit for HIV-1 Tg animals treated with
placebo (R2≥0.97), whereas a segmental linear regression afforded the best fit for
control animals (R2≥0.99). (C) Treatment with SE mitigated alterations in the
progression of preattentive processes in HIV-1 Tg animals. A segmental linear
regression, with maximal PPI observed at approximately PD 135 was the best fit
for HIV-1 Tg animals treated with SE (R2≥0.99). The progression of preattentive
processing in HIV-1 Tg animals treated with placebo, however, was welldescribed by a first-order polynomial (R2≥0.97). (D) Treatment with SE partially
restored the developmental trajectory of preattentive processes. Beginning at
approximately PD 135, HIV-1 Tg animals exhibited a decline in preattentive
processes. Control animals, however, continued to display significant preattentive
processing development through PD 210.
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CHAPTER 7
HIV-1 VIRAL PROTEINS ALTER THE MATURATIONAL PROCESSES OF
PYRAMIDAL NEURONS IN THE MEDIAL PREFRONTAL CORTEX
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INTRODUCTION
The PFC, located at the anterior pole of the mammalian brain, is well-recognized
as an anatomically and functionally complex brain region (Siddiqui et al., 2008). In a
seminal study, Rose and Woolsey (1948) defined the rodent PFC as areas connected with
the mediodorsal nucleus of the thalamus. More recent research, however, has supported
expanding the definition of the rodent PFC to also include functional considerations (e.g.,
Kesner, 2000) and additional cortico-cortical connections (e.g., Uylings & Van Eden,
1990). Utilization of these criteria has provided an opportunity to further subdivide the
PFC into three distinct regions in the rat, including the mPFC, lateral PFC, and ventral PFC
(for review, Dalley et al., 2004). Functionally, the PFC has two broad roles, including the
temporal organization of behavior (Fuster, 2008) and executive functions (Fuster, 2008);
neurocognitive functions which are fundamentally altered by HIV-1 viral proteins (e.g.,
Heaton et al., 2011; Chan & Brew, 2014; Moran et al., 2014a; Moran et al., 2019).
Longitudinal experimental designs have afforded a key opportunity to assess the
progression of neurocognitive impairments associated with HAND, which afflict
approximately 40-70% of HIV-1 seropositive individuals (Heaton et al., 2010; Letendre et
al., 2010; McArthur et al., 2010). Clinical studies have reported progressive neurocognitive
decline in a significant proportion (i.e., 13-30%) of HIV-1 seropositive individuals (e.g.,
Heaton et al., 2015; Sacktor et al., 2016; Rubin et al., 2017; Gott et al., 2017); results which
were translationally modeled and extended in the HIV-1 Tg rat (McLaurin et al., 2018b;
McLaurin et al., 2019b). Across the functional lifespan, the HIV-1 Tg rat displayed agerelated disease progression across multiple neurocognitive domains commonly associated
with the PFC (e.g., McLaurin et al., 2018b; McLaurin et al., 2019b; temporal processing:
Ellenbroek et al., 1996, stimulus-reinforcement learning: Rolls, 2004, sustained attention:
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Kim et al., 2016). Although recent research has enhanced our understanding of the
progression of neurocognitive impairments in HAND, to date, longitudinal experimental
designs remain underutilized for the investigation of the pathogenesis of HAND, with one
notable exception (e.g., Casas et al., 2018). To address this knowledge gap, the present
study examined the progression of synaptic dysfunction, a putative neural mechanism
underlying HAND (e.g., Gelman & Nguyen, 2010; Desplats et al., 2013; Roscoe et al.,
2014; McLaurin et al., 2019b), in the PFC.
Mature neuronal circuits are formed during a series of progressive (i.e., growth)
and regressive (i.e., pruning) events throughout development (for review, Riccomagno &
Kolodkin, 2015). Synaptogenesis, which involves the establishment, maintenance,
refinement and elimination of synapses (Sachana et al., 2017), serves as one key example.
In 1976, Changeau and Danchin proposed the selective-elimination hypothesis, whereby
the development of mature neuronal circuits depends upon the selective stabilization of
developing synapses (Changeau & Danchin, 1976). Observations of the initial
overproduction and subsequent pruning of excitatory synapses, independent of brain region
(e.g., Huttenlocher, 1979; Bourgeois et al., 1994; Huttenlocher & Dabholkar, 1997;
Petanjek et al., 2011), provided strong evidence for the selective-elimination hypothesis.
The PFC specifically exhibits the greatest overproduction of dendritic spines, a proxy for
excitatory synapses (Berry & Nedivi, 2017), and the slowest rate of synaptic pruning
(Elston et al., 2009). In regards to timing, synaptic pruning in the PFC typically begins at
puberty and is completed during early adolescence (Huttenlocher et al., 1979; Drzewiecki
et al., 2016). Notably, the timing of synaptic pruning coincides with the development of
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higher-order cognitive processes supporting its potential functional significance (e.g.,
Selemon, 2013).
Evaluating the morphological parameters of dendritic spines, which are a key
structural and functional element of neurons, may afford insight into the functionality and
connectivity of synapses (Lai & Ip, 2013). Dendritic spine volume serves as a
morphological parameter that encapsulates dendritic spine backbone length, head diameter,
and neck diameter. Specifically, increased dendritic spine volume is associated with
increased synaptic area (Freire, 1978; Arellano et al., 2007), which is correlated with the
number of presynaptic vesicles (Harris & Stevens, 1988), the number of docked vesicles
(Schikorski & Stevens, 1999), and the number of postsynaptic receptors (Yuste, 2010).
Evaluation of dendritic spines across development, therefore, may not only provide
information about synaptogenesis, but also the functional capacity of synapses.
Synaptic function has been examined in HIV-1 seropositive individuals (e.g.,
Gelman & Nguyen, 2010; Desplats et al., 2013), as well as biological systems used to
model key aspects of HAND (e.g., Fitting et al., 2013; Roscoe et al., 2014; McLaurin et
al., 2019b); results which illustrate profound functional deficits. In the mPFC, synaptic
dysfunction, accounting for 64.6% of the genotypic variance, is characterized by prominent
alterations in dendritic branching complexity, synaptic connectivity, and dendritic spine
morphology (McLaurin et al., 2019b). Additional support for the importance of synaptic
dysfunction is evidenced by the generalizability of observations across brain regions (i.e.,
mPFC (McLaurin et al., 2018a; McLaurin et al., 2019b), Nac (Roscoe et al., 2014;
McLaurin et al., 2018c), hippocampus (Fitting et al., 2013)) and ages (i.e., 4 months
(Roscoe et al., 2014); 14-17 months (McLaurin et al., 2018a); 20 months (McLaurin et al.,
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2018c; McLaurin et al., 2019b). The cross-sectional nature of these studies, however,
precludes evaluating key progressive (i.e., growth) and regressive (i.e., pruning) events
and/or the progression of synaptic dysfunction across time; a critical consideration given
the characterization of HAND as a progressive, age-related neurodegenerative disease
(Cohen et al., 2015; McLaurin et al., 2019b).
In light of previous studies, the aim of the present study was to assess the
progression of synaptic dysfunction in pyramidal neurons from layers II-III of the mPFC
in the HIV-1 Tg rat in the absence of neurocognitive testing. A ballistic labeling technique
was utilized to visualize neurons and distinguish dendritic spines (O’Brien & Lummis,
2007) at six ages across development (i.e., PD 30 to PD 180). Furthermore, use of
sophisticated neuronal reconstruction software provided an opportunity to investigate
neuronal structure (i.e., total dendrite length, Sholl analysis, dendritic branching) and
morphological characteristics of dendritic spines (i.e., volume, backbone length, head
diameter). Understanding how HIV-1 viral proteins alter progressive and/or regressive
processes, as well as synaptic function, in the mPFC may afford a key target for the
development of innovative therapeutics.
METHODS
Animals
Fischer (F344/N) control animals were procured from Envigo Laboratories Inc.
(Indianapolis, IN) and delivered to the animal vivarium at least one week prior to sacrifice.
All F344/N control animals were pair- or group-housed until sacrifice. HIV-1 Tg animals
were bred at the University of South Carolina by pairing an F344/N female with an HIV-1
Tg male. At approximately PD 24, HIV-1 Tg animals were weaned and pair- or grouphoused with animals of the same sex until sacrifice. To control for independence of
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observations, the goal was to utilize no more than one rat pup per sex from each litter for
each age.
HIV-1 Tg and control animals were sacrificed at six different ages (i.e., PD 30, PD
60, PD 90, PD 120, PD 150, and PD 180) to assess the progression of synaptic dysfunction
in pyramidal neurons from layers II-III of the mPFC (Control: PD 30, n=20 (male, n=10,
female, n=10), PD 60, n=20 (male, n=10, female, n=10), PD 90, n=20 (male, n=10, female,
n=10), PD 120, n=20 (male, n=10, female, n=10), PD 150, n=20 (male, n=10, female,
n=10), PD 180, n=18 (male, n=10, female, n=8); HIV-1 Tg: PD 30, n=15 (male, n=7,
female, n=8), PD 60, n=18 (male, n=10, female, n=8), PD 90, n=17 (male, n=10, female,
n=7), PD 120, n=20 (male, n=10, female, n=10), PD 150, n=20 (male, n=10, female, n=10),
PD 180, n=20 (male, n=10, female, n=10). Ages for sacrifice were selected based on a
longitudinal study of brain volumetric measurements in the HIV-1 Tg rat, suggesting the
most prominent brain injury occurs earlier in life (Casas et al., 2018).
HIV-1 Tg and control animals were maintained in AAALAC-accredited facilities
using recommendations in the Guide for the Care and Use of Laboratory Animals of the
NIH. The targeted environmental conditions for the animal vivarium were 21°± 2°C, 50%
± 10% relative humidity and a 12-h light:12-h dark cycle with lights on at 0700 h (EST).
The project protocol was approved under federal assurance (# D16-00028) by the IACUC
at the University of South Carolina.
Estrous Cycle Tracking
Estrous cyclicity was examined prior to sacrifice by performing a vaginal lavage.
Cellular cytology was examined in vaginal smears, as previously described (Booze et al.,
1999), using a light microscope (10x). Stage of the estrous cycle was determined by the
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predominant cell type (Waynforth & Flecknell, 1992; Westwood, 2008). The diestrus
phase was characterized by the predominance of leukocytes (Marcondes et al., 2002).
Synaptic Dysfunction
Methodology for the ballistic labeling technique utilize to assess synaptic
dysfunction was initially described by Seabold et al. (2010) and has been adapted for use
in our laboratory (Li et al., 2020). For female animals, the goal was to sacrifice animals
during the diestrus phase of the estrous cycle.
Preparation of Cartridges and Tefzel Tubing
In brief, dissolve polyvinylpyrrolidone (PVP; 100 mg) in double deionized H2O (10
mL), vortex lightly and utilize the PVP solution to coat the Tefzel tubing (IDEX Health
Sciences, Oak Harbor, WA). Cartridges were prepared by dissolving tungsten microcarrier beads (170 mg; Bio-Rad, Hercules, CA) in methylene chorlide (250 μL). Separately,
lipophilic DiIC18(3) dye (6 mg) was combined with methylene chloride (300 μL) and
vortexed thoroughly. The tungsten bead suspension was pipetted onto a glass slide and
allowed to air dry. Subsequently, the lipophili DiIC18(3) dye solution was pipetted on top
of the tungsten bead suspension layer and mixed. The mixture was placed into centrifuge
tubes filled with H2O and sonicated. The dye mixture was drawn into the PVP-coated
tubing, placed in the tubing prep station (Bio-Rad) and allowed to dry under nitrogen gas.
Cartridges were cut into 13 mm segments.
Preparation of Brain Tissue
Animals were deeply anesthetized using sevoflurane (5%; Abbot Laboratories,
North Chicago, IL) and transcardially perfused using 100 mM phosphate buffered saline
(PBS; 50 mL) followed by 4% paraformaldehyde buffered in 100 mM PBS (100 mL). The
brain was removed and postfixed for 10 minutes with 4% paraformaldehyde. Coronal
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sections were cut (500 μm) using a rat brain matrix (Ted Pella Inc., Redding, CA) and
placed in a well-plate with 100 mM PBS (1 mL).
Ballistic Labeling
Pyramidal neurons from layers II-III of the mPFC were visualized using a ballistic
labeling technique. The previously prepared cartridges were loaded into the Helios gene
gun (Bio-Rad) and delivered through pore filter paper (3 µm) using Helium gas (90 PSI).
The Helios gene gun was targeted at the center of the well and placed approximately 2.5
cm away from the sample before firing the cartridges. After completing the ballistic
labeling, brain sections were washed three times in 100 mM PBS (500 µL) and stored in
the dark at 4°C for three hours. Subsequently, slides were transferred onto glass slides,
mounted using Pro-Long Gold Antifade (Invitrogen, Carlsbad, CA) and coverslipped.
Glass slides were stored in the dark for two days to allow for drying.
Confocal Imaging
Z-stack images were obtained on three to four pyramidal neurons (3.7 mm to 2.2
mm anterior to Bregma; Paxinos & Watson, 2014) from each animal using a Nikon TE2000E confocal microscope and Nikon’s EZ-C1 software (version 3.81b). Images were
taken at 60x magnification (A/1.4, oil) using a Z-plane interval of 0.15 µm with a pinhole
size of 30 μm and back-projected pinhole radius of 167 nm. A helium-neon laser with a
543 nm wavelength was used to acquire images.
Neuronal Analysis and Spine Quantification
Neuronal reconstruction software (Neurolucida 360 (MicroBrightfield, Williston,
VT) was utilized to analyze morphological characterstics of pyramidal neurons and
dendritic spines. To control for independence of observations, only one neuron was chosen
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for analysis using selection criteria. Selection criteria, illustrated in Li et al. (2020), include
continuous dendritic staining, low background/dye clusters, and minimal diffusion of the
DiI dye into the extracellular space. Neurons not meeting the selection criteria were not
included in the analysis, yielding (Control: PD 30, n=19 (male, n=9, female, n=10), PD
60, n=19 (male, n=10, female, n=9), PD 90, n=18 (male, n=10, female, n=8), PD 120, n=17
(male, n=9, female, n=8), PD 150, n=18 (male, n=8, female, n=10), PD 180, n=14 (male,
n=9, female, n=5); HIV-1 Tg: PD 30, n=14 (male, n=7, female, n=7), PD 60, n=17 (male,
n=10, female, n=7), PD 90, n=15 (male, n=8, female, n=7), PD 120, n=20 (male, n=10,
female, n=10), PD 150, n=19 (male, n=9, female, n=10), PD 180, n=17 (male, n=9, female,
n=8).
Neuronal morphology was examined using two approaches, including the classical
Sholl analysis (Sholl, 1953) and branch order. Specifically, Sholl analysis affords an
opportunity to infer alterations in neuronal complexity by counting the number of
intersections at each successive radii (10 µm). A centrifugal branch ordering method was
utilize to assign each dendrite with a branch order by counting the number of segments
traversed; an assessment of dendritic branching complexity. Output from the Sholl analysis
was also utilized to evaluate synaptic connectivity by examining the number of dendritic
spines between each successive radii.
Morphological characteristics of dendritic spines were examined using three
parameters, including volume (µm3), backbone length (µm), and head diameter (µm).
Volume served as the primarily morphological parameter given that it encapsulates both
backbone length and head diameter. Spine parameters were defined using well-accepted
previously published results [i.e., volume, 0.05 to 0.85 µm: Hering & Sheng, 2001;
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backbone length, 0.4 to 4.0 µm: Ruszcycki et al., 2012; head diameter, 0 to 1.2 µm: Konur
et al., 2003].
Statistical Analysis
Data were statistically analyzed by conducting ANOVA and regression techniques
(SAS/STAT Software 9.4, SAS Institute, Inc., Cary, NC; SPSS Statistics 26, IBM Corp.,
Somer, NY; GraphPad Software, Inc., La Jolla, CA). An alpha criterion of p≤0.05 was
established for statistical significance.
Regression analyses (GraphPad Software, Inc., La Jolla, CA) were utilized to assess
measures of neuronal morphology, including total dendrite length, area under the Sholl
curve, and the total number of dendritic branches. Additionally, the area under the Sholl
curve, the total number of dendritic branches, and the total number of dendritic spines were
analyzed using a repeated-measures ANOVA (SPSS Statistics 26, IBM Corp., Somer, NY).
Between subjects’ factors included genotype (HIV-1 Tg vs control), biological sex (Male
vs. Female), and age (PD 30, PD 60, PD 90, PD 120, and PD 180). The number of
intersections at each radii (Sholl) or the number of dendrites at branch orders on through
ten (Branch Order) served as the dependent variable.
Measures of synaptic dysfunction included the total number of dendritic spines, an
assessment of synaptic connectivity, and dendritic spine morphological parameters. The
total number of dendritic spines was examined using both regression analyses (GraphPad
Software, Inc., La Jolla, CA) and a univariate ANOVA. A generalized linear mixed effects
model with a Poisson distribution and an unstructured covariance pattern (SAS/STAT
Software 9.4, SAS Institute, Inc., Cary, NC) was utilized to assess synaptic connectivity,
by evaluating the total number of dendritic spines between each radius, and dendritic spine
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volume, by examining the number of dendritic spines in each bin. Additionally, the median
dendritic spine volume, dendritic spine backbone length, and dendritic spine head diameter
were calculated for each animal to evaluate how dendritic spine morphology changes
across time. Regression analyses (GraphPad Software, Inc., La Jolla, CA) and univariate
ANOVAs were conducted on the median dendritic spine volume, dendritic spine backbone
length, and dendritic spine head diameter.
RESULTS
Sholl Analysis
Total dendrite length was examined as one measure of neuronal morphology.
Regression analyses revealed a differential dendrite development across time (Figure 7.1).
Independent of genotype, a segmental linear regression provided a well-described fit for
total dendrite length across age. In HIV-1 Tg animals (R2≥0.91), there was no significant
growth from PD 30 to PD 120. However, HIV-1 Tg animals exhibited a linear increase in
total dendrite length from PD 120 to PD 180. In control animals (R2≥0.75), a linear decrease
in total dendrite length was observed from PD 30 to PD 60, followed by no additional
changes in total dendrite length from PD 60 to PD 180. HIV-1 Tg animals, therefore,
displayed a differential developmental growth trajectory for total dendrite length in
pyramidal neurons from layers II-III of the mPFC.
The classical Sholl analysis was conducted to evaluate change in dendritic arbor
complexity. To investigate if and/or how dendritic arbor complexity changes across time,
the area under the Sholl curve was calculated for each animal. HIV-1 Tg animals,
independent of biological sex, exhibited a differential development of dendritic arbor
complexity relative to control animals (Figure 7.1; Genotype x Age interaction, [F(5,
183)=2.8, p≤0.020, ηp2=0.070]). In HIV-1 Tg animals, a segmental linear regression
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provided a well-described fit for the progression of area under the Sholl curve (R2≥0.93).
Specifically, there was no evidence for increase in area under the Sholl curve from PD 30
to PD 120, but a linear increase in area under the Sholl curve from PD 120 to PD 180. In
control animals, the progression of area under the Sholl curve was also best fit using a
segmental linear regression (R2≥0.76), whereby a linear decrease in area under the Sholl
curve was observed from PD 30 to PD 60, followed by a plateau.
Observations revealed by examining the area under the Sholl curve were confirmed
by conducting a repeated-measures ANOVA on the number of intersections per radii, a
more traditional statistical approach for Sholl analysis. Specifically, a statistically
significant genotype x age interaction [F(5, 183)=2.8, p≤0.019, ηp2=0.070) was also
observed when utilizing a more traditional statistical approach for Sholl analysis. Although
a statistically significant main effect of radius [F(24, 4392)=225.1, p≤0.001, ηp2=0.552],
there were no two-way or higher-order interactions with radius.
Branch Order
A centrifugal branch ordering method was utilized, whereby sophisticated neuronal
reconstruction software counts assigns each dendrite with a branch order based on the
number of segments traversed, to assess dendritic branching complexity. Branch orders
one through ten were evaluated in the present study. Consistent with observations in Sholl
analysis, HIV-1 Tg animals exhibited a differential development of dendritic branching
complexity relative to control animals (Figure 7.1; Genotype x Age interaction,
[F(5,183)=3.3, p≤0.006, ηp2=0.084]). Specifically, in HIV-1 Tg animals, the total number
of dendritic branches across time was well-described by a segmental linear regression,
whereby, a plateau was observed from PD 30 to PD 120, followed by a subsequent linear
increase in branches (R2≥0.98). A segmental linear regression also afforded the best fit for
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control animals evidenced by a plateau from PD 30 to PD 90, followed by a linear decrease
in branches (R2≥0.86).
Most critically, however, a prominent shift in the distribution of dendritic branches
at each branch order was also observed (Genotype x Age x Branch interaction,
[F(45,1647)=1.9, pGG≤0.013, ηp2=0.049]); results which are illustrated at PD 30 and PD
180. At PD 30 (Figure 7.1), HIV-1 Tg animals exhibited an increased relative frequency
of dendrites on lower-order branches relative to control animals. However, at PD 180
(Figure 7.1), a prominent shift was observed whereby HIV-1 Tg animals displayed an
increased relative frequency of dendrites on higher-order branches relative to control
animals. Taken together, results support a differential development of dendritic branching
complexity which may indicate alterations in dendritic pruning.
Excitatory Synapses
The dendritic spine head typically contains a single type 1 asymmetric synapse,
thereby the total number of dendritic spines may serve as a surrogate for the approximate
number of excitatory synapses on a neuron. Investigations of the average total number of
spines revealed a differential progression of spine development across time (Figure 7.2;
Genotype x Age interaction, [F(5, 183)=4.8, p≤0.001]). HIV-1 Tg animals exhibited a
linear increase in the total number of spines across age, well-described by a first-order
polynomial (R2≥0.71). In contrast, control animals displayed the greatest number of
dendritic spines at PD 30, followed by a subsequent plateau; a pattern which was best fit
by a segmental linear regression (R2≥0.68).
Further evidence for alterations in synaptic connectivity is afforded by examining
the distribution of dendritic spines on pyramidal neurons from the mPFC. HIV-1 Tg
animals displayed a prominent shift in the distribution of dendritic spines dependent upon
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biological sex and age (Genotype x Age x Sex x Radii interaction, [F(5,4944)=131.0,
p≤0.001]); results which are illustrated, dependent upon biological sex, at PD 30 (Figure
7.2) and PD 180 (Figure 7.2). At both PD 30 and PD 180, HIV-1 Tg animals exhibited an
increased relative frequency of dendritic spines on more distal branches relative to control
animals. Notably, the magnitude of the effect is dependent upon the factor of biological
sex. Although HIV-1 Tg animals exhibited an increased number of dendritic spines across
age, the distribution of dendritic spines was shifted towards distal branches supporting
alterations in synaptic connectivity.
Dendritic Spine Morphology
Morphological characteristics of dendritic spines fall along a continuum (for
review, Yuste, 2010) and may reflect functionality and capacity for structural change.
Dendritic spine volume, encapsulating both backbone length and head diameter, was the
primary morphological parameter investigated in the present study.
To investigate changes in dendritic spine volume across time, median volume (μm3)
was calculated for each animal. HIV-1 Tg animals, independent of biological sex, exhibited
a differential progression of median dendritic spine volume relative to control animals
(Figure 7.3; Genotype x Age interaction, [F(5, 183)=29.8, p≤0.001, ηp2=0.449]). A linear
decrease in median dendritic spine volume is observed in HIV-1 Tg animals across time
(R2≥0.83). In sharp contrast, control animals exhibited a linear increase in median dendritic
spine volume across time (R2≥0.89).
Examination of the distribution of dendritic spine volume in HIV-1 Tg and control
animals as a function of age (Figure 7.3) confirmed these observations (Genotype x Age x
Bin interaction, [F(5,3288)=25.9, p≤0.001]). At PD 30, PD 60, and PD 90, HIV-1 Tg
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animals displayed a prominent population shift towards increased dendritic spine volume
relative to control animals. However, at PD 120, PD 150, and PD 180, a prominent
population shift towards decreased dendritic spine volume was observed in HIV-1 Tg
animals relative to control animals. Notably, a statistically significant genotype x age x sex
x bin interaction [F(5, 3288)=19.7, p≤0.001] was also observed, reflecting a difference in
the magnitude, but not pattern, of the shift in male and female HIV-1 Tg animals.
Dendritic spine backbone length and head diameter were also assessed as
complementary measures of dendritic spine morphology. First, investigation of median
dendritic spine backbone length revealed a differential progression in HIV-1 Tg and control
animals, independent of biological sex (Figure 7.4; Genotype x Age interaction, [F(5,
183)=4.7, p≤0.001, ηp2=0.114]). A segmental linear regression provided a well-described
fit for median backbone length in HIV-1 Tg animals (R2≥0.96), characterized by a linear
decreased through PD 120, followed by a plateau. Median backbone length in control
animals, however, is best fit using a first-order polynomial (R2≥0.64), illustrating the linear
increase in median dendritic spine backbone length across time. Second, a differential
progression of median dendritic spine head diameter was observed, independent of
biological sex, in HIV-1 Tg animals relative to control animals (Figure 7.4; Genotype x
Age interaction, [F(5,183)=4.0, p≤0.002, ηp2=0.100). HIV-1 Tg animals exhibited a linear
decrease in median head diameter across time (R2≥0.60), whereas control animals
displayed a linear increase in median head diameter across time (R2≥0.63). Thus, a
differential progression in dendritic spine morphology, characterized by changes in
volume, backbone length, and head diameter, were observed in HIV-1 animals relative to
controls.
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DISCUSSION
Prominent alterations in regressive (i.e., pruning) processes, as well as synaptic
function, were observed, independent of biological sex, in pyramidal neurons from layers
II-III of the mPFC in the HIV-1 Tg rat. Specifically, HIV-1 Tg animals exhibited a
differential development of morphological parameters of pyramidal neurons, including
total dendrite length, dendritic arbor complexity and dendritic branching complexity,
relative to control animals; results which support an alteration in neurite pruning. Failure
to effectively prune synapses was evidenced by a linear increase in the number of dendritic
spines, a proxy for the number of excitatory synapses (Berry & Nedivi, 2017), in HIV-1
Tg animals across development. Furthermore, synaptic dysfunction was evidenced by
profound alterations in synaptic connectivity and synaptic efficacy. Specifically, HIV-1 Tg
animals exhibited an increased relative frequency of dendritic spines on more distal
branches, supporting an alteration in synaptic connectivity. The linear decrease in dendritic
spine volume, backbone length, and head diameter during development, observed in HIV1 Tg animals relative to controls, may be associated with decreased synaptic efficacy.
Understanding how the presence of HIV-1 viral proteins alters key progressive and
regressive processes and synaptic function across time may afford a key target for the
development of innovative therapeutics.
HIV-1 Tg animals, independent of biological sex, exhibited developmental
alterations in dendritic pruning in pyramidal neurons from layers II-III of the mPFC (Figure
7.5). Specifically, an increase in total dendrite length, dendritic arbor complexity, and
dendritic branching complexity was observed in HIV-1 Tg animals from PD 120 to PD
180; a developmental trajectory that was significantly different from control animals. In
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sharp contrast, a cross-sectional study investigating neuronal morphology in HIV-1 Tg
animals at an advanced age (i.e., approximately 20 months) failed to reveal a statistically
significant alteration in either total dendrite length or dendritic arbor complexity (McLaurin
et al., 2019b). However, at an advanced age, HIV-1 Tg animals displayed alterations in
dendritic branching complexity characterized by an increased relative frequency of
dendrites on lower-order branches. Advanced age and/or repeated neurocognitive testing
may underlie differences in the inferences drawn from these two studies.
Synaptic pruning, a key regressive event that is important for the development of
mature neuronal circuits (Riccomagno & Kolodkin, 2015), was altered in HIV-1 Tg
animals. A linear increase in the total number of dendritic spines across time was observed
in HIV-1 Tg animals. Observations in control animals, however, were consistent with the
selective-elimination hypothesis, which suggests profound synaptic pruning during
puberty (i.e., approximately PD 42 in the rat; Sengupta, 2013) that is completed by early
adolescence (i.e., approximately PD 63 in the rat; Sengupta, 2013). Microglia, which serve
as a viral reservoir for HIV-1 in the brain (e.g., Cosenza et al., 2002; Ko et al., 2019), may
underlie deficits in synaptic pruning observed in the HIV-1 Tg rat. Specifically, during
normal development, microglia engulf both the pre- and postsynaptic components of
synapses (Paolicelli et al., 2011). Cx3cr1 (Paolicelli et al., 2011) and the classical
complement cascade (e.g., Stevens et al., 2007; Schafer et al., 2012) are two signaling
mechanisms which may guide microglia-dependent synaptic pruning. Notably, both
Cx3cr1 (e.g., Duan et al., 2014) and complement receptor 3 (e.g., Mishra et al., 2018) are
altered by HIV-1 viral proteins. Therefore, the presence of HIV-1 viral proteins leads to
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activated microglia, as well as alterations in Cx3cr1 and complement receptor 3, which
may underlie the failure to effectively prune synapses.
Profound deficits in synaptic connectivity were evidenced by a prominent
rightward shift in the distribution of dendritic spines along the apical dendrite in HIV-1 Tg
animals relative to controls. An increased relative frequency of dendritic spine on more
distal dendrites, which extend from layers II-III of the mPFC into layer I, were observed in
HIV-1 Tg animals relative to control animals. The PFC, which receives afferent projections
from multiple brain regions (e.g., thalamic nuclei, the limbic system, hypothalamus; Fuster,
2008) and neurotransmitter systems (e.g., DA, NE, serotonin; Fuster, 2008), integrates and
coordinates an extensive number of neural processes (Miller & Cohen, 2001). Examination
of the predominant neurotransmitter receptors in each layer of the mPFC revealed DAergic,
noradrenergic, and serotonergic receptors in layer II-III of the mPFC (Santana & Artigas,
2017). In sharp contrast, little receptor expression was observed in layer I of the mPFC
(Santana & Artigas, 2017). The preponderance of dendritic spines on distal dendrites,
which extend into layer I of the mPFC, supports a decreased number of monoamine
receptors, and therefore neurotransmitter innervation, in HIV-1 Tg animals; a result which
is consistent with neurotransmitter system alterations in HIV-1 seropositive individuals
(e.g., Wang et al., 2004; Kumar et al., 2009) and biological systems utilized to model HIV1 (e.g., Denton et al., 2019).
Progressive synaptic dysfunction, evidenced by profound alterations in the
morphological parameters of dendritic spines, was also observed in HIV-1 Tg animals.
Specifically, HIV-1 Tg animals displayed a linear decrease in dendritic spine volume
across time, whereas control animals exhibited a linear increase in dendritic spine volume
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throughout development. The continuous decline in dendritic spine volume supports an
age-dependent decrease in PSD (Freire, 1978; Arellano et al., 2007), which may result in
decreased synaptic efficacy, in the HIV-1 Tg rat. The PSD, which is a protein rich region
located at the tip of postsynaptic dendritic spines, is a primary characteristic of
glutamatergic excitatory synapses (for review, Boeckers, 2006). Notably, the downregulation of the PSD and profound alterations in glutamate receptors (e.g., Haughey et al.,
2001; Aksenov et al., 2012; Atluri et al., 2013), resulting from HIV-1 viral proteins, support
functional alterations in the PSD.
Furthermore, the linear decrease in backbone length, which plateaus at PD 120, and
the linear decrease in head diameter, support a morphological shift towards parameters
consistent with a ‘stubby’ spine (Peters & Kaiserman-Abramof, 1970). ‘Stubby’ spines,
which are prevalent during early, but not late, development, reflect an immature spine
phenotype relative to other classical (i.e., ‘thin’ or ‘mushroom’) spine types (Harris et al.,
1992). Morphologically, ‘stubby’ spines are characterized by the absence of a dendritic
spine neck, an approximately equal head to neck ratio, and a smaller PSD (Peters &
Kaiserman-Abramof, 1970; Schmidt & Eilers, 2009); parameters which suggest poor
neurotransmitter

innervation.

Specifically,

excitatory

synapses,

which

receive

neurotransmitter signals (Lodish et al., 2000), are primarily located on the head (e.g., Gray,
1959), but also the neck (Yuste, 2010), of dendritic spines (Figure 7.5). Thus, the
morphological parameters of dendritic spines support prominent synaptic dysfunction,
which likely results in deficits in synaptic connectivity.
In conclusion, the present study reveals profound alterations in dendrite and
synaptic pruning, as well as progressive synaptic dysfunction, in the HIV-1 Tg rat. Given
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evidence for decreased synaptic connectivity, weakened synapses, immature spines, the
increase in dendritic spines throughout development may reflect an, albeit unsuccessful,
compensatory mechanism. Notably, the factor of biological sex had no statistically
significant effect on the pattern of results observed. However, there were differences in the
magnitude, which deserves further consideration given sex differences in neurocognitive
function (e.g., Maki et al., 2018; McLaurin et al., 2019b). Understanding how the presence
of HIV-1 viral proteins alters key progressive and regressive processes and synaptic
function across time may afford a key target for the development of innovative
therapeutics.
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Figure 7.1 Progression of Neuronal Morphology. Morphological characteristics of
pyramidal neurons from layers II-III of the mPFC were assessed using total dendrite
length (A), Sholl analysis (B), and branch order (C). HIV-1 Tg animals exhibited a
differential developmental trajectory of dendritic pruning evidenced by the increased
dendrite length, area under the Sholl curve, and total number of branches between
PD 120 and PD 180; a trajectory that was significantly different from control animals.
Furthermore, a shift in the relative frequency of dendritic branches was observed as
a function of age (i.e., PD 30 (D), PD 180 (E)). Specifically, at PD 30, HIV-1 Tg
animals exhibited an increased relative frequency of dendritic branches at lower
branch orders relative to controls. At PD 180, however, an increased relative
frequency of dendritic branches was observed at higher order branches in HIV-1 Tg
animals relative to controls.
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Figure 7.2 Excitatory Synapses. (A) A prominent alteration in synaptic
pruning was observed in HIV-1 Tg animals, evidenced by the linear increase in
total dendritic spines across time. Furthermore, at both PD 30 (B, C) and PD
180 (D,E), HIV-1 Tg animals exhibited a rightward shift in the distribution of
dendritic spines, relative to control animals; the magnitude of which was
dependent upon the factor of biological sex. HIV-1 Tg animals displayed an
increased relative frequency of dendritic spines on more distal branches,
supporting an alteration in synaptic connectivity, relative to control animals.
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Figure 7.3 Dendritic Spine Volume. Dendritic spine volume, which encapsulates
dendritic spine backbone length, head diameter, and neck diameter, was examined as a
key morphological parameters of dendritic spines. (A) HIV-1 Tg animals exhibited a
linear decrease in median dendritic spine volume, while control animals displayed a
linear increase in median dendritic spine volume, across time; results which support
profound alterations in synaptic function. (B-G) Examination of the distribution of
dendritic spine volume in HIV-1 Tg and control animals as a function of age confirmed
the observations inferred from median dendritic spine volume. Specifically, at PD 30,
PD 60, and PD 90, HIV-1 Tg animals exhibited a distributional shift towards increased
dendritic spine volume relative to control animals. However, at PD 120, PD 150, and PD
180, HIV-1 Tg animals displayed a distributional shift towards decreased dendritic spine
volume relative to control animals.
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Figure 7.4 Morphology of Dendritic Spines.
Median dendritic spine backbone length (A) and
head diameter (B) were examined as additional
morphological parameters. HIV-1 Tg animals
exhibited a the linear decrease in backbone length,
which plateaus at PD 120, and a linear decrease in
head diameter across time; results which support
a morphological shift towards parameters
consistent with a ‘stubby’ spine. In sharp contrast,
a linear increase in both backbone length and head
diameter throughout development.
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Figure 7.5 Age Related Change in Pyramidal Neurons. Pyramidal neurons from
layers II-III of the mPFC are illustrated at PD 30 (A, C) and PD 180 (B, D) dependent
upon genotype (Control (A,B), HIV-1 Tg (C, D)). Control animals exhibited an
overproduction of dendritic branches and dendritic spines during early development
(i.e., PD 30); an overproduction which was pruned during puberty consistent with
normal development (Elston et al., 2009). At PD 180, control animals exhibited longer
dendritic spines with increased volume and head diameter that were predominantly
located on more proximal dendrites supporting the reception of DAergic afferents
from the VTA and noradrenergic afferents from the LC. In sharp contrast, HIV-1 Tg
animals exhibited a shorter total dendrite length and decreased total number of
dendritic spines during early development (i.e., PD 30). HIV-1 Tg animals exhibited
abnormal neuronal and dendritic spine development, whereby at PD 180, they
displayed a greater total dendrite length and increased number of dendritic spines.
Furthermore, HIV-1 Tg animals displayed shorter dendritic spines with decreased
volume and head diameter, consistent with a ‘stubby’ phenotype, that were located on
more distal dendrites; results which suggest poor reception of DAergic and/or
noradrenergic afferents. Abbreviations: DA: Dopamine, DAT: Dopamine Transporter,
DA1 Receptor: Dopamine Receptor D1, VMAT2: Vesicular Monoamine Transporter
2, NE: Norepinephrine, NET: Norepinephrine Transporter, α1A Receptor: Alpha-1A
Adrenergic Receptor, α1D Receptor: Alpha-1D Adrenergic Receptor, NMDAR:
NMDA Receptor, AMPAR: AMPA Receptor, VGLUT: Vesicular Glutamate
Transporter, mGLUR: Metabotropic Glutamate Receptor, EAAT2: Excitatory Amino
Acid Transporter 2. (Adapted from McLaurin et al., 2019b).
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CHAPTER 8
GENERAL DISCUSSION
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The HIV-1 Tg rat, resembling HIV-1 seropositive individual on lifelong cART,
exhibits age-related progressive NCI in the absence of sensory or motor system deficits
and comorbidities. Specifically, independent of biological sex, the HIV-1 Tg rat exhibits a
differential progression of long-term episodic memory, temporal processing, stimulusreinforcement learning, sustained attention, and flexibility and inhibition relative to
controls. Prominent developmental alterations in regressive (i.e., pruning) processes, as
well as synaptic function, were observed, independent of biological sex, in pyramidal
neurons from layers II-III of the mPFC in the HIV-1 Tg rat, supporting a key neural
mechanism underlying HAND. Critically testing the therapeutic efficacy of SE in the HIV1 Tg rat revealed an innovative therapeutic approach for the prevention of NCI in HAND;
a therapeutic that, at least partially, restored the developmental trajectory of neurocognitive
function. Mechanistically, SE remodels neuronal circuitry at the synaptic level, evidenced
by profound long-term modifications in neuronal morphology and dendritic spines in
pyramidal neurons from layers II-III of the mPFC. Taken together, the present studies have
defined HAND as a neurodegenerative disease characterized by progressive NCI and
synaptic dysfunction; a disease trajectory that can be modified by therapeutics (i.e., SE)
that mechanistically target synaptic dysfunction.
Neurocognitive assessments (e.g., PPI, locomotor activity, signal detection)
conducted throughout the present studies evaluated the perception of time, which has been
implicated as an elemental dimension of HAND (e.g., Chao et al., 2004; Moran et al.,
2013a; McLaurin et al., 2019a), across a continuum of time interval manipulations (i.e.,
from milliseconds to days). Prominent deficits in timing, observed in the HIV-1 Tg rat,
generalized across the factor of biological sex, age, neurocognitive assessment and time
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interval manipulation. Treatment with SE prevented the development of alterations in the
perception of time in preattentive processes (Moran et al., 2019), the temporal components
of sustained attention, as well as the temporal components of reversal and flexibility.
Therefore, the generalizability and sensitivity of temporal processing deficits supports a
key target for the development of a diagnostic and/or prognostic biomarker for HAND.
Current diagnostic tools for milder forms of HAND lack both sensitivity and
specificity (e.g., Haddow et al., 2013; Sakamoto et al., 2013; Zipursky et al., 2013), which
has led to a quest for an innovative biomarker for HAND in the post-cART era. A series
of studies have proposed PPI, an assessment of temporal processing, as a novel diagnostic
and/or prognostic biomarker for HAND (for review, McLaurin et al., 2019c). The
diagnostic utility of PPI was critically tested using DFA (e.g., McLaurin et al., 2016b;
McLaurin et al., 2017c) and receiver operator characteristic curves (for review, McLaurin
et al., 2019c). PPI accurately diagnoses (i.e., 86.7-97.1%) the presence of the HIV-1
transgene with high sensitivity (i.e., 89.3-100%) and high specificity (i.e., 79.5-94.1%).
Additional utilization of advanced statistical techniques, including regression and
statistical mediation, have further tested the potential utility of PPI. Specifically, early
alterations in PPI are predictive of later NCIs in a sex-dependent manner (i.e., Males:
Sustained Attention; Females: Flexiblity and Inhibition); results which support its utility
as a prognostic biomarker for HAND. Furthermore, statistical mediation analyses also
revealed that preattentive processes, indexed using PPI, partially mediate alterations in
higher-order cognitive processes supporting a causal neurobehavioral mechanism
underlying HAND (McLaurin et al., 2019e). In addition to the strong statistical evidence
supporting PPI, its brevity (i.e., approximately 15-25 minutes; Fournier & Hebert, 2013;
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Minassian et al., 2013), ease of administration and test-retest reliability (e.g., Braff et al.,
1978) make it an attractive biomarker for HAND in the post-cART era.
The factor of biological sex was an integral component of the experimental design
for the studies presented herein. Women, who account for approximately 51% of HIV-1
seropositive individuals worldwide (UNAIDS, 2016) are inadequately represented in
studies investigating HAND (Maki & Martin-Thormeyer, 2009). There remains, therefore,
a critical need to directly compare neurocognitive function in males and females to address
this knowledge gap (Maki et al., 2015). Investigation of sex differences in neurocognitive
function have revealed greater NCI in HIV-1 seropositive females relative to HIV-1
seropositive males (e.g., Hestad et al., 2012; Royal et al., 2016; Maki et al., 2018); results
which were translationally modeled in the HIV-1 Tg rat. Specifically, as demonstrated in
the present study, female HIV-1 Tg animals exhibited greater NCI relative to male HIV-1
Tg animals in assessments of temporal processing, sustained attention, and flexibility and
inhibition (Chapters 2, 3, 4). Critically, however, SE served as a efficacious therapeutic for
NCI in both male and female HIV-1 Tg animals.
Notably, the neural mechanisms underlying HAND may also be influenced by the
factor of biological sex. Cross-sectional studies in the HIV-1 Tg rat revealed sex
differences in dendritic spine morphology with male HIV-1 Tg animals exhibiting a
population shift towards shorter dendritic spines relative to their control counterparts
(Chapter 4, 5). In sharp contrast, female HIV-1 Tg animals displayed a population shift
towards longer dendritic spines (Chapter 4, 5). A longitudinal examination of pyramidal
neurons from layers II-III of the mPFC, however, revealed no prominent effect of
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biological sex on the pattern of neuronal and spine alterations (Chapter 7); an effect that
may be due to age and/or the absence of neurocognitive testing.
In conclusion, the present study demonstrated progressive, age-related NCI and
synaptic dysfunction in the HIV-1 Tg rat, in the absence of sensory or motor system
functions and comorbidities. Treatment with SE, targeting alterations in synaptic
dysfunction, selectively precludes the development of NCI, independent of biological sex.
Most critically, SE restores, at least partially, the developmental trajectory of preattentive
processes supporting an innovative therapeutic that modifies disease progression. Taken
together, the present studies have defined HAND as a neurodegenerative disease
characterized by age-related, progression neurocognitive impairments and synaptic
dysfunction; a disease which can be modified by therapeutics (i.e., SE) that mechanistically
target synaptic dysfunction.
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Figure A.1 Point of Maximal Inhibition. The ASR at the point of maximal
inhibition is illustrated for auditory (A) and visual (B) prepulse inhibition (PPI) as
a function of genotype (HIV-1 Tg, control) and age (±95% CI). (A) In auditory
PPI, a linear increase in ASR at the point of maximal inhibition was observed in
both HIV-1 Tg and control animals as a function of age. A global first-order
polynomial was the best fit for both HIV-1 Tg and control animals; no significant
differences in the rate of increase in ASR at the point of maximal inhibition was
observed between genotypes [F(2,14) =3.2, p≥0.05]. (B) In visual PPI, both HIV1 Tg and control animals displayed a linear increase in the ASR at the point of
maximal inhibition as a function of age. Although the ASR at the point of maximal
inhibition increased significantly faster in HIV-1 Tg animals relative to controls
[F(1,14)=14.5, p≤0.002], robust inhibition to the visual prestimulus was observed
at all test sessions.
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Phase 1: Original Acquisition
Signal Detection
The signal detection test sessions, which began with a 5-minute habituation period,
were conducted during the light-cycle in a darkened operant chamber. After each trial
began, two retractable levers were extended for 2 sec and remained extended for 6 sec for
the animal to make a response. A variable ITI of 9±3 sec was present, during which time
the levers were retracted. Approximately half of the animals were trained to press the left
lever during signal trials and the right lever during non-signal trials (hits and correct
rejections, respectively). The other half of the subjects were trained using the reverse set
of rules. A correct response, including hits and correct rejections, was rewarded with a
sucrose pellet. Incorrect responses, including misses and false alarms, were not rewarded.
Animals were trained on each vigilance program until meeting criteria of at least 70%
accuracy for 5 consecutive or 7 non-consecutive test sessions, at which point they were
promoted to the next program. Percent accuracy was calculated as follows: (Total Number
of Hits and Correct Rejections)/(Total Number of Correct and Incorrect Responses x 100).
Statistical Analysis
The temporal process of learning (i.e., the number of days to meet criterion) during
original acquisition, as a function of retest assessment, and during reversal acquisition was
analyzed using a generalized linear mixed effects model with a Poisson distribution and an
unstructured covariance pattern (SAS/STAT Software 9.4, SAS Institute, Inc., Cary, NC).
Genotype (HIV-1 Tg vs. control) and sex (male vs. female) were included as betweensubject’s factors. For reversal acquisition, only the animals with at least 60 days to
complete the task were included in the figures and analysis (Control: N=17 litters; male,
n=24, female, n=24; HIV-1 Tg: N=18 litters; male n=17; female, n=21).
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The number of days meeting criterion during 18 month acquisition, to directly
assess functional form, was analyzed using a curve-fitting analysis and fit with a 95% CI
(GraphPad Software, Inc., La Jolla, CA, USA).
Signal duration data during original acquisition, as a function of retest assessment,
during the 18 month acquisition, and the reversal task was analyzed using a mixed-factor
ANOVA (SPSS Statistics 24, IBM Corp., Somer, NY) with genotype (HIV-1 Tg vs.
control) and sex (male vs. female) serving as between-subject’s factors. Response type (hits
vs. misses), signal duration (e.g., 1000, 500, 100 msec) and retest assessment served as the
within-subject’s factors, as appropriate. During original acquisition and retest assessments,
signal detection data was analyzed for the first 5 consecutive or 7 non-consecutive days
that an animal achieved 70% accuracy. For the 18-month acquisition assessment, all 5 days
were included in the analysis. For the reversal task, when an animal met criteria, the first 5
consecutive or 7 non-consecutive days that an animal achieved 70% accuracy were
included. In the reversal assessment, if an animal failed to meet criteria, but had 60 days or
had completed 45 days by approximately 20 months of age, the 7 days with the highest
percent accuracy were included in the analysis. To illustrate the profound genotype
differences in the progression of sustained attention across retest assessments, data in
Figure 4.4 were statistically extrapolated to 10 msec; the 10 msec point was not included
in the statistical analysis. The factor of retest assessment was included in the statistical
analysis of the 18-month challenge and reversal task, thus only the animals that completed
both assessments were included in the statistical analysis; figures represent all animals that
completed a given assessment.
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Censored data, either due to euthanization, an equipment malfunction, or failure to
complete the retest assessment was handled using the mean series imputation method
(Retest Assessment 3: HIV-1 Tg female, n=2; Retest Assessment 4: control female, n=1;
Retest Assessment 5: control female, n=1, control male, n=1, HIV-1 Tg female, n=4, HIV1 Tg male, n=2; 18 Month Challenge: control female, n=1, control male, n=1, HIV-1 Tg
female, n=1; Reversal Assessment: control male, n=3, HIV-1 Tg female, n=1).
Neuronal morphology was assessed using two measures, including the number of
segments at each branch order and the number of intersections at successive radii (i.e.,
Sholl analysis). The number of segments at each branch order were analyzed using a
generalized linear mixed effects model with a Poisson distribution and an unstructured
covariance pattern (SAS/STAT Software 9.4, SAS Institute, Inc., Cary, NC) with genotype
(HIV-1 Tg vs. control), sex (male vs. female) and branch order (Branches 1 – 10) included
as factors in the analysis. The number of intersections at successive radii was analyzed
using a mixed-design ANOVA, restricted maximum likelihood estimation model
parameters, a variance components covariance structure (Wilson et al., 2017), and a
random intercept and random slope (i.e., Radius; SAS/STAT Software 9.4, SAS Institute,
Inc., Cary, NC).
Dendritic spine connectivity was evaluated using the number of dendritic spines,
dependent upon spine type (i.e., thin, stubby, mushroom), between each radii. Dendritic
spine backbone length, head diameter, and volume were examined as assessments of
dendritic spine morphology. A generalized linear mixed effects model with a Poisson
distribution and an unstructured covariance pattern was conducted using PROC GLIMMIX
(SAS/STAT Software 9.4, SAS Institute, Inc., Cary, NC) for both dendritic spine
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connectivity and dendritic spine morphology. Analyses were conducted on the number of
dendritic spines between each successive radii or the number of dendritic spines within
each bin. Between-subject’s factors included genotype (HIV-1 Tg vs. Control) and
biological sex (male vs. female).
The gene expression of each neuroinflammatory marker was analyzed individually
using a two-way ANOVA, with genotype (HIV-1 Tg vs. control) and biological sex (male
vs. female), serving as the between-subject’s factors.
A DFA was utilized to examine the utility of neurocognitive impairments across
the lifespan or dendritic spine alterations to correctly classify animals based on their
genotype (SPSS Statistics 24, IBM Corp., Somer, NY).
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Table B.1 Primers for Neuroinflammatory Markers.
Rat genes
TNF-α
IL-1β
IL-6
β-Actin

Forward (5’-3’)
ACCACGCTCTT
CTGTCTACTG
GCAATGGTCGG
GACATAGTT
GCCCTTGCTGG
TGGATGTT
AAGTCCCTCAC
CCTCCCAAAAG

Reverse (5’-3’)
CTTGGTGGTTT
GCTACGAC
AGACCTGACT
TGGCAGAGGA
GAGAGGGAGT
GCTGCTTGGA
AAGCAATGCT
GTCACCTTCCC
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GenBank Identifiers
NM 013693.3
NM 031512.2
NM 010559.3
NM 007393.5
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Figure B.1 Cumulative Frequencies of Acquisition. Temporal process of
acquisition as a function of retest session (N=17-20 litters per genotype). At
each individual retest session (i.e., Retest 1: A, Retest 2: B, Retest 3: C, Retest
4: D, Retest 5: E) HIV-1 Tg animals, independent of biological sex, took a
significantly greater number of days to acquire the signal detection task
(p≤0.05); an impairment which progressed as a function of retest session. Data
are presented as cumulative frequencies with 95% confidence intervals fit to the
curve.
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Figure B.2 Synaptic Connectivity: Biological Sex: The
distribution of dendritic spines on successive radii is illustrated
as a function of spine type (i.e., Thin Spines (A,B), Stubby
Spines (C,D), and Mushroom Spines (E,F)) and biological sex
(i.e., Male (A,C,E), Female (B,D,F)) (N=16-19 litters). HIV-1
Tg animals exhibited an increased relative frequency of thin
dendritic spines on more distal branches relative to controls; the
magnitude of which was influenced by the factor of biological
sex. In sharp contrast, an assessment of stubby dendritic spines
revealed a population shift with an increased relative frequency
on more proximal branches in HIV-1 Tg animals relative to
controls; an effect influenced by the factor of biological sex. No
significant differences in the distribution of mushroom dendritic
spines were observed.
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Figure B.3 Dendritic Spine Morphology. Presence of the
HIV-1 transgene and the factor of biological sex influenced
dendritic spine morphology. Male HIV-1 Tg animals
exhibited a distributional shift towards shorter dendritic
spines (A) relative to male control animals; no significant
alterations in dendritic spine head diameter (C) or volume
(E) were observed in male HIV-1 Tg animals. Female HIV1 Tg animals displayed a distributional shift towards longer
dendritic spines (B) with increased head diameter (D)
relative to female control animals; no significant alterations
in dendritic spine volume (F) were observed in female HIV1 Tg animals. A generalized linear mixed effects model
with a Poisson distribution confirmed these observations,
revealing a significant genotype x sex x bin interaction for
both backbone length [F(1,1659)=37.2, p≤0.001] and head
diameter [F(1,1154)=68.2, p≤0.001]; an effect not observed
for dendritic spine volume (p>0.05). Data are illustrated as
relative frequencies.
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